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Abstract 
Stereotactic ablative radiotherapy (SABR) is a guideline-specified treatment option for 
patients with early stage non-small cell lung cancer. This high-precision treatment delivers a 
high dose of radiation to the tumour while avoiding surrounding normal tissue. After 
treatment, patients are followed up regularly with computed tomography (CT) imaging to 
determine treatment response. However, benign radiographic changes to the lung known as 
radiation-induced lung injury (RILI) frequently occur. Due to the large doses delivered with 
SABR, these changes can mimic the appearance of a recurring tumour and confound 
response assessment. The objective of this work was to evaluate the accuracy of radiomics, 
for prediction of eventual local recurrence based on CT images acquired within 6 months of 
treatment. We calculated quantitative image features within manually delineated regions of 
common post-SABR changes (consolidation and ground-glass opacity (GGO)). Second-order 
texture features could predict recurrence in individual patients with an area under the receiver 
operating characteristic curve (AUC) of 0.8. To eliminate the need for time-consuming 
manual delineations, a semi-automated graph cuts based segmentation algorithm was adapted 
for the consolidative regions. A peri-consolidative region, intended to subsample regions of 
GGO surrounding the consolidative region, was automatically derived and demonstrated 
consistent classification performance, with non-inferiority to manual delineations. Physician 
ability to detect timely local recurrence was also measured on CT imaging, and compared 
with that of the radiomics tool. Within 6 months post-SABR, physicians assessed the 
majority of images as no recurrence whereas our radiomics system produced an AUC of 0.85 
on the same images. These results suggest that radiomics can detect early changes associated 
with local recurrence that are not typically considered by physicians. Patients with recurrence 
tend to have increased presence of ground-glass opacity surrounding consolidative changes 
compared to patients with benign injury at the early follow-up time point. These appearances 
detected by radiomics may be early indicators of the promotion and progression to local 
recurrence. This has the potential to lead to a clinically useful computer aided decision 
support tool based on routinely acquired CT imaging, which could lead to earlier life-saving 
salvage opportunities for patients with recurrence and fewer unnecessary invasive 
investigations of patients with only benign injury. 
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 Introduction 1
1.1 Lung Cancer Epidemiology  
 Lung cancer remains the leading cause of cancer death in Canada. It is estimated 
that 26,600 Canadians will be diagnosed and 20,900 Canadians will die from lung cancer 
in 2015 [1]. On average, 1 in 12 Canadian men and 1 in 15 Canadian women are 
expected to develop lung cancer in his or her lifetime, and 1 in 13 men and 1 in 17 
women are expected to die from it [1]. Five-year survival rates for lung cancer are 
typically poor, around 15%, as the majority of patients are diagnosed with advanced stage 
disease [2]. Smoking cigarettes, as well as second-hand or passive smoking, are the 
predominant risk factors for developing lung cancer [3]. Environmental and occupational 
factors including air pollution and asbestos have been shown to increase the risk of 
developing a primary lung cancer [3].  
 Non-small cell lung cancer (NSCLC) arises in the epithelial cells of the lung from 
the central bronchi to the alveoli. NSCLC accounts for around 80% of all lung cancers 
and includes adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma 
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[4]. The majority of peripheral tumours are adenocarcinomas, whereas squamous cell 
tumours tend to be located centrally [5]. The majority of patients with NSCLC present 
with advanced stage III or IV disease [6]. The remaining 20% of lung cancers are small 
cell lung carcinoma (SCLC), which is typically found in smokers and has a very poor 
prognosis [4]. 
1.2 Lung Cancer Presentation   
 Patients with clinical signs and symptoms of lung cancer typically present with 
cough, hemoptysis, dyspnea, or chest pain [7]. However, these symptoms can be non-
specific and detection of new symptoms can be more difficult in patients with co-existing 
lung diseases including chronic obstructive pulmonary disease. Physicians should be alert 
to possible lung cancers when patients present with these symptoms, especially if they are 
smokers, ex-smokers, or over the age of 50 [8]. When lung cancer is suspected, initial 
imaging with chest radiography and computed tomography (CT) imaging are typically 
performed. Once a lung nodule is determined, work-up for a suspected lung cancer will 
include both diagnostic and staging tests. 
1.2.1 Lung Cancer Screening 
 In patients with a high risk of developing lung cancer, including those between 
the ages of 55 and 74 who have a history of cigarette smoking of at least 30 pack-years, 
screening has the potential to find lung cancers early. A recent study by the National 
Lung Screening Trial (NLST) demonstrated that low-dose CT for screening showed a 
20% relative reduction in lung cancer mortality compared with chest radiography [9]. 
However, approximately 98% of all positive CT screening exams are benign and do not 
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result in a diagnosis of lung cancer, which may result in unnecessary invasive procedures. 
The Canadian Task Force on Preventive Health Care now recommends low-dose CT lung 
cancer screening annually for up to 3 years, for Canadians aged 55 to 74 with at least a 30 
pack-year smoking history, who currently smoke or have quit within 15 years. [10]. The 
introduction of low-dose CT screening will result in an increase in detection of stage I 
NSCLC. 
1.3 Lung Cancer Diagnosis 
 A physical examination and medical history will assist a physician in determining 
any signs, symptoms and risk factors associated with a primary lung cancer. Medical 
imaging, including chest radiography, CT, and positron emission tomography (PET) is 
also used to diagnose a lung cancer. CT can be used to determine the size, shape, and 
location of the suspicious lung nodule. On CT imaging, a suspicious lung nodule is 
typically a rounded or irregular region of increased attenuation. The size of the tumour is 
measured based on the longest axial diameter and is important for staging. Lung nodules 
can be classified as solid, sub-solid, or ground-glass [11]. Cavitation of a lesion is a 
frequent finding in SCC. A contrast-enhanced CT is typically performed to determine if 
the tumour is invading the mediastinum and to differentiate mediastinal lymph nodes 
from vascular structures. Suspicious lymph nodes in the mediastinum are typically larger 
than 10 mm in diameter [12].  
 Once a lung cancer has been suspected on imaging, a biopsy must be performed 
to confirm a diagnosis of cancer. Flexible bronchoscopy is a standard procedure to obtain 
tissue samples for diagnosis of central lesions with high sensitivity [13]. A transthoracic 
image guided biopsy can be performed for peripheral lesions not accessible by 
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bronchoscopy [14]. The use of CT-guided transthoracic core needle biopsies has risen 
over the past decade and is currently recommended for peripheral lung nodules [15]. 
Pathologic assessment of the tissue will distinguish a NSCLC from a SCLC as well as 
determine the histological subtype. The histological grade of the tumour is also classified, 
from well differentiated (grade 1) to undifferentiated (grade 4). 
1.4 Lung Cancer Staging 
 After a diagnosis of NSCLC is made, tumour node metastasis (TNM) 
classification is critical for determining the appropriate treatment. The TNM 
classification characterizes a lesion according to the primary tumour (T), nodal status (N), 
and distant metastasis (M). Staging is determined based on TNM data and in NSCLC 
there are four primary stages (I, II, III and IV) [16]. Early stage lung cancer is considered 
stage I disease with small tumours (less than 5 cm) contained within the lung that have 
not spread to the nearby lymph nodes. Cancers which have spread to bronchial or hilar 
lymph nodes are considered stage II. Stage III disease, or locally advance disease, has 
spread to mediastinal lymph nodes. Tumours which have metastasized outside of the lung 
are considered stage IV disease. 
 Standard CT imaging has the ability to classify the primary tumour. For 
mediastinal lymph node staging, CT imaging has a sensitivity and specificity of 83% and 
82% respectively [12]. For suspicious lymph nodes adjacent to the mediastinum, a 
mediastinoscopy is the standard approach for obtaining tissue samples. In this approach a 
mediastinoscope is inserted through a small incision in the throat to sample a lymph node 
of interest. Significant advances in staging have developed from the introduction of 
endoscopic ultrasound and endobroncial ultrasound.  These techniques are less invasive 
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than a standard mediastinoscpy and allow for efficient sampling of regional lymph node 
stations.18-fluorodeoxyglucose (FDG) PET imaging also has an increasing role in lung 
cancer staging and for regional nodal staging the detection of distant metastases [17, 18]. 
FDG-PET images the metabolic uptake of glucose in tissue and allows for the 
differentiation of normal and malignant tissue [19]. 
1.5 Lung Cancer Treatment  
 The treatment of NSCLC is dependent on the stage and patient’s overall health 
and lung function [20]. Treatment options can include surgery, radiation therapy (RT), 
and/or chemotherapy. The role of personalized medicine in lung cancer treatment is also 
emerging where targeted therapies have the potential to improve outcomes in patients 
with a known gene mutation [17]. For stage I disease, patients are typically treated with 
surgery or radiation therapy alone. In stage II disease, surgery may be performed 
followed by adjuvant chemotherapy and radiation therapy. A combination of surgery, 
chemotherapy, and/or radiation therapy is typically considered for stage III disease [20].  
Patients with stage IV disease are generally considered palliative, but may benefit from a 
combination of the chemotherapy, radiation therapy, and/or targeted agents [17]. 
1.5.1 Early Stage NSCLC 
1.5.1.1 Surgery 
 Surgery remains the standard treatment option for patients with early-stage 
(T1/T2 N0) NSCLC. To determine if a patient is eligible for surgery, pulmonary function 
or lung function tests are completed to measure lung capacity and function. For patients 
who are then considered medically operable, a lobectomy is the guideline-recommended 
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treatment option [21, 22]. Wedge or sublobar resection is recommended for patients with 
small tumours who are at higher risk with a lobectomy. However, several studies have 
demonstrated sublobar resection has inferior clinical outcomes compared to standard 
lobectomy [22, 23]. Minimally invasive surgery through video-assisted thoracic surgery 
has been shown to have fewer post-operative complications with comparable outcomes to 
traditional thoracotomy [24]. 
 The most common cause of death following surgical resection of early stage 
disease is tumour recurrence. Therefore long term survival is moderate, with five-year 
survival rates in stage I NSCLC following surgery ranging between 55-80% [25-27].  
Rates of recurrence following surgical resection range from 30-55%, with most patients 
failing at distant sites [28].  Local control rates following surgical resection are quite 
favorable; greater than 90% in many studies [29]. 
1.5.1.2 Stereotactic Ablative Radiotherapy 
Stereotactic ablative radiotherapy (SABR) has become a standard treatment 
option for patients with early-stage (T1/T2 N0) NSCLC who refuse surgery or are 
considered medically inoperable [21, 30]. The use of SABR, which is also known as 
stereotactic body radiation therapy (SBRT), for curative-intent treatment of NSCLC has 
been rapidly increasing over the last decade [31]. SABR differs from conventional 
radiotherapy techniques in that it delivers high doses per fraction (approximately 7.5–18 
Gy per fraction versus 2 Gy per fraction) over a shorter treatment time (typically 3–8 
fractions over 1–2 weeks versus 20–30 fractions over 4–6 weeks). Evidence suggests that 
a biologically effective dose (BED) in excess of 100 Gy10 is required for optimal local 
control [32]. These high doses are achievable with the use of highly conformal treatment 
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plans, which include precise planning, targeting, and treatment delivery. SABR is 
arguably one of the largest medical breakthroughs in the curative treatment of early stage 
NSCLC in the last two decades, with improved population-based survival rates 
demonstrated after the implementation of SABR [33-35]. 
In addition to treatment of primary lung cancer, the use of SABR has also been 
rapidly increasing for oligometastatic disease [36, 37]. Several single-institution studies 
have demonstrated high rates of local control, with favorable comparisons to surgery in 
overall survival outcomes [38, 39]. However, for colorectal cancer, rates of local control 
after SABR may be lower than other histologies, approximately 70–80% [39]. The 
impact of SABR on overall survival in patients with oligometastatic disease is currently 
being evaluated in a randomized trial [40]. 
1.5.1.2.1 Comparison to Surgery 
 The effectiveness of SABR for local tumour control has been well established. 
Reported three-year local control rates often exceed 90% [29, 41]. SABR outcomes 
appear not only superior to more fractionated regimens [42] (e.g. 55 Gy in 20 fractions 
[43]), but are comparable to standard surgical resection, as supported by retrospective, 
single- or multi-institution, and modeling studies, with the largest single-institution 
retrospective study reporting a 5-year local control rate of 89.5% [29, 44, 45]. Three 
randomized trials comparing resection vs. SABR have closed due to poor accrual. A 
pooled analysis of the accrued patients from two trials has been completed, and although 
the sample size was small, results showed the two treatment options to be comparable 
[41]. SABR was better tolerated (10% grade 3 toxicity with SABR vs. 44% grade 3–4 
toxicity with surgery), with better post-treatment quality of life [46]. SABR achieved 
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better overall survival than surgery (3-year OS 95% vs. 79%, p=0.037); however, larger 
studies are needed to confirm these findings. 
In high-risk patients with severe pulmonary comorbidities, SABR offers 
comparable rates of local control without the attendant short-term mortality risks of 
surgery [47]. In the operable patient population, promising outcomes are reported by two 
prospective clinical trials: RTOG 0618, reporting a primary tumour failure rate of 7.7% 
[48], and JCOG 0403, reporting a preliminary 3-year tumour control rate of 86% [49]. 
For institutions without the capability to deliver SABR, other hypofractionated regimens 
can also achieve reasonable local control at early time-points: a recent Canadian 
multicenter study of hypofractionated RT delivering 60 Gy in 15 fractions (BED of 75 
Gy10) achieved a two-year local control rate of 88% [50]. 
1.5.1.2.2 Recurrence Following SABR 
 Outcomes following SABR are favourable, with recent studies demonstrating 5-
year local and regional control rates of 90% and 87% respectively. Local recurrences, 
typically defined as failure within the treated area, typically manifest at a median time of 
15 months post-SABR, but they may present up to 5 years following treatment [51]. 
Despite high rates of local control, patients still remain at risk of lobar recurrence: the 
multicenter RTOG 0236 trial demonstrated a 5-year primary tumour recurrence rate of 
7%, but an involved lobar recurrence rate of 20% [45, 52]. However, lobar recurrence 
after SABR may be difficult to distinguish from development of second primary lung 
cancers (SPLC). Regardless of the classification as recurrence or SPLC, many patients 
with lobar recurrence can be salvaged with surgical resection [41, 53-55]. 
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Many factors have been identified in the literature as predictive of local control 
based on Cox multivariable analysis. These include both dose factors, including the 
biologically effective dose (BED) and minimum planning target volume (PTV) dose, as 
well as tumour factors including T-stage and gross tumour volume (GTV) size [56-58].  
1.6 Lung Cancer Follow-up 
 After SABR treatment, patients are typically followed with physical examination 
and CT imaging every 3–6 months for the first 3 years following treatment [51]. 
Although FDG-PET scans are recommended in lung cancer diagnosis and re-staging, 
functional imaging currently has a limited role in the evaluation of tumour response [19]. 
1.6.1  Computed Tomography Imaging 
CT imaging plays an important role in lung cancer diagnosis, treatment, and 
follow-up. Current recommendations for imaging follow-up after SABR are generally 
based on retrospective evidence and expert opinion, rather than randomized data. Such 
follow-up serves 3 major goals: detection of local recurrence, detection of regional 
recurrence that may be amenable to salvage, and detection of new primary lung tumours, 
which occur at a rate of 2-10% per person-year [51, 59]. Based on the results of the 
National Lung Screening Trial [60], the American Association for Thoracic Surgery 
guidelines recommends 4 years of CT follow-up for patients who have undergone 
treatment for lung cancer and are eligible for additional treatment [61]. 
1.6.1.1 Radiation-Induced Lung Injury 
Following radiotherapy to the lungs, the development of radiographic radiation-
induced lung injury (RILI) on CT imaging can occur.  Radiation delivered to the tumour 
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and surrounding lung parenchyma results in radiologic lung injury (pneumonitis and 
fibrosis) appearing as increased density on CT. The amount of radiation damage to 
normal tissue varies according to delivered dose, fractionation, dose rate, irradiated 
volume, and beam arrangement [62]. The appearance and patterns of RILI can also vary 
across follow-up time intervals. Radiation pneumonitis is typically seen in the acute 
setting within 6 months of treatment, following which it is classified as fibrosis [63]. 
From histopathological studies obtained after resection for false-positive imaging studies, 
these areas of lung injury are made up of a benign mixture of inflammatory cells, 
fibrocytes and other benign features [64].  Lung injury following traditional 3D-
conformal radiation therapy (CRT) is often characterized by straight edges that conform  
to treatment portals [65], as shown in Figure 1-1. 
 
Figure 1-1: Radiation induced lung injury following a traditional anterior/posterior 
parallel opposed pair (treatment plan shown in (a)); (b) The resulting benign injury 
conforms to the treatment portals and is easily distinguished by a straight line. 
 
(b)(a)
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1.6.1.2 Common Appearances after SABR 
Following SABR, benign RILI is nearly always present on follow-up CT imaging. 
Ablative doses of radiation result in radiographic changes appearing as an increased 
density and opacity on CT in the area of the high-dose region [66, 67]. Such CT changes 
correlate closely with local delivered dose [68]. The total dose, fractionation, treatment 
delivery technology, and tumour size are all factors which may affect the degree of 
radiographic lung injury [68, 69]. Such findings are not unique to lung SABR; they have 
also been described in other organs treated with stereotactic radiotherapy including brain 
and liver [70, 71]. 
The appearance of fibrosis is very common, occurring in 62% of patients within 6 
months of treatment (acute) and 91% thereafter (late), as classified by a common 
classification scheme (Figure 1-2) [66, 67]. This scheme classifies acute radiation 
pneumonitis into consolidative or ground-glass opacity changes, which can further be 
subdivided into diffuse (> 5cm) or patchy (≤ 5cm). Late radiation fibrosis can be 
categorized into modified conventional, mass-like, or scar-like patterns [66, 72]. A 
modified conventional pattern has been described, defining a fibrosis pattern that is larger 
than the original tumour size, may be associated with ground-glass opacity, and may 
include consolidation, volume loss, and bronchiectasis that is similar to or less extensive 
than conventional radiation fibrosis [66, 73]. These radiographic changes can persist and 
continue to evolve even after 2 years following treatment.  
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Figure 1-2: Classification of post-SABR radiological changes. Adapted from Dahele et 
al. [66] 
 
Morphologic patterns of fibrosis can also vary with treatment type; patients who 
underwent arc-based SABR had a predicted probability of a modified conventional 
pattern of 96.3% versus 68.9% for those who underwent fixed-beam treatment [69]. 
Although such radiologic lung injury occurs in nearly all patients by 2-years [66], only a 
small minority of patients develop clinical symptoms. 
Several studies have examined simple dose-response relationships of HU changes 
following SABR.  Increasing densities on CT post-SABR are seen with larger planning 
target volumes and longer time post-SABR, and these are most evident in regions 
receiving doses greater than 20 Gy [68]. Density changes post-SABR have also been 
shown to linearly increase to doses of 35-40 Gy and then plateau thereafter [68, 74]. The 
spatial location of fibrosis following SABR is on average 2.6 cm from the GTV position, 
although displacement of the fibrotic changes of  >5 cm can also be observed [75]. 
Diffuse Consolidation (>5cm) Patchy Consolidation (≤5cm) Diffuse GGO (>5cm) Patchy GGO (≤5cm)
Scar-like Mass-like Modified Conventional
Acute: ≤ 6 months
Late: > 6 months
  
13 
1.6.1.2.1 Radiation-Induced Lung Injury versus Recurrence 
As a direct result of the highly ablative and conformal doses delivered with 
SABR, these benign radiographic changes can appear similar to a recurring tumour 
(Figure 1-3). Against the background of asymptomatic radiation-induced lung injury, 
accurate assessment of local recurrence is of paramount importance. These changes on 
CT can result in a major clinical dilemma with respect to accurately distinguishing 
patients with local recurrence from benign RILI, especially in cases with mass-like 
changes [76]. Although the classification scheme previously described is used to 
categorize radiological changes following SABR, it is not used to distinguish recurrence 
from fibrosis.  
 
Figure 1-3: Planning CT image for SABR treatment and subsequent follow-up imaging 
after radical treatment for early-stage primary lung cancer. 
 
 Distinguishing a recurrent tumour from fibrotic lung changes on CT can be 
challenging for several reasons, as demonstrated in Figure 1-4. Both radiation-induced 
lung injury and recurrent disease follow a similar temporal course, with lung fibrosis 
continuing to evolve two years after treatment, during which time, the majority of local 
recurrences occur [51, 66]. In contrast to lung injury following traditional 3D-CRT, 
which was often characterized by straight edges that conform to treatment portals (Figure 
+3 m +6 m +16 m +2 y +3 y +4 y+10 m
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1-1), the pattern of lung injury on CT following SABR can be mass-like, due to the 
conformal nature of SABR [66, 76, 77]. Fibrosis may even appear on CT as an enlarging 
density and therefore can the mimic the growth of a local recurrence [77].  
Misclassification of a recurrence as “benign fibrosis” can result in a missed 
window of opportunity for curative-intent salvage treatment. Conversely, 
misclassification of fibrosis as a recurrence may lead to unnecessary interventions, such 
as biopsy, imaging, chemotherapy, and even surgery, exposing patients to unnecessary 
risks and morbidity [64, 77-80]. The ability to accurately assess response is particularly 
important in light of the changing practice patterns for early stage NSCLC. As a growing 
number of patients are being treated by SABR [81], this clinical scenario will become 
more common. The treatment of a fitter patient population may result in a larger 
proportion of patients who are candidates for salvage treatment in the case of recurrence. 
Finally, since recent data on potentially operable SABR patients suggest that failure may 
be higher than in the inoperable SABR cohort (with two-year lobar failure rates in one 
recent multicenter study [defined as recurrence anywhere in the irradiated lobe] as high 
as 19.2% [48]), accurate distinction between recurrence and fibrosis to permit early 
salvage is pressing clinical problem. 
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Figure 1-4: Radiological changes following SABR for an 85-year-old gentleman with 
biopsy proven adenocarcinoma. This patient received 54 Gy in 3 fractions with the 
treatment plan shown in (a). Radiological changes are seen (b) where 0m indicates the 
pre-treatment lesion measuring 2.0 cm. At 3 months post-SABR, there is presence of an 
enlarged ground-glass and semi-solid opacity measuring 4.3 cm. At 6 months there is 
interval reduction in size and a decrease in ground-glass opacity, with ongoing reduction 
in size at 18 months and 3 years post-treatment. 
 
Several groups have reported patients with suspicious findings on CT and/or 
FDG-PET imaging who underwent salvage lung resection to have pathology show no 
viable tumour cells [77, 80, 82]. Takeda and colleagues demonstrated an enlarging solid 
(a)
(b) 0m +3m +6m +18m +3y
Absolute
60 Gy
56.7 Gy
54 Gy
52.9 Gy
51.3 Gy
48.6 Gy
43.2 Gy
27 Gy
20 Gy
10 Gy
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mass on CT follow-up for a patient treated with SABR (as shown in Figure 1-5) [77]. 
This was suspicious for recurrence and the patient underwent surgical resection, which 
demonstrated only a benign fibrotic scar. In most cases, persistent CT findings do not 
indicate recurrence: a recent study determining the fate of residual masses after SABR 
found that in 50 patients with masses present greater than 1 year following treatment, 
only 8 developed local recurrence [83].  
 
Figure 1-5: (a) Pre-treatment CT image of a 79 year old gentlemen treated with  
stereotactic radiotherapy and (b-d) post-treatment follow-up CT images at 3, 6, and 9 
months respectively. Enlargement of the nodule at 6 and 9 months raised suspicion of 
local recurrence and the patient was sent for surgical resection. (e) A 7 mm diameter 
tumour-like fibrous scar was observed on pathology, with sharply defined regions of 
fibrosis surrounding the scar and mild pleural thickening. Adapted from Takeda et al. 
[77] 
 
1.7 Response Assessment Following SABR  
 With the increase in number of patients receiving SABR for primary lung cancer 
or metastatic disease, determining the appropriate follow-up and management of patients 
is critical [84]. With a shift toward the use of SABR for patients declining surgery, or 
borderline operative candidates, modern cohorts receiving SABR are fit with longer life 
expectancies. As a result, surgical or nonsurgical salvage opportunities are available if 
failure occurs [53, 54, 85].  
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1.7.1 Response Evaluation Criteria in Solid Tumours 
 Response Evaluation Criteria in Solid Tumours (RECIST) is the standard measure 
of imaging response in oncology. RECIST, first published in 2000, have been widely 
adopted by many institutions and provide a clear set of guidelines to perform 
unidimensional measurements for overall evaluation of tumour response. In 2009, the 
RECIST guidelines were updated to version 1.1 [86] and specific criteria are used to 
determine tumour response for a target lesion based on measurement of the sum of 
longest diameters of all target lesions. The baseline sum of longest diameters is used as 
the reference to characterize response. A complete response denotes the disappearance of 
all target lesions. A partial response is at least a 30% decrease in sum of longest diameter 
of the target lesions (reference being the baseline sum of longest diameters). Progressive 
disease is at least 20% increase in sum of longest diameter of the target lesions (reference 
being the smallest sum of longest diameter since treatment has started), or the appearance 
of one or more new lesions. Lastly, stable disease does not have sufficient shrinkage to be 
considered partial response or sufficient increase in size to be considered progressive 
disease (less than 20% increase or less than 30% decrease in diameter of the target 
lesion), again taking as reference the smallest sum of longest diameters since treatment 
has started.  
Response is determined through measurement of the longest diameter of the target 
lesion within the imaging plane (axial for CT imaging). In the event of isotropic 
reconstructions, measurements can be made on the reconstructed images in the non-
imaging planes. However, since not all radiology sites are capable of producing isotropic 
reconstructions, caution must be taken to avoid the undesirable situation in which 
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measurements are taken on different imaging planes at subsequent assessments. It is 
worth noting that for CT scans of the chest, in which typical slice thicknesses of 5 mm 
are used; target lesions should have a minimum size of 10 mm to be considered 
measurable. There are also several other CT image acquisition parameters which should 
be taken into account for consistency when evaluating lesions using RECIST. These 
include anatomic coverage, contrast administration, slice thickness, and reconstruction 
interval which can all impact the evaluation of lesion response [86]. 
1.7.1.1 Limitations of RECIST 
Although RECIST provides a clear set of guidelines for response assessment, they 
have several limitations [87, 88]. Response assessment based on RECIST relies on 
physician measurement of lesion diameter. It was been well-described that variability in 
target lesion diameter exists and this can have an impact on accurately assessing response 
[89-91]. Inter-observer variability is greater than intra-observer variability, and 
measurement differences are greatest when there is an irregular edge or spiculated lesion 
[91]. For consistent measurements, one should consider having a single observer measure 
the target lesion response across the course of follow-up. The limitation of non-
measureable disease in which the lesion diameter is less than 10 mm can be a major 
limitation after SABR for small lung nodules [87]. The requirement that measurements 
be taken in the imaging plane can also be a limitation in the context of post-SABR 
response assessment, since cranio-caudal growth may be a major predictor of recurrence 
and is measured in the sagittal/coronal plane [92]. Re-evaluation of RECIST 1.1 has been 
proposed [93]. 
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In the context of response assessment following SABR, the presence of benign 
fibrotic changes within the high dose region on CT can affect the ability to accurately 
assess response [35]. When measuring the longest axial diameter of post-SABR changes, 
it can be unknown if these changes represent viable tumour cells or benign fibrotic tissue. 
Another limitation of RECIST is in non-spherical lesions which can be difficult to 
measure. This is specifically important in patients treated with SABR as the appearance 
and morphology of post-SABR changes can be quite irregular with pleural attachment (as 
seen in Figure 1-3).This makes accurately determining local lesion response very difficult 
in the light of significant fibrotic changes following SABR. An example of RECIST 
failure in a patient treated with SABR is shown in Figure 1-6.  
 
Figure 1-6: Demonstration of RECIST failure in a patient who received stereotactic 
radiotherapy for stage I NSCLC. Radiation planning scan (A) shows the prescribed dose 
(red; 54 Gy in 3 fractions), 50% of prescribed dose (orange) and 25% of prescribed dose 
(yellow). 3 month scan (B) showed a large area of consolidation meeting RECIST criteria 
for progressive disease, but the patient was observed. Ongoing observation at 6 months 
(C) and 40 months (D) showed development of fibrosis with no progression. 
A DCB
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1.7.2 High-Risk CT Features (HRFs) 
 A series of HRFs on CT imaging have been identified for detection of local 
recurrence following SABR. These include the presence of an enlarging opacity, 
enlargement after one year, sequential enlargement from one scan to the next, bulging 
margin, linear margin disappearance, and air bronchogram loss [94]. These HRFs were 
identified based on a systematic review of the literature and then validated in a blinded 
study of patients with pathologic proof of recurrence [92]. Patients with recurrence were 
matched 1:2 to patients without local recurrence according to baseline factors. A new 
HRF of cranio-caudal growth was identified in this cohort. All HRFs were significantly 
associated with local recurrence and the odds of recurrence increased 4-fold for each 
additional HRF [92]. A recent validation of these features was performed on an 
independent patient cohort and demonstrated a bulging margin, linear margin 
disappearance and craniocaudal growth as the best predictors (Table 1-1) [95]. 
Combining HRFs was also shown to increase sensitivities and specificities over number 
of HRFs.  
However, not all studies have found all HRFs to be useful. A study by Halpenny 
et al. examined the predictive value of qualitative CT features for predicting local 
recurrence following SABR. Eight patients with local recurrence and 83 patients without 
local recurrence were evaluated for the following signs of local recurrence on CT: a new 
bulging margin, opacification of air bronchograms, a new or enlarging pleural effusion, a 
new or enlarging mass, or increased in lung density in the irradiated field. They found 
that the only feature significantly associated with local recurrence was a new bulging 
margin at the treatment site [96].  
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The use of HRFs is subject to limitations. Early detection of local recurrence is 
difficult, as many require sequential assessments (i.e. sequential enlargement, loss of air 
bronchograms, loss of linear margin) and may vary depending on frequency of scanning. 
One HRF cannot be detected until more than a year following treatment. Inter- and intra-
observer variability in detecting HRFs is not well-established.  
Table 1-1: High-risk features for recurrence prediction on computed tomography (CT) 
imaging. 
High-risk feature 
Sensitivity (%) Specificity (%) 
Huang et al. 
[92] 
Peulen et al. 
[95] 
Huang et al. 
[92] 
Peulen et al. 
[95]  
Enlarging opacity at 
primary site 92 100 67 31 
Sequential enlargement 67 62 100 77 
Enlargement after 12 
months 100 92 83 50 
Bulging margin 83 85 83 100 
Linear margin 
disappearance 42 85 100 100 
Loss air bronchogram 67 15 96 100 
Cranio-caudal growth of ≥ 5 
mm and  ≥ 20% 92 100 83 50 
 
1.7.3  Positron Emission Tomography 
 The increased opacity on CT is occasionally found with a corresponding increase 
in metabolic activity on functional imaging in the months following SABR [66, 67]. The 
use of FDG-PET in the context of response assessment post-SABR has been well studied; 
however, the data are quite heterogeneous [97-100]. Some studies have shown that the 
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maximum standardized uptake value (SUVmax) [101-104] and residual SUV uptake 12 
weeks post-treatment [105] are strong predictors of local recurrence. Additional work has 
found that a pre-treatment SUVmax ≥ 5, post-treatment SUVmax ≥ 2 or a reduction in 
SUVmax < 2.55 were associated with a higher risk of distant failure [106]. Although 
optimal SUV cutoffs vary across studies, a SUVmax > 5, or greater than the pre-
treatment value, appears to be most indicative of recurrence [94, 98, 103-105]. However, 
many of these studies are subject to type I errors, as multiple SUV cutoffs were assessed 
for statistical significance. 
 A major limitation of PET is that inflammatory reaction in areas of the lung 
receiving high doses from SABR can result in elevated uptake on PET imaging, resulting 
in false positive findings [107, 108]. These metabolically active FDG-avid lesions may 
rise transiently immediately post-SABR and persist after 12 months [107-109]. False-
positive PET SUVmax readings as high as 7.0 have been reported [64, 110].  
 Another limitation of the use of FDG-PET imaging is in regard to the 
standardization of image acquisition across scanners and institutions, which must be 
considered in the context of these studies [111]. PET is also more costly than standard CT 
imaging and may not be a routine post-treatment investigation at some institutions. Lack 
of PET/CT standardization can be an important confounder: measured SUVs can be 
affected by multiple factors, including technical, physical, and biologic [111]. In order to 
generalize PET/CT findings, minimum performance or harmonizing standards are needed 
for many factors including uptake period, patient motion, inflammation, blood glucose 
level correction, as well as scan acquisition and reconstruction parameters.   
  
23 
 A systematic workflow for imaging follow-up post-SABR has been published 
based on HRFs and SUVmax on PET imaging [92]. This workflow classifies patients as 
having a low, intermediate, or high risk of recurrence. A more rigorous follow-up might 
be indicated in patients with a higher likelihood of disease recurrence, including those 
patients with larger tumours or sub-optimal radiation doses [112, 113]. As more data 
become available in the management of patients following SABR, applicability of this 
follow-up recommendation is expected to change.  
1.7.4 Other Novel Imaging Methods 
Novel imaging modalities may allow for better assessment of treatment responses 
following SABR.  In addition to standard FDG-PET reporting SUVmax values, functional 
imaging with additional metrics such as metabolic tumour burden markers may show 
improvement for assessing response. Preliminary studies have investigated using pre-
treatment measures such as metabolic tumour volume and total lesion glycolysis for 
assessing clinical outcomes after SABR, however further studies with larger samples and 
follow-up periods are needed [114]. Additional PET tracers such as 18-fluoroazomycin-
arabinoside (FAZA) and 18F-fluoromisonidazole (F-MISO) are used for imaging 
hypoxia in head and neck cancers [115, 116] and could also be investigated for assessing 
response following hypofractionated radiotherapy.  
Perfusion imaging, such as dynamic-contrast-enhanced (DCE) CT or magnetic 
resonance imaging (MRI) characterizes vascular properties of a tissue and can 
quantitatively map their spatial distributions. Measures such as blood volume, blood 
flow, permeability, and mean transit time can be calculated after administration of a 
contrast agent. Both DCE-CT and DCE-MRI have shown promise as prognostic or 
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predictive biomarkers in oncology, and their value in assessing response after SABR 
warrants investigation [114, 117, 118]. CT perfusion imaging has been investigated for 
response assessment in pulmonary metastases treated with SABR [119]. Although 
changes in perfusion data were not statistically significant, a qualitative trend consisting 
of an early increase followed by a decrease in tumour perfusion was noted. Validation on 
a larger data set is required to determine the role of CT perfusion in response assessment 
post-SABR. Enhancement patterns have also been investigated following SABR and 
have shown that patients with recurrence showed a more rapid wash-in and wash-out 
phenomenon, compared to the continuous enhancement observed in RILI [120]. 
1.7.5 Limitations of Current Studies Assessing Response Post-SABR 
Several potential pitfalls must be considered when evaluating novel imaging 
modalities for response assessment. First, the gold-standard definition of “recurrence” 
varies across studies, and many studies use imaging-based definitions of recurrence, 
rather than pathologic confirmation. Such imaging-based definitions of the endpoint may 
introduce substantial bias and create a self-fulfilling prophesy: if imaging features are 
used to define “recurrence” (e.g. sequential growth of lesion) and then the same features 
are assessed to predict these “recurrences”, their performance may be artificially inflated.  
The majority of studies include only a small number of biopsy-proven recurrences, and 
with remainder of patients defined as recurrence an increase in tumour size on successive 
CT scans [98, 102, 105].  Many also use a modified progression criterion of two 
consecutive enlargements on CT to define recurrence, therefore suggesting the difficulty 
in response assessment at an early time point and that the usefulness of PET is limited. 
Since recurrences are uncommon after SABR, large databases are required to have 
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sufficient events for analysis, and any new promising markers require robust external 
validation, since the chances of type I error are high when multiple features are being 
assessed. Variations in standardization of imaging protocols in both CT and PET studies 
must assessed for their impact of predictive ability. Finally, post-SABR surgical studies, 
including registration of digitized histology to CT, would be valuable for correlating 
imaging findings at the voxel level with true pathologic outcome. 
1.8 Radiomics  
In contrast to qualitative image assessment, quantitative image feature analysis 
extracts measurable information from within an image, such as intensities or densities, 
shape or morphology, or texture. Radiomics is an emerging area of study which aims to 
extract more information from medical images [121, 122]. The use of radiomics and 
texture analysis in oncology, and specifically radiation oncology, has been rapidly 
expanding over the past decade to quantify tumour heterogeneity and predict response 
[123]. The goal of radiomics is to potentially tailor a patient’s radiotherapy treatment 
based on predicted response on pre-treatment imaging, or to detect treatment failure at an 
earlier time point post-treatment [124]. Radiomics look to quantify tumour phenotypes 
based on a large number of quantitative image features [125]. This can involve the 
extraction of quantitative image features from regions of interest on either pre- or post-
treatment images.  
Image feature analysis has emerging roles in general medicine and oncology. 
Numerous imaging modalities can be used for quantitative image analysis at different 
body sites, including CT, MRI, ultrasound, and mammography [126, 127]. Applications 
in oncology include the computer-aided detection or diagnosis of diseases such as breast 
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and bladder cancer [126, 127].  Texture analysis of the liver has suggested that texture 
parameters may distinguish high-risk from low-risk colorectal cancer patients [128]. 
Texture analysis on MRI, CT, and PET has been able to diagnose and characterize 
tumour heterogeneity for several tumour types and is showing promise in response 
assessment and as a predictive biomarker [129, 130].  In the thorax, the use of 
quantitative image feature analysis on CT has been widely investigated in many benign 
diseases, including characterizing pulmonary infections as well as varying benign lung 
disease patterns [131-133].  Texture analysis, specifically the product of tumour 
uniformity and gray-level, has also been correlated with tumour response following 
chemotherapy in advanced stage NSCLC [134]. The use of CT texture analysis has also 
been applied to quantify radiation-induced lung damage. Predictive modelling of 
radiation pneumonitis using texture analysis on CT has been studied following definitive 
radiation for lung and esophageal cancer [135, 136].  Future work integrating radiomics 
and genomics (radiogenomics) could aid in characterizing tumour phenotypes and 
genotypes to associate with outcomes [137]. Many studies have demonstrated the 
potential of radiomic features to provide additional tumour phenotypic information that 
may not be visible to the human eye. This information may augment standard clinical or 
genomic information to provide a more comprehensive analysis of the disease as a whole. 
1.8.1 Workflow 
An overview of a standard radiomic workflow is shown in Figure 1-1. Following 
image acquisition, a region of interest (ROI) is defined and within it a series of radiomic 
image features can be calculated [125]. Following feature extraction, feature selection 
can be performed to obtain the optimal set of radiomic features. Machine learning using 
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unsupervised or supervised analysis options, is then performed to summarize information 
on the data or to build models to predict outcomes or a response variable [138]. 
 
Figure 1-7: Radiomics involves image acquisition and region of interest delineation. An 
example CT image and corresponding region of interest are shown in red. Within the 
region of interest several image features can be extracted, including first-order statistics, 
second-order texture and size and shape-based features. These features can be used to 
predict patient outcomes. 
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1.8.1.1 Segmentation 
Radiomic analysis can be performed on any ROI, such as tumour, normal lung, or 
fibrotic regions; such ROIs can be selected by means of manual, semi-automated, or 
fully-automated methods. A manual method involves delineation of an ROI by an 
investigator on each individual slice using imaging software. Manual methods do not 
require specialized algorithms, but can be tedious and time consuming, and are subject to 
intra- and inter-observer variability [139]. A semi-automated method requires a smaller 
amount of user input, and may require a user to initialize the segmentation by selecting a 
point or region of interest. A fully automated approach requires no user interaction or 
input and the image is automatically segmented based on a series of predetermined 
parameters. This makes a fully automated approach quick and reproducible; however the 
lack of user input or knowledge can be an issue in terms of the reliability. Therefore, 
semi-automated approaches to segmentation have become increasingly popular as they 
are reproducible, fast, and require minimal user input or knowledge [140].  
Several algorithms exist for semi-automated and fully automated segmentations 
[141]. In general, segmentation algorithms can be separated into two main categories: 
low-level and model-based methods. Low-level methods perform the segmentation 
exclusively based on features in the image. Model-based methods allow for high-level 
knowledge about the region of interest to be incorporated into the algorithm, including 
boundary smoothness, appearance, or shape information. The choice of image 
segmentation algorithm relies on the specific imaging modality being used as well as 
characteristics of the region to be segmented [142]. 
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Low-level methods include thresholding, clustering methods, and region-growing 
techniques. The simplest method is thresholding which relies on the selection of a 
threshold value to convert a grey-scale image into a binary image. Although this is a 
simple and fast segmentation technique, in some cases selection of the optimal threshold 
is done manually and this technique does not guarantee object coherency, therefore post-
processing may needed. However more advanced thresholding techniques including 
Otsu’s method have been developed to select the optimal value by minimizing the 
variance between regions [143]. Clustering methods partition an image into a specified 
number of clusters according to similar grey-levels. The k-means clustering algorithm is 
the most common and allows for image segmentation into multiple classes by computing 
a mean intensity for each class [144]. Region-growing methods work by comparing each 
pixel with its neighbours and they assume that neighbouring pixels within one region 
have similar values [145]. In seeded region growing, initialization of the segmentation 
requires the selection of seeds to mark the object to be segmented. This technique is good 
for regions with clear edges, however it can be sensitive to image noise, seed point 
selection and segmentation parameters [146].  
Model-based methods can include parametric deformable models and level set 
algorithms. To achieve the desired segmentation result, parametric deformable models 
are initialized with a measure of curvature and a contour surrounding the region of 
interest that is represented parametrically [147]. The algorithm is evolved to minimize an 
energy/objective function according to image (e.g. edges) and internal (e.g. curvature) 
terms. These techniques can automatically search for the minimum state and are 
advantageous as they can incorporate curvature characteristics; however they do require 
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manual interaction to initialize the model and parameters and can be sensitive to the 
convergence criteria and local minima [141]. Another limitation of parametric 
deformable models is their inability to evolve and split into multiple curves to segment 
multiple disjointed regions of interest. Level set methods address this issue by 
representing the boundary implicitly. The level set is represented using a signed distance 
function where zero is the actual contour [148]. Level sets can account for different 
topologies and provide a direct way to estimate the geometric properties of the structure. 
Another class of segmentation methods includes graph partitioning methods 
[149]. These methods involve having a pixel or group of pixels associated with nodes and 
edge weights to define similarity between neighbouring pixels. The graph, or image, is 
then segmented according to different criterion to model specific clusters. Graphs are 
typically partitioned by finding the minimum cut, by either cutting the minimum number 
of edges or so that the sum of the cut edges is as small as possible based on a specified 
cost function [150]. Boykov and Jolly introduced an interactive graph cuts based 
segmentation for binary image segmentation by minimizing an energy function based on 
user defined foreground and background samples [151]. Graph cut segmentations can be 
biased towards producing small contours since it aims to find the minimum cut in the 
graph. They are also limited to binary segmentations problems: foreground versus 
background image segmentation. However, it is computationally fast, can be optimized 
for 3D images, and can achieve a globally optimal solution. Several methods exist for 
trying to optimize for graph construction, criterion for graph partitioning, and efficient 
partitioning [152]. 
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1.8.1.2 Feature Extraction 
Following region of interest segmentation, qualitative or semantic features of the 
region of interest can be developed and characterized by expert observers. Such features 
could include tumour characteristics such as spiculation or pleural attachment. Radiomic 
image features can be also be extracted from the ROI. These features can include first-
order statistics based on the distribution of the intensity histogram. These features include 
things such as the mean, median, standard deviation, variance, skewness, and kurtosis. 
Intensity refers the brightness of an individual voxel; in CT imaging this can also be 
described as density and is quantified in Hounsfield Units (HU). HUs measure the 
attenuation of a material relative to water (HU=0).  
CT image texture is a set of more complex measurements which describe local 
brightness variation or the spatial arrangement of intensities in an image [153, 154]. 
Second-order texture features take into account the neighbouring relationships of voxels 
within the region of interest. Extraction of second and third-order texture features can be 
performed in many ways, including statistical methods, structural methods, model-based 
methods, and transform-based methods [155]. Statistical texture analysis is the most 
frequently cited method of texture analysis. This approach describes texture through 
high-order statistics of an image intensity histogram [155]. These features can include 
grey-level co-occurrence matrix (GLCM) texture features as well as grey-level run length 
matrix (GRLM) texture features [156-159]. GLCM features are analyzed by assessing 
neighbouring voxel pairs; however it can be done with multiple spatial directions and 
distances. GLRM texture features assess grey-level run lengths in an image which are 
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defined as consecutive pixels with a specific grey-level. These features are also 
calculated for a specified spatial direction from a pixel of interest. 
Structured approaches obtain descriptions of the spatial relationships of textures 
through Voronoi tessellation [160]. Model based texture analysis generate an empirical 
model of each pixel in the image based on neighbouring pixel intensities, and include 
Markov random fields and fractal models [155]. Transform based texture analysis 
techniques convert the image into a new form based on the spatial frequency information 
regarding pixel intensity variations. A common method in radiomics is the use of wavelet 
features, in which the image is transformed into low and high frequency domains, similar 
to Fourier analysis, and texture is then calculated on the transformed images [125].   
Size and shape based features of the region can also be calculated. Size can be 
quantified by measures such as longest axial diameter, 3D volume, and surface area 
[161]. The shape or morphology of a region describes the geometry of the external 
boundary. Shape-based features can include sphericity, roughness, or spiculation. More 
advanced quantitative features to characterize shape complexity can also be developed in 
radiomics to correlate with observed qualitative or semantic image features [162].  
1.8.1.3 Machine Learning 
Optimal features or sets of features for predictive or prognostic biomarkers must 
be determined and validated through training and testing on multiple data sets.  This can 
include analyzing individual features alone or a combination of these features together. 
Machine learning refers to algorithms that can learn and make predictions from data and 
operate by building models from inputs to make an output based on predictions or 
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decisions [163]. There are two main types of machine learning: supervised and 
unsupervised machine learning. In unsupervised machine learning, there are no labels on 
the training data and the goal is to discover patterns in the data. On the other hand, 
supervised machine learning is given a set of labels or outputs, and an algorithm tries to 
determine a rule to map the inputs, or features, to the outputs. Machine learning can also 
be classified depending on the desired output of the machine learning tool. Classification 
has a discrete set of labels for the data, for example cancer or non-cancer. In linear 
regression the outputs are continuous, for example likelihood of cancer. Logistic 
regression can also be used for predictive analysis and describes the relationship between 
one dependent binary label and one or more independent variables. 
There are several different classification algorithms which can be used in machine 
learning. Linear classifiers use a linear combination of features to obtain a classification 
decision [164]. Support vector machine (SVM) classifiers are a maximal margin classifier 
which can efficiently perform linear classification. One benefit of SVM classifiers is the 
flexibility to perform non-linear classification. When features are not separable by a 
linear decision surface, a kernel trick can be performed to achieve non-linear 
classification. The kernel trick maps the features into a high-dimensional feature space 
such that is separable by a linear hyperplane.  [165]. Decisions trees are another method 
which can easily visualize and explicitly represent the decision making. Random forests 
use multiple decision trees to improve classification performance [166]. Artificial neural 
networks are based on biological neural networks and are used to model complex 
interactions between inputs and outputs [167]. 
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An emerging area of machine learning is the use of deep learning. Deep learning 
attempts to model high-level abstractions of data based on multiple processing layers 
[168].  Many deep learning approaches are based on neural networks with many 
variations on network architecture to obtain optimal classification performance. A major 
advantage of deep learning is that it can learn the features from the data itself. However, a 
major limitation to deep learning is the requirement for extensive amounts of training 
examples to learn the data. 
Machine learning may also include feature selection in which a subset of relevant 
features are chosen for use in model building.  This is done to remove redundant or 
irrelevant features and to enhance generalizability of the model [169]. There are two main 
classes of feature selection algorithms: filter and wrapper methods [170]. Filter methods 
analyze the intrinsic properties of the data by ranking and selecting a subset of the 
features while ignoring the classifier. These methods are fast and avoid overfitting of the 
data. Unlike filter methods, wrapper methods evaluate the interaction between a subset of 
features and can risk overfitting on the data with a high computation time. Some 
algorithms, including decision trees and random forests, perform feature selection as part 
of their overall classification operation [166]. Due to the large number of features 
available as well as the large number of possible combinations of these features, the high-
risk of type I error must be recognized when comparisons and cross-validations are 
performed.  As a result, initial exploratory studies in radiomics must be considered 
hypothesis-generating, and validation on external datasets is crucial.  
There are several approaches to evaluate classification performance. In a binary 
classification problem, the true positive, true negative, false positive and false negative 
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conditions can all be determined. Based on these values overall accuracy, false positive 
rate, false negative rate, positive predictive value (precision), sensitivity (recall or true 
positive rate), and specificity (true negative rate) can be calculated. To determine the 
trade-off between true and false positive classification, the area under the receiver 
operating characteristic curve (AUC) can also be calculated. The F1 score can also be 
measured to convey the balance between precision and recall.  
1.8.2 Challenges and Limitations 
There are several limitations and challenges when performing radiomic studies 
[121]. In general, image acquisition should be standardized to minimize any variability 
between scanners, imaging parameters, or reconstruction techniques. Standardization 
includes the use of the same scan protocol for imaging acquisition, with consistencies in 
settings such as kV, mAs, slice collimation, and slice thickness. Breathing instructions 
and the use of intravenous contrast should also be consistent across all patients, although 
patients with contra-indications to contrast injection must be noted and studies analyzing 
the effect of contrast on image feature analysis should be performed. Reconstruction 
kernels or filters are used to determine image quality of a CT scan and are chosen based 
on the intended clinical application of the scan.  Such decisions are a compromise 
between spatial resolution and noise, and depending on the organ being scanned, may 
require a smoother image with less noise or a sharper image with higher noise.  
Reconstruction kernels should also be consistent across all images and a higher sharpness 
thorax kernel should be used when available. However, optimal scan parameters and 
reconstruction kernels must be investigated for the effect of variations among these 
settings on quantitative image feature analysis. 
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1.8.3 State of the Art in Lung Cancer Radiomics 
 The work presented in this thesis was one of the first studies to assess the utility 
of quantitative image features for response assessment in lung cancer. A summary of 
other studies using radiomics to assess outcomes and response following lung cancer 
treatment is shown in Table 1-2. One of the first large scale studies determining the 
prognostic power of radiomics was by Aerts et al. [125]. They examined 440 intensity, 
shape, and texture features on CT for predicting outcomes in lung and head and neck 
cancer patients. They demonstrated the association of radiomic features with clinical 
data, including TNM descriptors, stage, and histology. They also showed the association 
of a radiomic signature with overall survival and gene-expression, demonstrating the 
potential of a radiogenomics analysis to associate quantitative image features with 
underlying gene-expression patterns. More recent studies have also evaluated complex 
shape and appearance descriptors to predict overall survival (OS) following lung cancer 
surgery [162]. 
 Additional studies have determined the potential of radiomics on pre-treatment 
CT images to predict outcomes in later stage disease (stage II or III) following 
chemotherapy and radiation therapy [171, 172]. Predictive models incorporating texture 
features and conventional prognostic factors demonstrated a significant improvement for 
predicting overall survival (OS), loco-regional control (LRC) and freedom from distant 
metastases (FFDM) compared to conventional prognostic factors alone [171].  Radiomic 
features were also found to be associated with distant metastasis (DM), which was 
validated in an independent validation set [172]. When combining this radiomic signature 
with a clinical model, prediction of DM was significantly improved, demonstrating the 
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potential of radiomics to provide additional information regarding tumour phenotype 
compared to clinical data alone.  
 For early stage I lung cancers, several studies have investigated the use of pre-
treatment CT radiomic features for predicting recurrence after surgery [173, 174]. 
Emaminejad et al. found that a radiomics and genomic biomarker based classifier could 
predict recurrence after surgery with an area under the receiver operating characteristic 
curve (AUC) values of 0.78 and 0.68 respectively [173]. Combining these two classifiers 
significantly improved performance with an AUC of 0.84. Higher order wavelet features 
and CT intensities of solid and GGO tumour components demonstrated the ability to 
predict tumour recurrence with an AUC of 0.8 [174]. These studies demonstrate the 
potential to assess patients who may be at a higher risk of recurrence pre-treatment to 
facilitate individualized patient care.  
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Table 1-2: A summary of previous studies using radiomics to assess outcomes and 
response following lung cancer treatment. 
Authors Treatment Outcome Modality Stage N Method 
Mattonen et al. 
2013 [175] 
SABR LR 
CT  
(post-tx) 
I 24 Texture 
Mattonen et al. 
2014 [176] 
SABR LR 
CT  
(post-tx) 
I 24 Radiomics 
Mattonen et al. 
2015 [177] 
SABR LR 
CT  
(post-tx) 
I 24 
Radiomics with semi-
automated system 
Mattonen et al. 
2016 [178] 
SABR LR 
CT  
(post-tx) 
I 45 
Physician performance 
vs. Radiomics 
Emaminejad et 
al. 2015 [173] 
Surgery Recurrence CT  
(pre-tx) 
I 79 Radiomics/Genomics 
Depeursinge et 
al. 2015 [174] 
Surgery Recurrence CT  
(pre-tx) 
I 101 Reisz wavelets 
Pyka et al. 2015 
[179] 
SABR LR PET/CT 
(pre-tx) 
I 45 Texture 
Wu et al. 2016 
[180] 
SABR DM PET/CT 
(pre-tx) 
I 101 Radiomics 
Aerts et al. 2014 
[125] 
RT & 
ChemoRT 
OS CT 
(pre-tx) 
I-IV 1019 Radiomics 
Fried et al. 2014 
[171] 
ChemoRT OS, LRC, 
FFDM 
CT 
(pre-tx) 
III 91 Texture 
Coroller et al. 
2015 [172] 
ChemoRT DM CT 
(pre-tx) 
II-III 182 Radiomics 
Grove et al. 
2015 [162] 
Surgery OS CT 
(pre-tx) 
I-IV 108 Tumour shape and 
heterogeneity 
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LR = local recurrence, DM = distant metastases, FFDM = freedom from distant 
metastases, OS = overall survival, LRC = loco-regional control, N = number of patients. 
 
 The use of radiomics to quantify the appearance of FDG-PET SUV changes can 
also be performed [179, 180]. This may be an important area of study to determine 
regional variations in SUV uptake pre- or post-treatment. A study by Pyka et al. 
evaluated the use of second-order GLCM texture features on pre-treatment FDG-PET 
images for predicting local recurrence following SABR for 45 patients with early-stage 
lung cancer [179]. They found that the entropy texture feature demonstrated an AUC of 
0.87. Wu et al. analyzed 101 patients treated with SABR and found radiomic features on 
pre-treatment PET were associated with DM [180]. These techniques may be valuable for 
predicting outcomes in this patient population following SABR treatment. However, all 
of these studies need to ensure standardization of methodology as discretization of SUV 
values can have a major impact on the resultant texture features [181].  
1.9 Thesis Hypothesis and Objectives 
 SABR has been shown to be to surgery for the treatment of patients with early-
stage NSCLC. However, the presence of benign radiographic changes on post-SABR CT 
can occur and appear with similar shape and size to a recurring tumour. Being able to 
differentiate benign fibrotic changes from local tumour recurrence remains a major 
clinical challenge for timely response assessment following SABR. There is currently a 
great unmet clinical need to provide timely and accurate assessment of response 
following SABR for early stage NSCLC. Therefore, a reliable measure of recurrence on 
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CT imaging is critically needed, as the utilization of SABR is rapidly increasing and CT 
imaging remains the standard measure of imaging follow-up for these patients.  
There are several advantages to the use of CT, rather than routine functional 
imaging, in assessment of response post-SABR. In contrast to FDG-PET imaging, CT is 
more accessible and inexpensive, does not rely on isotopes with short half-lives, and is 
already part of standard-of-care follow-up for patients who have received curative 
treatment for early-stage lung cancer, and who are eligible for salvage. Importantly, 
standardization of CT across centres is much less complex than standardization of 
PET/CT.  Standard machine settings and reconstruction algorithms are widely available 
for CT imaging of the chest, increasing the generalizability of any follow-up 
recommendations. As such, new algorithms for early detection of recurrence based on 
standard-of-care CT imaging could be easily integrated into current clinical practice. 
However, novel imaging techniques must move beyond qualitative image analysis and 
simple RECIST measurements.  
Quantitative image analysis allows for maximal information to be obtained from 
images already being performed in clinical practice, and can easily be translated into a 
useful clinical tool to aid in outcome prediction and treatment response assessment. 
Radiomics on pre-treatment imaging has demonstrated the potential to predict outcomes 
in all stages of lung cancer. To the best of our knowledge, there has been no previous 
work using radiomics to predict response using follow-up CT imaging. Physicians 
currently rely on qualitative image analysis to try to distinguish patients with recurrence 
from those with only benign injury, and typically rely on features of an enlarging mass. 
No prior studies have assessed physician performance or inter-physician variability and 
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reliability in detecting recurrence after SABR. We conjecture that post-SABR 
radiological changes can be quantified through the use of a radiomic software system to 
aid in response assessment after treatment. 
To address the unmet clinical need to provide timely and accurate assessment of 
response following SABR for early stage NSCLC, the overarching objective of this thesis 
is to develop a radiomic software system to aid in treatment response assessment on 
follow-up CT after SABR. This objective will be evaluated by testing the following 
central hypothesis; a radiomic software system will outperform physicians in the early 
assessment of response post-SABR. To test the central hypothesis, this thesis has the 
following four aims: 
1) To determine group differences in radiomic features between patients with 
recurrence and benign injury. 
2) To develop a radiomics system to predict recurrence in individual patients. 
3) To develop a semi-automated segmentation system to predict recurrence in 
individual patients. 
4) To compare a radiomics decision support system to physician performance. 
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1.10 Thesis Outline 
1.10.1 Chapter 2: Distinguishing radiation fibrosis from tumour 
recurrence after SABR for lung cancer: a quantitative analysis of 
CT density changes 
This work was a hypothesis generating study to determine if quantitative image 
feature analysis could be used for distinguishing groups of patients with and without local 
recurrence following SABR. Quantitative image features were extracted from manually 
delineated regions of common post-SABR changes; consolidation and GGO. This will 
allow us to assess the potential for quantitative image appearance features to provide 
additional information over traditional size measurements. This could allow for 
quantitative appearance features to be used in a decision support tool for aiding in 
response assessment post-SABR. We hypothesized that there would be quantitative 
differences in appearance features between recurrence and benign fibrosis patient groups. 
1.10.2 Chapter 3: Early prediction of tumour recurrence based on CT 
texture changes after SABR for lung cancer 
The objective of this work was to evaluate quantitative image feature analysis and 
machine learning techniques for predicting local recurrence in individual patients 
following SABR. A more comprehensive set of first- and second-order image features 
was extracted from regions of post-SABR changes and machine learning was performed 
to evaluate classification performance. We wanted to work towards the goal of 
understanding if second-order quantitative image features can predict local recurrence in 
individual patients within 6 months of SABR treatment. We also aimed to assess the 
impact of variations in manual segmentation boundaries on classification performance 
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and compare the quantitative appearance features to traditional measure of response post-
SABR. We hypothesized that quantitative appearance features can predict recurrence 
within 6 months of SABR with accuracies greater than 75%.  
1.10.3 Chapter 4: Imaging texture analysis for automated prediction of 
lung cancer recurrence after stereotactic radiotherapy 
The objective of this work was to develop and evaluate a semi-automated graph 
cuts based approach to segment and sample regions of post-SABR radiological changes. 
The work in Chapters 2 and 3 relied on manual delineations of post-SABR radiological 
changes on CT which are time consuming and subject to operator variability. We look to 
determine if semi-automated segmentation methods can decrease segmentation time and 
produce consistent segmentations between operators. In addition to developing a semi-
automated segmentation approach, we wanted to determine if this system can be used 
with the radiomic decision support system to predict local recurrence following SABR. 
We hypothesized that a semi-automated segmentation algorithm could demonstrate 
consistent segmentations and prediction accuracies between operators, with non-
inferiority to manual segmentations. 
1.10.4 Chapter 5: Detection of local cancer recurrence after SABR for 
lung cancer: physician performance versus radiomic assessment 
The objective of this work was to perform an observer study to assess how well 
physicians can distinguish between benign fibrosis and local recurrence on follow-up CT 
after SABR. This would allow for a basis of comparison for our radiomics system and 
allow us to move towards the goal of understanding how physicians perform in response 
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assessment post-SABR. To the best of our knowledge, there has been no study to date 
assessing a physician’s performance in distinguishing fibrosis from recurrence following 
SABR for lung cancer. An additional objective of this work was to develop and evaluate 
a multi-feature radiomic signature to predict local recurrence following SABR. In this 
chapter we compared our radiomic signature to physician performance for the early 
prediction of recurrence within 6 months of treatment. We hypothesized that a radiomic 
software system will outperform physicians in the early assessment of response post-
SABR.  
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Chapter 2  
Towards the goal of understanding the quantitative image features between benign 
radiation induced lung injury and local recurrence, we evaluated quantitative image 
feature analysis for distinguishing groups of patients with and without local recurrence 
following SABR. 
The contents of this chapter were previously published in the journal Acta Oncologica: 
SA Mattonen, DA Palma, CJ Haasbeek, S Senan, and AD Ward. Distinguishing radiation 
fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung 
cancer: A quantitative analysis of CT density changes. Acta Oncol 2013; 52:910–918; 
http://dx.doi.org/10.3109/0284186X.2012.731525. Permission to reproduce this article 
was granted by Taylor & Francis Group and is provided in Appendix A.3. 
 DISTINGUISHING RADIATION FIBROSIS FROM 2
TUMOUR RECURRENCE AFTER SABR FOR LUNG 
CANCER: A QUANTITATIVE ANALYSIS OF CT 
DENSITY CHANGES 
2.1 Introduction 
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body 
radiotherapy (SBRT), employs image guidance and precise treatment delivery to deliver a 
high dose of radiation to tumours while sparing surrounding normal tissue [1]. 
Treatments are typically delivered with high doses per fraction, over 3-8 fractions [2]. 
SABR is becoming a standard treatment option for stage I non-small cell lung cancer 
(NSCLC) patients who are medically inoperable or refuse surgery [2, 3]. Following lung 
radiotherapy, radiation-induced lung injury (RILI) can occur in the acute phase (within 6 
months) as radiation pneumonitis and in the late phase (after 6 months) as fibrosis [4]. 
With SABR, the incidence of acute- and late-onset RILI is high: 54-79% of patients 
develop acute benign CT changes, and 80-100% of patients develop late changes [5]. 
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 With older radiotherapy techniques,  benign computed tomography (CT) changes 
typically follow the edges of the treatment fields, consisting of straight borders and 
allowing for easier diagnosis of RILI [4]. Due to the high doses delivered and steep dose 
gradients with SABR, as well as the 3D conformity of the treated region to the 
morphology of the target, benign CT changes are common and can mimic tumour 
recurrence, especially when they develop as mass-like patterns [5, 6]. Therefore, 
distinguishing between benign fibrosis and recurrence becomes of major importance in 
identifying patients who are candidates for salvage treatment [7]. Misclassification of 
injury as recurrence can cause patients to undergo unnecessary investigations and 
interventions for no oncologic benefit. Conversely, misclassification of recurrence as 
injury can result in a missed opportunity for salvage [6]. 
   18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging has 
been investigated to detect recurrence, but has several limitations: hypermetabolic 
activity has been observed in benign SABR-treated lesions [8], optimal SUV cut-offs 
have not been defined, and repeated PET scanning of all SABR patients would be costly. 
A biopsy can be considered for a definite diagnosis of recurrence; however, high risks of 
complications such as pneumonthorax (~20%) and hemoptysis (5-10%) prevent it from 
being a first line tool for differentiating fibrosis from recurrence [9]. As a result, better 
methods are needed to aid in distinguishing RILI from recurrence. A reliable measure of 
recurrence on CT imaging would be a valuable clinical tool, as the utilization of SABR 
for early stage lung cancer is increasing [10], and CT scanning is the standard measure of 
imaging follow-up for SABR patients [11]. 
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 The goal of this study is to measure the utility of CT image feature analysis in 
differentiating RILI from recurrence, when compared to Response Evaluation Criteria in 
Solid Tumours (RECIST) measurements, which is the standard method used for response 
assessment in trials of oncology [12]. Specifically, this study compares the imaging 
characteristics of CT density, texture and 3D volume of contoured regions of interest: 
consolidative regions (increased density with no visibility of vessels) and ground-glass 
opacity (GGO: an increase in normal lung parenchyma density but with visibility of 
vessels). Analysis was completed on planning and follow-up CT images, and determines 
which measures may provide the earliest differentiation of local recurrence from injury. 
2.2 Methods and Materials 
2.2.1 Patient Selection and Treatment 
A total of 22 patients with 24 tumours treated with SABR for Stage I NSCLC at 
the VU University Medical Center between February 2004 and February 2010 were 
selected for this study. Patients without recurrence were selected from a previous study 
[13] based on presence of CT findings of moderate/severe fibrosis that were ultimately 
found to be benign. Of the 24 lesions, 13 developed only benign RILI, and 11 developed 
recurrence. Of the latter, pathological evidence of recurrence was available in 8 of 11 
lesions; the other 3 were deemed to be recurrences based on sequential imaging findings 
and multidisciplinary group consensus, as biopsy was not feasible. One patient had 2 
treated lesions in close proximity; these were considered as a single lesion for analysis as 
the post-SABR CT changes spanned the location of both lesions.  
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All patients were treated with SABR using a risk-adapted fractionation scheme as 
previously described [13-15]. Briefly, patients were treated with one of three 
fractionation regimens: 60 Gy in 3 fractions for T1 tumours surrounded by lung 
parenchyma; 60 Gy in 5 fractions for T2 tumours or those in broad contact with the chest 
wall; and 60 Gy in 8 fractions for tumours within 2 cm of the mediastinum or close to the 
brachial plexus. For 3D-conformal treatments, done using 9-11 fixed beams, planning 
was completed using BrainLab software (Brainscan version 5.2; BrainLab Inc., 
Feldkirchen, Germany) and a pencil beam dose calculation algorithm. For those patients 
treated with volumetric modulated arc therapy (VMAT) using RapidArc (Varian Medical 
Systems, Palo Alto, USA), the anisotropic analytical algorithm (AAA) was used for dose 
calculations. With the latter, the prescribed doses for the 3- and 5- fraction regimens were 
54 Gy and 55 Gy respectively, due to differences in dose calculation with the more 
advanced algorithm. Follow-up was routinely conducted with a diagnostic CT scan 
approximately 3, 6, and 12 months post treatment and every 6-12 months thereafter.  
2.2.2 Contours 
All pre-treatment and follow-up scans were manually contoured on every axial 
slice using a lung window setting (window width of 1500 HU and window level of -600 
HU). For tumours or fibrosis abutting the mediastinum, a mediastinal window setting 
(window width of 350 HU and window level of 40 HU) was also used. All contours were 
completed using ITK-SNAP [16] (Version 2.2.0). Two regions were contoured in the 
follow-up scans based on the patterns of post-SABR CT changes which have been well 
described [13, 15, 17]. The first, containing consolidative changes around the treatment 
site, was defined as a region of increased density with no visibility of vessels. The 
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second, containing ground glass opacities (GGO), was defined as an increase in normal 
lung parenchyma density but with visibility of vessels [18]. Figure 2-1 shows an example 
of the contours created for a single subject throughout the course of follow-up post-
SABR. All contours were completed by a single investigator (SAM) and subsequently 
edited and approved by a thoracic radiation oncologist (DAP). Further details pertaining 
to image acquisition and analysis are outlined in Appendix B.  
 Inter- and intra-observer variability has been reported in contouring of lung 
tumours [19]. To simulate the effect of contouring variability, we implemented computer 
software to expand and contract the contour borders by 1 mm in the axial plane, and 
determined the effect of the expansion and contraction on the mean differences measured 
between patients with RILI and recurrence. At the earliest significant time point for both 
the consolidative and GGO regions, we expanded and contracted the borders by 1 mm 
and recalculated our results. 
 
Figure 2-1: Manual contours throughout a course of follow-up for a patient whose cancer 
recurred.  The solid lines represent consolidative changes, and the dashed lines represent 
ground-glass opacity (GGO). 
0m +4m +8m +14m +27m+24m
  
67 
2.2.3 Data Analysis 
Four measures were calculated for the contoured regions: (1) mean 3D volume, 
(2) mean CT density, (3) standard deviation of CT density, and (4) mean RECIST 
measurements. RECIST measurements were taken for only the solid consolidative areas 
according to RECIST 1.1. MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA) was 
used in the calculation of the 3D volume and CT densities of the contoured regions. The 
standard deviation (SD) of CT density was used as a basic texture metric, where larger 
standard deviations correspond to more variegated image textures within the contoured 
regions. Figure 2-2 shows an example of this image texture measure for three sample 
image regions containing increasingly variegated texture, with the corresponding 
standard deviations shown in HU. 
 
Figure 2-2: The standard deviation (SD) of CT density was used as a basic texture 
measure.  Three examples from GGO regions of patients in this study, showing the 
differences in texture with the varying SDs: a) 50.1 HU, b) 85.8 HU, c) 123.4 HU 
 
 For each lesion, the measures were analyzed cumulatively throughout the course 
of follow-up up to a specified time point. This resulted in a mean RECIST size, mean 3D 
volume, mean CT density, and standard deviation of CT density for each lesion over each 
specified follow-up time interval. The time points we used for analysis were every 3 
 (a) (b) (c) 
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months up to 2 years, then yearly thereafter. These time points were more frequent that 
the regular follow-up scan intervals as there is occasionally some variability in CT scan 
timing due to individual patient scheduling and potentially due to clinical indications. 
The end date of treatment was considered day 0 of follow-up. Differences between 
groups were assessed using an independent samples t-test with unequal variances in 
MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA). All statistical tests were two-
sided with p ≤ 0.05 indicative of statistical significance.   
2.3 Results 
A total of 136 CT scans were reviewed with a median imaging follow-up of 26 
months (range: 6 - 44 months). The mean number of scans per patient was 6 (range 2-8); 
patients with recurrence had a mean of 4 follow-up scans, and patients without recurrence 
had a mean of 6 follow-up scans. Baseline patient and treatment variables are shown in 
Table 2-1. We observed that over 50% of tumours were found in the upper lobe, which is 
consistent with epidemiologic studies of lung cancer [20]. Three patients developed 
clinical grade 3 pneumonitis, and no grade 4 or 5 thoracic clinical toxicity was observed 
in this patient cohort. All patients without recurrence had a minimum follow-up of 2 
years. 
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Table 2-1: Baseline patient and treatment variables. 
 Total (n=22 patients, with 24 tumours) 
Median (range) or Number (%) 
Age (n=22) 69 (49-84) 
Gender (n=22)  
Male   14 (63.6%) 
Female 8 (36.4%) 
Charlson Score* (n=22) 5 (1-10) 
Planning target volume (n=24) 20.4 cc (4.5-144.4 cc) 
Fractionation schedule (n=24)  
3 x 20 Gy 14 (58.3%) 
5 x 11 Gy 1 (4.2%) 
5 x 12 Gy 4 (16.7%) 
8 x 7.5 Gy 5 (20.8%) 
Treatment type (n=24)  
Fixed beam 21 (87.5%) 
RapidArc 3 (12.5%) 
Tumour location (n=24)  
Left upper lobe 4 (16.7%) 
Left lower lobe 2 (8.3%) 
Right upper lobe 10 (41.7%) 
Right middle lobe 3 (12.5%) 
Right lower lobe 5 (20.8%) 
*age adjusted Charlson, current lung cancer not scored as comorbidity. 
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2.3.1 Pre-treatment lesions 
Table 2-2 shows the baseline pre-treatment imaging characteristics for patients 
with recurrence and RILI. No significant differences were observed at baseline in mean 
CT density, volume, or RECIST size, comparing lesions of patients whom would later 
develop recurrence versus those with RILI. Since GGO was not contoured on the pre-
treatment scan, the standard deviation of CT density was not included in the 
aforementioned table. 
Table 2-2: Baseline pre-treatment imaging characteristics. 
 Recurrence 
Mean ± 95% CI 
Benign Fibrosis 
Mean ± 95% CI 
Pre-treatment CT Density 
(p=.434) 
-104.8 ± 34.40 HU -124.6 ± 34.43 HU 
Pre-treatment RECIST  
(p=.052) 
3.55 ± 1.01 cm 2.36 ± 0.43 cm 
Pre-treatment 3D Volume 
(p=.096) 
22.29 ± 16.27 cc 6.67 ± 4.66 cc 
 
2.3.2 Post-SABR Measures of Size 
A significant difference in RECIST measurements was detected between patients 
with recurrence vs. those with RILI as early as 15 months post-treatment (p=0.028). 
Patients with recurrence had a mean cumulative RECIST [± 95% CI] of the consolidative 
changes at 15 months of 4.34 ± 1.13 cm versus 2.63 ± 0.84 cm for patients with benign 
RILI.   
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Patients with recurrence had significantly larger solid consolidative changes as 
measured with 3D volume, detected as early as 15 months post-treatment compared to 
patients with RILI (mean at 15 months [± 95% CI] of 30.1 ± 19.3 cc vs. 5.1 ± 3.6 cc, 
respectively; p=0.030). No significant difference was observed in the 3D volumes of the 
GGO regions. Figure 2-3 shows the significant measures of size (both RECIST and 3D 
volume measurements) of the consolidative regions for patients with recurrence and 
RILI, during the course of follow-up post-SABR. 
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Figure 2-3: Cumulative size measures of the consolidative regions throughout follow-up 
post-SABR; all values are the mean ± 95 % CI. a) RECIST and b) 3D volume.  
* Indicates statistical significance at p ≤  0.05. 
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2.3.3 Post-SABR Appearance Measures 
Patients with recurrence had significantly denser mean [± 95% CI] solid 
consolidative changes of -96.4 ± 32.7 HU versus -143.2 ± 28.4 HU for patients with 
RILI, and this was detected as early as 9 months post-treatment (p=0.046). No significant 
difference was observed in the CT density of the GGO at any point in follow-up.   
Significantly increased variability of CT densities in the GGO areas was detected 
at 9 months post-treatment (p=0.0078). Patients with recurrence had a standard deviation 
of CT density at 9 months [± 95% CI] of 210.6 ± 14.5 HU vs. 175.1 ± 18.7 HU for 
patients with RILI. This is indicative of larger variability in the HU of the GGO, or more 
variegated texture, in patients with recurrence. No significant difference was observed in 
the variation of CT densities within the consolidative regions. Figure 2-4 and Figure 2-5 
show the cumulative appearance measures (CT density and standard deviation of CT 
density), in the GGO and consolidative regions respectively, during post-SABR follow-
up for patients with recurrence and RILI. 
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Figure 2-4: Cumulative appearance measures of the ground glass opacity regions 
throughout follow-up post-SABR; a) Mean [± 95% CI] CT density, and b) standard 
deviation [± 95% CI] of CT density. 
* Indicates statistical significance at p ≤ 0.05 
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Figure 2-5: Cumulative appearance measures of the consolidative regions throughout 
follow-up post-SABR; a) Mean [± 95% CI] CT density, and b) standard deviation [± 95% 
CI] of CT density. 
* Indicates statistical significance at p ≤ 0.05 
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2.3.4 Contouring Variability 
  In the consolidative regions at 9 months, we expanded and contracted the borders 
by 1 mm and recalculated our results. In all cases, including the original results, the 
differences between the two groups remained between 36-59 HU, with the patients with 
recurrence having higher HU density than patients with only RILI: [1 mm expansion: 
RILI = -220.02 ± 35.70 HU, recurrence = -161.67 ± 36.26 HU; 1 mm contraction: RILI = 
-95.43 ± 28.48 HU, recurrence = -59.58 ± 33.06 HU]. 
 Similarly, for the GGO texture measure at 9 months, patients with recurrence had 
a higher standard deviation of CT density compared to those with RILI, and the 
difference between the two groups remained between 35-39 HU: [1 mm expansion: RILI 
= 194.77 ± 14.99 HU, recurrence = 229.97 ± 10.85 HU; 1 mm contraction: RILI = 
167.86± 21.71 HU, recurrence = 206.60 ± 17.16 HU].  
2.4 Discussion 
CT density changes are common after SABR and distinguishing recurrence from 
RILI is becoming increasingly important. As SABR utilization increases, ambiguous CT 
findings will become a more common clinical problem. A technique for early and 
accurate diagnosis of post-SABR recurrence could allow for early salvage of recurrence, 
and avoid unnecessary imaging and intervention in patients with RILI only. This study 
suggests that changes in the cumulative mean density of consolidative regions and 
textural analysis of the GGO have the potential to distinguish RILI from cancer 
recurrence as early as 9 months post-SABR, compared to 3D volume and RECIST at 15 
months. For RECIST of the consolidation and texture analysis of the GGO, we 
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acknowledge the possibility that they may be inferior predictors as there does not appear 
to be an increase in separation between the groups over time. To our knowledge, this is 
the largest series of recurrences analysed for post-SABR radiological changes in the 
literature.   
We observed a significant difference in mean HU for the consolidative regions, 
but not in the GGO regions, and conversely we observed a significant difference in the 
standard deviation of HU in the GGO regions, but not in the consolidative regions. A 
more detailed investigation is required in order to more fully understand the reasons 
behind this observation. Since the consolidative regions are relatively opaque and 
homogeneous in appearance on CT imaging, the standard deviation of HU in these 
regions may be a less sensitive measure of difference between the groups, and the 
significant difference in mean HU could potentially be due to changes in tissue 
composition of the recurrent tumour (such as microvasculature and soft tissue) compared 
to fibrotic tissue within radiation-induced lung injury.   
The GGO regions contained a relatively greater amount of variation in the CT 
densities as some areas have lower density lung tissue, and others have higher density 
vessels; this may have rendered the standard deviation of HU measure a relatively more 
sensitive measure of difference between the groups in the GGO regions. We surmise that 
RILI results in a more uniform GGO density within these regions, whereas recurrences 
seemed to have a more variegated appearance potentially representing tumour nodularity 
or increased vascularity in areas of tumour recurrence. Further work is required to gain an 
understanding of the exact reasons behind the association of our significant measures 
with the consolidation or GGO regions for patients with recurrence and RILI. 
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The findings of this study are consistent with previously published literature but 
extend these previous findings in several important ways. Previous studies have shown 
that an enlarging opaque region after 12 months is indicative of recurrence [21, 22], 
consistent with the RECIST findings reported herein. We hypothesize that the decrease in 
RECIST and volume of the consolidative regions for the recurrence groups at 3 months is 
indicative of a partial response to treatment, and following this time point the rise we see 
may possibly be a sign of progressive disease. However, an enlarging mass may not be 
specific for recurrence: based on biopsy and further imaging, only a few patients with 
enlarging masses are deemed to ultimately have recurrence [6]. Most previous studies of 
radiological features of post-SABR recurrence are limited due to small sample size (of ≤5 
recurrences)  and mainly focused on the type and qualitative appearance of these changes 
[6, 21, 22]. Our study extends these findings by quantifying changes in density, texture, 
and 3D volume for patients, and suggests that these measurements may allow for the 
earlier detection of recurrence. 
A systematic review by Huang et al. identified several predictive factors of 
recurrence [5]. Since the primary imaging modality for follow-up post-SABR is CT, 
RECIST is traditionally used to determine a patient’s response to treatment. An enlarging 
mass with 20% increase in size, or an absolute increase in size of at least 5 mm from 
baseline, as described by RECIST 1.1, is suspicious for recurrence and warrants FDG-
PET for further investigation. Other high-risk features on CT include an enlarging mass-
like lesion, opacity enlargement after 12 months, bulging margin, disappearance of air 
bronchograms, linear margin disappearance, ipsilateral pleural effusion, or lymph node 
enlargement [5]. In terms of metabolic findings of recurrence, a SUVmax ≥ 5 using FDG-
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PET is highly suspicious of recurrence. In these cases, it is suggested a biopsy and/or 
resection should occur if feasible. Validation of the findings presented herein may 
improve this algorithm for imaging follow-up after SABR. 
The conclusions of this study must be considered in the context of its strengths 
and limitations. Although the number of recurrent lesions analyzed is more than in 
previous studies, and the length of follow-up is long, the sample size remains small, 
which may limit the power to detect small differences between groups. The patients 
included are not completely reflective of the overall SABR population, in that both the 
proportion of patients with recurrence, and the severity of benign RILI are higher than in 
a general SABR population. This sample was selected in order to determine if image 
feature analysis could differentiate recurrence from difficult RILI cases, but these 
findings require validation in a large, separate dataset. Inter- and intra-observer 
variability can exist in contouring of lung tumours [19], and further research is required 
to refine these metrics so they are invariant to individual contouring practices. As a result, 
it appears that even in the presence of contouring variability, the differences between the 
RILI and recurrence group appear consistent. Furthermore, data analysis was completed 
through cumulative analysis of measures up to a time point (0-3, 0-6, 0-9 months etc.), 
rather than using smaller time ranges (0-3, 3-6, 6-9 months etc.). Future studies will 
evaluate the relative benefits of using a cumulative analysis vs. using smaller time ranges. 
Furthermore, lung density can vary with regional blood flow, respiration, as well as co-
morbid illnesses such as COPD [23, 24], and these factors were not considered in this 
study. Further work must be completed on the effect of any co-morbidities on the 
measures analysed in this study. 
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 In conclusion, our study suggests that the use of CT density of consolidative 
changes as well as basic textural analysis of GGO may allow for early differentiation 
between RILI and recurrence. With further validation of our results on a larger sample 
size, and more detailed analysis of the features and changes observed throughout the 
course of SABR follow-up, there is the potential for an earlier detection of recurrence 
compared with traditional measures. This could potentially allow for earlier salvage of 
patients with recurrence, and result in fewer investigations for patients exhibiting only 
benign RILI.    
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Chapter 3  
Towards the goal of understanding if quantitative image features can predict local 
recurrence in individual patients, we evaluated quantitative image feature analysis plus 
machine learning techniques for predicting local recurrence in individual patients 
following SABR. 
The contents of this chapter were previously published in the journal Medical Physics: 
SA Mattonen, DA Palma, CJ Haasbeek, S Senan, and AD Ward. Early prediction of 
tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy 
(SABR) for lung cancer. Med Phys 2014; 41(3): 033502. Permission to reproduce this 
article was granted by the American Association of Physicists in Medicine and is 
provided in Appendix A.4. 
 EARLY PREDICTION OF TUMOUR RECURRENCE 3
BASED ON CT TEXTURE CHANGES AFTER SABR FOR 
LUNG CANCER  
3.1 Introduction 
 Stereotactic ablative radiotherapy (SABR) is now a standard treatment option for 
patients with early stage non-small cell lung cancer (NSCLC) who are medically 
inoperable or refuse surgery [1, 2]. SABR uses advanced treatment planning and delivery 
to treat the tumour to a high dose, while sparing surrounding normal tissue. Multiple 
collimated radiation beams are used to achieve a dose distribution highly conformal to 
the shape of the tumour with steep dose gradients at the tumour boundary. SABR 
treatments are typically delivered with high doses per fraction with relatively fewer 
fractions in the overall treatment (e.g. 7.5–18 Gy/fraction over 3–8 fractions for SABR, 
compared to approximately 2 Gy/fraction over 20–30 fractions for conventional therapy) 
[3]. 
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 Currently, the standard imaging modality recommended and clinically used for 
post-SABR follow up is computed tomography (CT) [2]. During follow-up assessment, a 
key clinical decision is whether to provide further, possibly more invasive intervention 
(e.g. surgery, chemotherapy) to treat or remove recurrent/residual disease. This decision 
rests on the ability to assess the success of the SABR treatment; i.e. to determine whether 
the patient’s cancer will recur. Since recurrent lung cancer typically progresses quickly, a 
decision to proceed with further intervention is most valuable if made early, since 
delayed detection of recurrence may reduce the options for salvage therapies. This 
decision is complicated by the fact that following radiotherapy to the lung, radiation-
induced lung injury (RILI) can occur as radiation pneumonitis and radiation fibrosis, 
which appear as an increase in lung density on CT [4, 5]. Following treatment with 
SABR, RILI can have similar size and morphology to a recurrent tumour [6, 7]. Several 
studies have examined the radiologic appearance of recurrence on follow-up CT post-
SABR, and suggest that an enlarging opacity after 12 months is most suggestive of 
recurrence; however, this criterion can only be met one year after treatment [8, 9]. A 
systematic review of the literature also suggests that other imaging features, such as a 
bulging margin and disappearance of air bronchograms, are also suggestive of recurrence 
[10, 11]. 
 Metabolic imaging modalities such as 18-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) imaging have been investigated for measuring treatment 
response post-SABR. Standardized uptake values (SUVs) greater than 5, or greater than 
the pre-treatment value, have been shown to be suggestive of recurrence; however, 
optimal SUV thresholds have not been determined [11]. Adding to the challenge of 
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interpreting FDG-PET images in the post-SABR context, hypermetabolic activity has 
been observed in benign fibrotic tissues years following SABR, likely due to an 
inflammatory response [12]. 
 A means for predicting recurrence within 6 months of treatment based on routine 
CT imaging would permit timely intervention for recurrence, which typically manifests 
after 1 year [3], and would be ideally suited to tailoring clinical management. Image 
texture analysis has been used for computer-aided diagnosis on lung CT, and second-
order texture statistics based on grey-level co-occurrence matrices (GLCMs) have been 
shown to quantify lung abnormalities [13, 14]. Our previous work presented in Chapter 2, 
demonstrated that a first-order texture feature [standard deviation (SD) of CT density] 
within the ground-glass opacity (GGO) regions, as well as the density of the 
consolidative regions, could statistically significantly differentiate recurrence and RILI 
patient groups at 9 months post-SABR [15]. Our preliminary analysis showed that a 
linear classifier could predict recurrence in individual patients at 9 months post-SABR 
with error of 26% using first-order texture of the GGO [16]. To the best of our 
knowledge, no previous work has demonstrated the ability to predict eventual cancer 
recurrence based on images acquired within 6 months of SABR treatment. 
 Based on our observations of the utility of quantitative appearance measures of 
the GGO in Chapter 2 [15], the primary objective of this study was to measure the 
accuracy of second-order GGO texture features on CT images acquired within 6 months 
of SABR treatment for prediction of recurrence, and to compare this with the accuracies 
obtained using first-order appearance features and measures of size of the consolidation 
regions. We analyzed texture features within GGO regions known to undergo 
  
86 
radiographic changes post-SABR [17]. Based on our observation that contouring of the 
consolidation regions is relatively straightforward in a clinical context, but GGO 
contouring is highly time-consuming and requires more careful judgment, our secondary 
objective was to measure the sensitivity of classification performance to perturbations of 
the GGO boundaries. This study is intended to generate hypotheses regarding the relative 
merit of GGO appearance features for predicting recurrence for further testing on a larger 
data set. 
3.2 Materials and Methods 
3.2.1 Patient Selection and Imaging 
 A group of 22 patients with T1 or T2 N0 non-small cell lung cancer was selected 
for this study, all of whom were treated with SABR at the VU University Medical Center 
in the Netherlands. These patients had a total of 24 tumours; 13 developed benign RILI, 
and 11 developed recurrence.  Pathological evidence of recurrence was available in 8 of 
the 11 tumour cases. Biopsy was not feasible in the remaining 3, and they were deemed 
to be recurrences based on sequential imaging findings, multidisciplinary group 
discussion, and eventual clinical outcome. All patients with benign RILI in this study had 
at least 2 years of imaging follow-up and were selected based on moderate to severe 
radiological findings [17], thus presenting a challenge to an algorithm designed to 
distinguish the substantial CT changes in these RILI cases from true recurrences. Patient 
characteristics and treatment variables are provided in Table 3-1. 
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Table 3-1: Baseline patient characteristics and treatment variables. 
 
Total (n=22 patients with 24 tumours) 
Median (range) or Number (%) 
Age (n=22) 69 (49-84) 
Gender (n=22)  
Male   14 (63.6%) 
Female 8 (36.4%) 
Charlson Score* (n=22) 5 (1-10) 
Tumour location (n=24)  
Left upper lobe 4 (16.7%) 
Left lower lobe 2 (8.3%) 
Right upper lobe 10 (41.7%) 
Right middle lobe 3 (12.5%) 
Planning target volume (n=24) 20.4 cc (4.5-144.4 cc) 
Fractionation schedule (n=24)  
3 x 20 Gy 14 (58.3%) 
5 x 11 Gy 1 (4.2%) 
5 x 12 Gy 4 (16.7%) 
8 x 7.5 Gy 5 (20.8%) 
Treatment type (n=24)  
Fixed beam 21 (87.5%) 
RapidArc 3 (12.5%) 
*Age adjusted Charlson, current lung cancer not scored as comorbidity. 
 
 All of the post-SABR follow-up CT images were acquired at the VU Medical 
Center in Amsterdam, Netherlands. Diagnostic CT scans were performed on one of three 
scanners: Siemens Volume Zoom 4-slice, Siemens Sensations 64-slice (Siemens 
Nederland N.V., Den Haag, Netherlands), or Philips Brilliance iCT 256-slice (Royal 
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Philips Electronics, Inc., Amsterdam, Netherlands). Standard machine settings were 120 
kVp, 100 mAs, spiral acquisition, 0.5 second rotation time, 2.5–5 mm slice thickness, and 
images were acquired at inspiratory breath hold. Intravenous contrast (Ultravist-300; 
Bayer Pharma AG, Berlin, Germany) was administered at a volume of 70 cc and a delay 
of 25 seconds.  Post-SABR diagnostic images were scheduled to be taken at 
approximately 3, 6, and 12 months following treatment, then every 6 to 12 months 
thereafter. However, due to practical considerations, the actual timing of follow-up scans 
does not conform exactly to the above schedule. Figure 3-1 shows the recorded timing of 
follow-up scans for the patients in our study, where the last date of treatment was 
considered day 0 of follow-up. We observed clustering of the first and second follow-up 
scans within the 2–5 and 5–8 month intervals post-treatment, respectively, and these were 
therefore the two time intervals used for this study. A total of 46 scans were analyzed 
within these two time intervals.   
 
Figure 3-1: Distribution of post-SABR CT scan time points for the patients in this study. 
Patients marked as recurrences on this plot experienced eventual cancer recurrence, 
diagnosed later than the imaging time points indicated on this plot. 
 
0 30 60 90 120 150 180 210 240 270 300
Days Post-SABR
RILI
Recurrence
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89 
3.2.2 Region of Interest Delineation 
 Manual segmentations of two regions of interest were obtained from the study 
presented in Chapter 2 [15]. Two three-dimensional (3D) regions of common post-SABR 
radiographic changes were manually contoured using the ITK-SNAP [18] (Version 2.2.0) 
software package: consolidative and GGO regions. Segmentations were completed on 
axial image slices using a lung window setting (window width of 1500 Hounsfield units 
[HU] and window level of -600 HU). A mediastinal window (window width of 350 HU 
and window level of 40 HU) was also used for delineation of any structures abutting the 
mediastinum. All segmentations were completed by a single graduate student, reviewed 
by a thoracic radiation oncologist with expertise in lung SABR, and approved after any 
necessary editing. Consolidative regions were defined as having increased density with 
respect to the surrounding region, with no visibility of blood vessels within. GGO regions 
were defined by an increase in the normal lung parenchyma density with respect to the 
surrounding region, with potential visibility of blood vessels within [19]. Figure 3-2 
illustrates the consolidative and GGO delineations for a patient with benign RILI and one 
with recurrence; note in this example the similarity of changes in the consolidative 
regions throughout the course of follow-up for the two patients, as well as qualitative 
differences between the recurrence and the RILI in the image textural qualities, 
particularly in the GGO regions. 
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Figure 3-2: Manual delineations of post-SABR consolidative and ground-glass opacity 
findings throughout follow-up for a patient with recurrence (A) and radiation-induced 
lung injury (B).  The zero-month (0m) time point indicates the pre-treatment lesion.  The 
solid lines enclose consolidative regions and the dashed lines enclose ground-glass 
opacity regions.   
 
3.2.3 Measures of Size  
 Two measures of size were taken in the consolidative region: the one-dimensional 
(1D) longest diameter as observed on any axial slice (henceforth referred to as the longest 
axial diameter) and the 3D volume. The largest axial diameter was used to make a 
Response Evaluation Criteria in Solid Tumours (RECIST) assessment for each 
consolidative region, according to RECIST 1.1[20]. All images were imported into 
ClearCanvas Workstation 2.0 (ClearCanvas Inc., Toronto, Canada) in anonymized form 
0m +3m +6m +12m
0m +3m +6m +12m
A) Recurrence
B) Benign radiation-induced lung injury
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and the longest axial diameter measurements were taken using the ClearCanvas 
Workstation ruler. The 3D volumes of the consolidative regions were calculated using 
MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA) by multiplying the number of 
voxels contained within each region by the voxel volume. 
3.2.4 Measures of Imaging Appearance 
 Two first-order appearance measures were calculated within the GGO regions: 
mean CT density, and standard deviation of CT density (the latter as a measure of image 
texture, with higher standard deviation values indicative of more variegated textures). 
MATLAB 7.13 was used to calculate these first-order measures. 
 Seven second-order appearance measures were calculated within the GGO 
regions. Second-order image texture features measure, in various ways, the intensity 
relationships between pairs of voxels in the image; typically, voxels forming a pair are 
spatial neighbours. The first step in calculating such measures is to compute a gray-level 
co-occurrence matrix (GLCM) [21]. This is a two-dimensional square matrix 𝑔 where the 
rows and columns correspond to observable gray levels (or gray level ranges) within the 
images, and where each matrix element 𝑔(𝑖, 𝑗) contains a non-negative integer indicating 
the number of voxel pairs whose elements have gray levels 𝑖 and 𝑗. Our chosen seven 
texture features were calculated based on the Conners, Trivedi, and Harlow feature set 
[22-24]: energy, entropy, correlation, inverse difference moment (IDM), inertia, cluster 
shade, and cluster prominence. Their definitions and equations are provided in Table 3-2, 
where the weighted pixel average 𝜇 =  ∑ 𝑖 ∙ 𝑔(𝑖, 𝑗) = 𝑖,𝑗 ∑ 𝑗 ∙ 𝑔(𝑖, 𝑗)𝑖,𝑗  (due to symmetry 
of 𝑔), and the weighted pixel variance 𝜎 = ∑ (𝑖 − 𝜇)2𝑖,𝑗 ∙ 𝑔(𝑖, 𝑗) =  ∑ (𝑗 − 𝜇)2𝑖,𝑗 ∙ 𝑔(𝑖, 𝑗) 
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(due to symmetry of 𝑔). These second-order texture features were calculated using the 
Insight Segmentation and Registration Toolkit (ITK) 4.3.1, an open source image 
processing software library available at www.itk.org [25].  
 Computation of second-order texture features requires the configuration of the 
GLCM histogram bins and the spatial directions used to establish pairings of 
neighbouring voxels. Histogram distributions of the CT densities within the GGO regions 
were analyzed to determine the appropriate number and density ranges of the bins for the 
GLCMs. Within the GGO, densities ranged from -1000 HU to 200 HU. The number of 
density bins was set accordingly to 60 bins, yielding 20 HU bin widths for analysis. In 
CT images there are thousands of possible greyscale values and therefore the allocation 
of a GLCM bin to every possible greyscale value will result in a very large GLCM.  This 
can cause texture feature values to become very sensitive to the number of voxels in the 
sample.  Since we are analyzing a small region of interest, we wanted to reduce the 
number of intensities per GLCM bin for analysis. Based on an inspection of one patient 
image, a bin width of 20 HU was chosen as a balance that both sufficiently quantizes the 
intensities while still having sufficient grey levels for discrimination of intensity 
differences in the image. This bin width parameter was not precisely tuned to optimize 
the results; improved results may be possible via optimization of this parameter in the 
context of a larger samples size. Neighbouring voxels were paired in four spatial 
directions within the 2D axial image planes [(-1, 0), (-1, -1), (0, -1), (1, -1)]. All second-
order texture measures were computed based on GLCMs calculated using each of these 
four directions, and were averaged over all directions. When calculating a second-order 
texture features a single direction for analysis results in a directional dependency of that 
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feature.  Therefore, calculating over multiple directions mitigates dependency on the 
spatial orientation of the image (the image could be rotated in any direction in the axial 
plane and the result would be similar). The four directions for analysis therefore include 
all possible directions from a reference pixel: horizontal, vertical, and both diagonals. By 
averaging across all directions we treat each direction of analysis equally and the result is 
spatially invariant. Through-plane directions were not used in this study due to the 
anisotropy of the voxels in our clinical images (5 mm slice thickness); such voxel 
anisotropy is typical of clinical CT follow-up imaging post radiotherapy 
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Table 3-2: Descriptions and equations of the second order texture features.  
 Equation Description 
Energy � 𝑔(𝑖, 𝑗)2
𝑖,𝑗  
Describes the uniformity of the image  
and is large for a constant image (all 
pixel intensity pairs are the same → 
high peak in the GLCM) 
Entropy 
−∑ 𝑔(𝑖, 𝑗)𝑖,𝑗 log2 𝑔(𝑖, 𝑗)  
or 0 if 𝑔(𝑖, 𝑗) = 0 
Describes the randomness of the 
GLCM  and is small for a constant 
image (all pixel intensity pairs are the 
same → high peak in the GLCM) 
Correlation �
(𝑖 − 𝜇)(𝑗 − 𝜇)𝑔(𝑖, 𝑗)
𝜎2
𝑖,𝑗  
Measures how correlated each pixel is 
to its neighbour and is high for a 
perfectly positively correlated image 
(the pixel intensity pairs are highly 
correlated in the GLCM) 
Inverse 
difference 
moment 
�
11 + (𝑖 − 𝑗)2 𝑔(𝑖, 𝑗)
𝑖,𝑗  
Measures the contrast in the image and 
is high when there are large values on 
the GLCM diagonal (pixel pairs have 
equal intensities → peak along the 
GLCM diagonal) 
Inertia �(𝑖 − 𝑗)2
𝑖,𝑗 𝑔(𝑖, 𝑗) 
Measures the contrast in the image and 
is low when there are large values on 
the GLCM diagonal (pixel pairs have 
equal intensities → peak along the 
GLCM diagonal) 
Cluster 
shade 
��(𝑖 − 𝜇) + (𝑗 − 𝜇)�
𝑖,𝑗
3
𝑔(𝑖, 𝑗) Describes the skewness (lack of symmetry) of the GLCM and is low when the image is symmetric with 
regard to its texture values (little 
variation in intensities) 
Cluster 
prominence 
��(𝑖 − 𝜇) + (𝑗 − 𝜇)�
𝑖,𝑗
4
𝑔(𝑖, 𝑗) Describes the skewness (lack of symmetry) of the GLCM  and is low when the image is symmetric with 
regard to its texture values (little 
variation in intensities and peak in the 
GLCM around the mean intensity)  
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3.2.5 Data Analysis 
Within the GGO regions, 9 features were computed:  mean density, first-order 
texture (standard deviation [SD] of density), and the seven second-order texture features 
described previously (energy, entropy, correlation, IDM, inertia, cluster shade, and 
cluster prominence). Within the consolidation regions, the longest axial diameter and 3D 
volume were measured. Group differences were assessed using an independent samples t-
test with unequal variances in SPSS Statistics Version 21.0 (IBM Corp., Armonk, NY, 
USA) to test the null hypothesis that the means of the recurrence and RILI groups are 
equal. A Kolmogorov-Smirnov test was also completed in SPSS to test for normality of 
distribution for all the measures. All statistical tests were two-sided with p ≤ 0.05 
indicative of statistical significance.   
 Figure 3-3 depicts the analysis performed on each of our features. To determine 
the predictive capabilities of each of these measures individually, classification was 
performed using the linear Bayes normal classifier [26-28] as implemented in the 
PRTools 4.2.1 (Delft Pattern Recognition Research, Delft, The Netherlands) [29] 
MATLAB toolbox.  Each feature underwent 2-fold cross validation over 100 repetitions, 
with all cross validations stratified to each fold. The means and standard deviations of the 
classification errors, false negative rates (FNRs), and false positive rates (FPRs) were 
measured over the 100 repetitions. These were compared between feature sets using a 
Wilcoxon signed rank test for nonparametric data in SPSS.  Receiver operating 
characteristic (ROC) curve analysis was also used to determine the predictive capabilities 
of each of these measures individually; specifically we calculated the area under the 
receiver operating characteristic curve (AUC) for each measure. Spearman rank 
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correlation coefficients were computed in SPSS to measure the correlations of all features 
in our data set. 
 
Figure 3-3: Flow diagram showing analysis performed on each of the 11 features. This 
workflow was executed 11 times; once for each of the 11 features used in our study (2 
size measures of the consolidation regions and 9 appearance measures of the GGO 
regions).  
 
3.2.6 RECIST Progressive Disease Criteria for Prediction 
 For this study, the longest axial diameter was used as an imaging-based size 
measure for the consolidative regions. This measure forms the basis of the RECIST 
response criteria which are used as the current clinical standard for determining disease 
progression or response based on percentage change in the lesion diameter. To compare 
the accuracy of RECIST for predicting recurrence post-SABR with the performance of 
our imaging features, we classified as a recurrence each patient having a 20% increase in 
the longest axial diameter, and classified all other patients as RILI, according to the 
Size/Appearance Feature
2-Fold Cross Validation
Linear Classifier
100 repetitions
Receiver Operating 
Characteristic Curve (ROC)
Linear Classifier
Spearman Rank Correlation
Correlation CoefficientArea Under the ROC (AUC)Mean Error
Mean False Positive Rate
Mean False Negative Rate
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current RECIST response guidelines. For each time period, the reference diameter was 
taken as the smallest previously measured diameter (either pre-treatment or post-
treatment) [20]. For the 2–5 month time period, the reference diameter was the pre-
treatment diameter. At the 5–8 month time period, the reference diameter was either the 
2–5 month time diameter or the pre-treatment diameter, whichever was smaller. 
3.2.7 Sensitivity of GGO Delineation 
 Although delineation of the consolidative regions is relatively straightforward for 
the operator (and computer-assisted delineation tools have been developed for this 
problem [30]), delineation of the GGO border requires more careful judgment and is 
substantially more time consuming. Thus, we sought to determine the sensitivity of 
classification performance to perturbations of the GGO boundaries. We performed a 
simulation study wherein manual GGO delineations were concentrically expanded and 
contracted in 1 mm increments, and classifier performance based on GGO features was 
re-evaluated for each such modification of the GGO delineations. Expansion of the GGO 
delineations was performed by varying a threshold on the distance transformation of the 
manually-delineated GGO region.  Thresholds were set between 1 mm to 5 mm, at 1 mm 
increments. The expansion was performed such that the expanded GGO region did not 
intersect with the manually delineated consolidative region, chest wall, or mediastinum. 
Contraction was performed by thresholding the distance transformation of the binary 
complement of the manual delineation. Contraction was performed at 1 mm and 2 mm 
thresholds, as larger distances resulted in nearly complete volume loss of many small 
GGO regions.  
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3.3 Results 
3.3.1 Group Differences 
 All samples passed a Kolmogorov-Smirnov normality test with p > 0.05. We 
report as follows all significant differences found; significant differences were not 
detected within either time period for all features not reported below. Within the 2–5 
month follow-up time interval, the mean density within the GGO regions was 
significantly different between the RILI and recurrence groups (p=.035).  Patients with 
recurrence had significantly denser GGO regions with a mean (±SD) density of -602.01 ± 
59.54 HU compared to those with RILI of -659.16 ± 55.93 HU. The mean values of the 
second-order texture features including energy (p=.036), entropy (p=.034), and inertia 
(p=.036) were significantly different between the recurrence and RILI groups during this 
time period. Patients with recurrence had significantly larger entropy (9.27 ± 0.65) and 
inertia (54.59 ± 25.85) values, and significantly lower energy (0.0021 ± 0.0015) values 
compared to patients with RILI (entropy = 8.66 ± 0.56, inertia = 33.42 ±15.84, and 
energy = 0.0034 ± 0.0012); all p < 0.05.   
 Within the 5–8 month time interval, the mean first-order texture feature 
(measured as the SD of CT densities) within the GGO regions was significantly different 
between the RILI and recurrence groups (p=.0019). Patients with recurrence had a more 
variegated first-order texture within the GGO with a mean (± SD) variability of 213.63 ± 
21.79 HU compared to those with RILI of 173.52 ± 30.40 HU. An illustrative example is 
shown in Figure 3-4, where a more variegated texture is demonstrated in (h) with a higher 
SD, compared to a smoother texture in (e) which has a lower SD. Patients with 
recurrence also had significantly denser consolidation regions (p=.021), mean density of -
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84.66 ± 72.34 HU compared to -158.28 ± 65.42 HU for those with RILI. The mean 
values of the second-order texture features including energy (p=.031), entropy (p=.015), 
inertia (p=.018), and correlation (p=.0025) were significantly different between the 
groups at this time point. Patients with recurrence had significantly larger entropy (9.24 ± 
0.55) and inertia (56.20 ± 17.24) values, and significantly lower energy (0.0020 ± 
0.0012) and correlation (0.0069 ± 0.0012) values compared to those patients with RILI 
(entropy = 8.69 ± 0.34, inertia = 38.50 ± 13.80, energy = 0.0031 ± 0.00081, and 
correlation = 0.011 ± 0.0036).   
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Figure 3-4: Sample texture images and their corresponding second-order energy, 
entropy, and first-order (standard deviation [SD] of densities) texture values. Samples (a-
d) show artificial examples and (e-h) show images taken from lung tissue. The plots show 
the change of each feature in the specified image relative to those in the leftmost image 
(a) or (e). 
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3.3.2 Classification Performance 
 Figure 3-5 shows the means and standard deviations of the overall errors, FNRs, 
and FPRs for each of the measures using 2-fold CV. The top three predictors were all 
second-order texture features within the GGO. GGO energy had the lowest prediction 
error of 23% (corresponding to 77% prediction accuracy) on 2-fold CV followed by 
GGO entropy and inertia with errors of 24-26%, compared to 40% and 42% error with 
the longest axial diameter and 3D volume respectively. The first-order measure also 
performed similarly with 27% 2-fold CV error, but had a larger standard deviation. The 
longest axial diameter and volume size measures were outperformed by all of the 
appearance measures, except for the cluster shade and cluster prominence second-order 
texture features. Of our top performing texture features, GGO energy had the largest 
FPRs but the lowest FNRs. GGO inertia had the most balanced FNR and FPR. Overall, 
the two size measures had the lowest FPRs, but highest FNRs. 
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Figure 3-5: (a) Cross validation errors, (b) false positive rates, and (c) false negative 
rates for 2-fold cross validation.  Glyphs indicate mean values, the error bars indicating 
the standard deviation over the 100 repetitions. 
 
 In 2-fold cross validation, the errors, FPRs, and FNRs were compared for all 
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0%
10%
20%
30%
40%
50%
60%
70%
Energy Entropy Inertia First-order
texture
Correlation Density Inverse
difference
moment
Cluster
prominence
Cluster
shade
Longest axial
diameter
Volume
M
ea
n 
Er
ro
r (
%
)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Energy Entropy Inertia First-order
texture
Correlation Density Inverse
difference
moment
Cluster
prominence
Cluster
shade
Longest axial
diameter
Volume
Fa
ls
e 
Po
si
tiv
e 
Ra
te
 (%
)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Energy Entropy Inertia First-order
texture
Correlation Density Inverse
difference
moment
Cluster
prominence
Cluster
shade
Longest axial
diameter
Volume
Fa
ls
e 
N
eg
at
iv
e 
Ra
te
 (%
)
(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
(c) 
                            Appearance Features                 Size Features 
                            Appearance Features                 Size Features 
                            Appearance Features                 Size Features 
  
103 
SPSS (p ≤ 0.05 indicative of statistical significance) since not all of these samples passed 
a Kolmogorov-Smirnov normality test with p < 0.05. The size measures of longest axial 
diameter and volume  had a significantly higher median 2-fold cross validation error 
when compared to each of the appearance measures, except each with cluster 
prominence. The longest axial diameter was also significantly different from the volume 
measure. There was no significant difference between the median errors for energy and 
entropy. First-order texture had a significantly different median error compared to all 
second-order features, except correlation and inertia. All other pairings were significantly 
different from one another. No significant difference was detected between the FPRs at 2-
fold cross validation for energy vs. entropy, first-order texture vs. inertia, and first-order 
texture vs. longest axial diameter. There was also no significant difference detected 
between the FNRs for IDM vs. entropy, correlation vs. entropy, and cluster shade vs. 
cluster prominence. All other combinations were significantly different in terms of their 
median FPRs and FNRs. 
 The top two features in terms of 2-fold classification error were: GGO energy and 
GGO entropy. To explore these features in more detail and to compare them with size 
measures, scatter plots of the recurrence and RILI patients in feature space, as well as 
receiver operating characteristic (ROC) curves, are shown for GGO energy and entropy 
(Figure 3-6) and solid volume and longest axial diameter (Figure 3-7). Figure 3-6 indicate 
that the two classes are approximately equally separable in both feature spaces (by each 
feature alone), with few outliers from both classes, whereas Figure 3-7 indicates 
substantially poorer class separation by longest axial diameter and solid volume; the ROC 
curves shown in the figures corroborate these observations. The AUCs for all measures at 
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this 2–5 month time interval are shown in the first column of Table 3-3. GGO energy and 
correlation produced the largest AUCs of 0.81 (energy is shown in Figure 3-6b), whereas 
the size measures of longest axial diameter and volume produced AUCs of 0.716 and 
0.652 respectively (shown in Figure 3-7c). GGO entropy and the first-order texture 
feature also performed similarly to energy and correlation in terms of AUC. Overall, 
energy was the best performer in terms of 2-fold cross-validation and AUC, with an error 
of 22.7% and AUC of 0.81.     
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Figure 3-6: (a) All lesions plotted by their energy and entropy values within the GGO at 
2–5 months post treatment.  Red circles indicate patients with recurrence and blue crosses 
indicate those with benign injury.  Qualitative example images of the patients indicated 
by arrows are shown in Figure 3-9. (b,c) The corresponding ROC curves for the linear 
classifier on each feature alone; AUC = 0.809 for energy and AUC = 0.800 for entropy. 
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Figure 3-7: (a) All lesions plotted by their solid (consolidative volume) and longest axial 
diameter at 2–5 months post treatment.  Red circles indicate patients with recurrence and 
blue crosses indicate those with benign injury. (b,c) The corresponding ROC curves for 
the linear classifier on each feature alone; AUC = 0.716 for longest axial diameter and 
AUC = 0.652 for 3D volume. 
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Table 3-3: Areas under the receiver operating characteristic curve (AUC) for each 
feature 
Feature 
AUC 
2 to 5 Months 5 to 8 Months 
Energy  0.809 0.875 
Entropy 0.800 0.808 
Inertia 0.782 0.800 
First-order texture 0.791 0.867 
Correlation 0.809 0.875 
Density 0.764 0.667 
Inverse difference moment 0.764 0.750 
Cluster Prominence 0.709 0.758 
Cluster Shade 0.618 0.675 
Longest axial diameter 0.716 0.723 
Volume 0.652 0.723 
 
 Due to the need to predict recurrence as early as possible after SABR treatment, 
we were most interested in features providing useful performance during the earlier 2–5 
month time interval. To evaluate the repeatability of these measures at a later time 
interval on the same patients, we measured their performance during the 5–8 month time 
interval. The mean 2-fold cross validation error of GGO energy and entropy performed 
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within ±3% of the 2–5 month time interval. Longest axial diameter showed improvement 
in error measurements of 3%. In terms of the AUCs at the 5–8 month time period (shown 
in second column of Table 3-3), the top first and second-order texture features performed 
similarly or better compared to the 2–5 month interval. Longest axial diameter and 
volume also performed similarly to the 2–5 month interval. 
3.3.3 Correlation of Measures 
 Spearman rank correlation coefficients were computed in SPSS to determine any 
dependence or relationship among or between the first and second-order texture features 
in our study. The correlations of GGO energy, entropy, and the first-order texture feature 
are shown in Table 3-4. We also measured the correlation of these texture features with 
the volume of the analyzed GGO region, as shown in Table 3-4. At 2–5 months post-
SABR, the highest correlation was observed with energy and entropy, with a coefficient 
of -0.969; this correlation is apparent in Figure 3-6. In general, the second-order texture 
features were better correlated with each other than they were with the first-order 
measure. This pattern held at the 5–8 month time period, but overall all correlations 
decreased at this time point. We observed no statistically significant correlations of the 
texture features with the 3D volumes of the GGO regions. 
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Table 3-4: Spearman rank correlation coefficients and significance values for features 
within the ground-glass opacity 
 2 to 5 Months 5 to 8 Months 
 Correlation 
Coefficient 
Significance 
Correlation 
Coefficient 
Significance 
Energy vs. Entropy -0.969* < 0.001 -0.919* < 0.001 
Energy vs. First-Order 
Texture 
-0.936* < 0.001 -0.687* < 0.001 
Entropy vs. First-Order 
Texture 
0.919* < 0.001 0.583* 0.004 
GGO Volume vs. Energy -0.171 0.457 -0.302 0.172 
GGO Volume vs. Entropy 0.062 0.788 0.064 0.778 
GGO Volume vs. First-
Order Texture 
0.243 0.289 0.382 0.079 
* Correlation is significant at the 0.01 level 
 
3.3.4 RECIST Progressive Disease Criteria for Prediction 
 The overall accuracy of RECIST for predicting tumour recurrence at 2–5 months 
post-SABR was 52.2%, with a FNR of 25% and FPR of 72.7%. At 5–8 months post-
SABR, RECIST provided an accuracy of 65.2%, with a FNR of 45.5% and FPR of 
27.3%. To measure whether a recurrence threshold other than the 20% increase given by 
the current RECIST guidelines would provide better performance, we trained the linear 
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classifier on our entire data set, using the percentage increase in longest axial diameter. 
The classifier found optimal decision points higher than the RECIST guideline of 20%, 
placing the decision boundary at 49% for 2–5 months and 77% at 5–8 months with 
overall errors of 52.2% and 34.8%, respectively. 
3.3.5 Sensitivity of GGO Delineation 
 Receiver operating characteristic curves were produced on the expanded and 
contracted GGO regions for classification using each of the top feature sets at the 2–5 
month time interval. Figure 3-8 shows the sensitivity of the AUC for prediction of 
recurrence for our top first and second-order texture features based on these variations in 
GGO delineation. After contraction of the regions by 1 or 2 mm, the first and second-
order texture features remained constant or decreased by 0.06 from their respective AUC 
values in the manual GGO. This decrease is likely due to the fact that many of the lesions 
had a small total volume of GGO, so a contraction of even 2 mm resulted in a large 
volume loss and the remaining region may not have provided sufficient voxel samples for 
a robust calculation of the texture features. With an expansion of the GGO up to 5 mm, 
the AUC values for all texture features remained constant with slight fluctuations across 
each level of expansion. First-order texture had fluctuations in its AUC up to 0.04, 
whereas the AUC for energy remained constant, throughout all levels of expansion. The 
AUCs for entropy were also stable, with a decrease of 0.06 at 3 mm, but returned to 
baseline at 4–5 mm. By 5 mm, all features remained within 0.04 of their respective 
baseline values from the manual GGO region. This demonstrates the robustness of the 
AUC measure at each level after GGO boundary contractions and expansions, suggesting 
robustness to variability in GGO delineation.   
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Figure 3-8: Sensitivity of the area under the receiver operating characteristic curve 
(AUC) for prediction of recurrence at 2-5 months post-SABR based on variations in 
GGO delineation.  The vertical dashed line indicates the AUC values for the manual 
GGO delineation. 
 
3.4 Discussion 
 Early detection of recurrence following SABR is critical to allow eligible patients 
to undergo salvage therapies, including surgery, chemotherapy, or possibly additional 
radiotherapy. Since CT scanning is the standard follow-up imaging modality, quantitative 
analyses of these images that are predictive of recurrence in individual patients at an early 
time point post-treatment could have great potential for translation to routine clinical use. 
This study has demonstrated the ability, based on texture measures of the GGO in CT 
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stage non-small cell lung cancer. This study also demonstrated that appearance changes 
in these regions precede changes in size of the consolidative/solid regions.   
 Previous studies have shown that current approaches to the interpretation of CT 
imaging are insufficiently accurate for clinical use in detection of local recurrence [31, 
32]; accurate prediction of eventual recurrence within 6 months of treatment is supportive 
of salvage intervention.  Although an increasing opacity on CT has shown to be 
indicative of recurrence, this feature is accurately predictive based on imaging acquired 
after 12 months post treatment [11]. FDG-PET alone or in combination with CT findings 
has also demonstrated the ability to detect recurrences more than a year post-treatment 
[33, 34]. However, one study has shown that residual FDG-PET uptake 12 weeks post 
treatment, with an SUV greater than or equal to 5.0, signifies an increased risk of local 
recurrence (sub hazard ratio for high SUV of 7.3) [35]. A recent study looked at texture 
features of the gross tumour volume on pre-treatment diagnostic CT scans (in a PET/CT 
context) of patients with stage IA–IV NSCLC being treated with SABR or conventional 
radiotherapy treatment [36]. Although the study did not find significant correlation of 
texture features with loco-regional recurrence, it was noted that motion artefact 
mitigation may be important to the prediction of local recurrence. In the context of the 
results of the Vaidya et al. study, our results suggest that assessment of the first follow-up 
scan, motion artefact mitigation, and analysis of the GGO region may be important to 
prediction of failure. To the best of our knowledge, this is the first study to show early 
prediction (within 6 months of SABR treatment) of eventual cancer recurrence based on 
measurements derived from CT imaging alone. 
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 Our decision to use second-order statistical texture measures was motivated by a 
qualitative observation of differences between patient groups that appears to be related to 
vascularity in the GGO regions, ranging from smooth to variegated appearance through 
small numbers of larger vessels to larger numbers of small vessels.  As these patterns 
may vary in terms of the number and magnitude of transitions from low to high density as 
one travels voxel-by-voxel through the image, we surmised that GLCM-based texture 
measures could capture such neighbourhood relationships explicitly, giving a relatively 
direct (and therefore understandable) quantification of this qualitative observation.  In 
addition, there is previous literature showing the utility of GLCM-based texture features 
with lung pathologies [13, 14].  Thus, for this exploratory study, we limited our 
investigation to this small number of more established texture features, leaving a more 
comprehensive study of a larger number of texture features within the scope of future 
work in the context of a larger sample size. 
 We observed that second-order texture features within the GGO were the most 
accurate in predicting recurrence within the early 2–5 month time period. Measures of 
size, and appearance measures within the consolidative regions, were not as accurately 
predictive during the same time period. The most useful features in our study were 
second-order energy and entropy which were shown to be highly correlated. The utility of 
the first-order texture feature in differentiating recurrence from RILI also suggests the 
importance of overall intensity variations within the GGO along with local, second-order 
variations. The effectiveness of the second-order energy feature suggests that variations 
in the spatial uniformity of densities within the GGO may be important for prediction.   
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 Energy and entropy are measures related to orderliness and how neighbouring 
pixels are organized. An ordered image is one in which the same pixel intensity pairs 
occur more frequently; this results in a few GLCM cells with higher values, compared to 
an unordered image where neighbouring pixels have different intensities throughout the 
image, resulting in more GLCM cells with lower values [37]. Energy increases with a 
more ordered image and, as indicated in Table 3-2, is weighted by the sum of squared 
elements in the GLCM. Entropy is weighted by the logarithm of the elements in the 
GLCM, which is also known as a statistical measure of randomness in the GLCM, 
decreases with a more ordered image, and is negatively related to energy. The difference 
between energy and entropy is in the weights put on the GLCMs, with energy increasing 
with orderliness and entropy increasing with disorder.  
 To illustrate the intuitive meanings of these features, Figure 3-4 shows sample 
texture images; artificial examples and qualitatively corresponding CT image samples of 
the lung. The resulting first-order texture, and second-order energy, and entropy values 
are shown for each example. A more ordered or constant image, for example reflecting a 
single vessel (Figure 3-4 a and e), results in relatively high energy and low entropy 
values, as compared to the other sample images in Figure 3-4. As the number of vessels 
increases, the first-order SD texture feature is either constant (Figure 3-4 a-c) or produces 
non-monotonic changes (Figure 3-4 e-g) but second-order energy is monotonically 
changing. In the lung image samples, as the number of vessels increases, energy 
consistently decreases and entropy consistently increases. However, note that in Figure 
3-4 g and h, the different patterns in the lung are better differentiated with the first-order 
SD feature. Overall, we can observe that the first-order texture measure is sensitive to 
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overall changes in contrast, but is less sensitive to the spatial arrangement of contrasting 
elements (e.g. it does not differentiate well between one large vessel and multiple smaller 
ones, such as depicted in Figure 3-4 a-c). The second-order measures are sensitive to the 
spatial relationships of these contrasting elements, since they take pixel neighbourhoods 
into account. 
 We observed that patients with recurrence have lower values of energy and higher 
values of entropy, suggesting that GGO patterns closer to Figure 3-4 (c) and (g) within 
the GGO are predictive of recurrence. To illustrate the qualitative meaning of varying 
energy values in the context of the recurrences and RILI cases in our data set, Figure 3-9 
shows four sample lesions from our study, sorted by increasing energy values in the GGO 
from (a) to (d). The lesion locations in feature space can also be observed in Figure 3-6, 
where Figure 3-9 (a) and (d) are at both extremes for energy values and thus easily 
separated, but Figure 3-9 (b) and (c) are much similar and harder to classify. The 
qualitative differences in GGO appearance between Figure 3-9 (a) and (d) are readily 
apparent, with the recurrence case in (a) having substantially greater variegation of image 
texture and contrast between the vasculature and the background, and (d) having an 
overall smoother GGO appearance. By comparison, the recurrence in Figure 3-9 (b) and 
the RILI in Figure 3-9 (c) are more difficult to qualitatively distinguish, and this is 
reflected in their more similar GGO energy texture values. We speculate that these 
observed differences (e.g. between Figure 3-9 (a) and (d)) may represent an increase in 
vasculature within these regions in the recurrence cases (e.g. Figure 3-9 (a)), perhaps 
indicating there are early vascular changes occurring which may eventually lead to a 
recurring tumour. Patients with RILI had a more homogenous GGO with fewer evident 
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vessels.  At this early time point following treatment, this perhaps indicates the presence 
of fibrotic tissue and other cells involved in the pathological response of radiation 
pneumonitis following radiotherapy [38]. Future work including histological 
examinations of these regions would be useful toward elucidating the tissue composition 
of these regions and thus the meaning of our imaging observations. 
 
Recurrence Recurrence RILI RILI 
Energy = 0.00086 Energy = 0.0023 Energy = 0.0026 Energy =0.0048 
Figure 3-9: The 2–5 month scans for four lesions in our study. The solid curves enclose 
consolidative regions and the dotted curves enclose ground-glass opacity (GGO) regions.  
Images of patients who had eventual cancer recurrence are shown in (a) and (b), and 
images of patients who developed RILI are shown in (c) and (d). The energy values in the 
GGO for these lesions progressively increased from (a) through (d). Their locations in 
feature space can be seen in Figure 3-6. (a) and (d) are at relative extremes in feature 
space on the recurrence and RILI sides, respectively, and are qualitatively distinct. (b) 
and (c) are examples of recurrence and RILI cases that are closer to the expected decision 
boundary, and are more difficult to distinguish qualitatively. 
  
 The results of this study must be considered within the context of its strengths and 
limitations. Although the sample size is small, this is one of the largest series of 
(a) (b) (c) (d) 
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recurrences in a study determining treatment outcomes post-SABR. Even with the small 
sample size, prediction accuracies remained robust using 2-fold cross validation; 
however, validation of all results on a larger data set must be performed and this study 
should be considered as hypothesis-generating. Intra and inter-observer variability in 
region of interest delineation was also not directly measured in this study; however, the 
robustness of our measures with expansion and contraction of the GGO suggests that 
variability in delineation has minimal impact on these measures for predicting recurrence. 
We also did not consider the effects of any co-morbidities, such as chronic obstructive 
pulmonary disease (COPD), respiration, or variations in blood flow on lung density [39]. 
Any variations between scanners and reconstruction techniques which may affect density 
measurements were also not considered [40]; however, all image acquisition parameters 
were set consistently to minimize any variations. In terms of the texture analysis, it may 
be valuable for future work to include a more extensive set of texture features and 
classifiers for analysis. 
 In conclusion, we have demonstrated the ability of first and second-order image 
texture features to predict eventual cancer recurrence based on CT images acquired 
within 5 months of SABR treatment with accuracies greater than 77% using a linear 
classifier. These appearance measures outperformed any measure of size during the same 
time interval, where accuracies of approximately 60% could be achieved. However, 
further validation of these results is needed on a larger sample size. We are also 
investigating a faster and more reproducible delineation or sampling method of the GGO 
regions to allow for clinical translation to a useful computer-aided diagnosis tool. The 
impact of these early measures on a clinician’s diagnosis of RILI versus recurrence, as 
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well as potential effects on clinical decision making must also be addressed in a user 
study. This could eventually prevent unnecessary, invasive, and risky procedures for 
patients with only benign disease and allow for the early salvage therapy for patients with 
recurrence. 
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Chapter 4  
Towards the goal of understanding if semi-automated segmentation methods can be used 
in this decision support system, we evaluated a semi-automated graph cuts based 
approach to segment and sample regions of post-SABR radiological changes to be used 
to predict local recurrence following SABR. 
The contents of this chapter were previously published in the Journal of Medical 
Imaging: SA Mattonen, S Tetar, DA Palma, AV Louie, S Senan, and AD Ward. Imaging 
texture analysis for automated prediction of lung cancer recurrence after stereotactic 
radiotherapy. J Med Imag 2015; 2(4):041010. Permission to reproduce this article was 
granted by the SPIE and is provided in Appendix A.5. 
 IMAGING TEXTURE ANALYSIS FOR AUTOMATED 4
PREDICTION OF LUNG CANCER RECURRENCE 
AFTER STEREOTACTIC RADIOTHERAPY 
4.1 Introduction 
 Stereotactic ablative radiotherapy (SABR) (also known as stereotactic body 
radiotherapy) is now the guideline-recommended treatment for patients with non-small 
cell lung cancer (NSCLC) who are medically inoperable or refuse surgery [1, 2]. 
Compared with conventional radiotherapy techniques, SABR involves the treatment of 
small lung tumours with higher doses per fraction in fewer fractions. Typically doses of 
up to 18 Gy per fraction are delivered in between 3-8 fractions over 1–2 weeks, in 
contrast to a dose of 2 Gy per day delivered over 4–6 weeks in conventional radiotherapy 
techniques. The higher doses used in SABR has led to local control rates of up to 90% at 
3 years post-treatment, similar to those reported after surgery [3, 4]. However, radiation 
induced lung injury (RILI), such as radiation fibrosis, can occur after SABR. Some forms 
of benign changes can appear with similar size and shape to a recurring tumour on 
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computed tomography (CT) imaging, which is routinely acquired every three months as 
part of follow-up care. This confounds the critical clinical decision to provide potentially 
life-saving additional salvage therapies in cases where the cancer is recurring after 
SABR. 
      Present guidelines recommend the use of serial CT scans for follow-up after 
SABR, with the use of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) 
imaging used only when appropriate [5]. FDG-PET is recommended when recurrence is 
suspected on CT; however, due to the high number of false positive findings on PET, 
patients eligible for salvage treatment should undergo a biopsy if feasible [5]. Qualitative 
image assessment has also been performed on CT images following SABR, and a high-
risk feature set has been developed to discriminate benign fibrosis from recurrence [6, 7]. 
These features include an enlarging opacity, sequential enlargement from one scan to the 
next, a bulging margin, loss of linear margin, and air bronchogram loss. However, these 
features typically do not manifest until 1 year post-SABR [6]. 
 Our overarching goal is to develop a fully automated system that will classify a 
CT image as recurrence or RILI, supporting the decision to prescribe salvage therapy to 
SABR patients with recurring tumours. This system will not require any manual 
delineation other than that which is performed during the normal clinical workflow, and 
will produce operator-independent, reproducible classification results. Quantitative 
radiomic image analysis has been increasingly utilized on CT, magnetic resonance 
imaging (MRI), and PET for differentiation of tumour types, grades, and for response 
assessment across many disease sites [8, 9]. Texture analysis has been investigated in 
predictive modeling of radiation pneumonitis after definitive lung radiotherapy [10]. It 
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has also been described for predicting the development of radiation pneumonitis after 
definitive radiotherapy for esophageal cancer [11, 12]. Cunliffe et al. compared 
radiologist-defined severity of normal tissue damage with CT texture features [11]. In an 
additional study, they demonstrated the ability to differentiate patients with and without 
clinical radiation pneumonitis by measurements of dose-dependent texture change 
between pre- and post-radiotherapy CT images [12]. To the best of our knowledge, these 
are the only papers present in the literature measuring CT texture for benign radiation 
induced lung injury. Our previous work presented in Chapters 3 evaluated quantitative 
CT image texture analysis for early prediction of recurrence after SABR [13, 14]. We 
have shown that second-order texture features based on grey-level co-occurrence 
matrices (GLCM) calculated within manually delineated ground-glass opacity (GGO) 
regions can predict recurrence within 6 months post-SABR. The regions of GGO refer to 
hazy regions of increased attenuation in the lung within which vascular regions can still 
be visualized, and these regions typically surround the consolidative mass. Texture 
features within these regions showed 2-fold cross-validation (CV) errors of 23–30% and 
areas under the receiver operating characteristic curve (AUC) of 0.78–0.81 [13]. As seen 
in Figure 4-1, patients with benign injury tended to have a smooth GGO appearance 
compared to a variegated appearance in patients with recurrence. 
However, there are two main limitations to clinical translation of this technique. 
First, although inter-operator variability in manual segmentations on radiographic images 
is a well-known problem, little is known about predicting recurrence based on texture 
feature analysis within GGO segmentations performed by different operators [15]. As 
GGO boundaries are often barely discernible, it is reasonable to expect substantial inter-
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operator variability. Second, manual 3D segmentation of the GGO is time-consuming, 
and automated GGO segmentation is extremely challenging due to the lack of any shape 
regularity and difficulty, even for the human medical expert, in judging the locations of 
the weak GGO boundaries. Inspired by our previous observation that a peri-consolidative 
region (defined by a concentric expansion of the consolidative mass) intended to sample 
GGO tissue yielded comparable classification performance to manually-delineated GGO 
[14], we conjectured that accurate classification performance could be obtained using an 
automatically-defined peri-consolidative region, rendering a complete GGO segmentation 
unnecessary.  
Based on these observations and challenges, our primary objectives in the current 
study are as follows. First, we aim to measure the accuracy of texture features for 
predicting recurrence based on the first 3 month follow-up scan, with a peri-consolidative 
region derived from a semi-automatic segmentation of the consolidative region [16]. This 
decision support system would eliminate the need for any time consuming manual 
segmentations. Although the segmentation algorithm is semi-automatic, its only input is 
the Response Evaluation Criteria in Solid Tumours (RECIST 1.1) line segment, which is 
routinely obtained as part of the clinical imaging workflow; no additional user interaction 
is required [17]. We also aim to determine the reproducibility of the system’s 
segmentations recurrence predictions to inputs from different operators.  Finally, we aim 
to compare the classification performance to manually delineated segmentations. 
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Figure 4-1: The 2–5 month follow-up image for four patients in our study. The solid 
lines encompass consolidative changes and the dashed lines encompass regions of 
ground-glass opacity, as delineated by a senior radiation oncology resident. The two 
lesions which developed benign radiation induced lung injury are shown in (A) and (B), 
and qualitatively the ground-glass opacity regions have a smooth appearance. (C) and (D) 
show two lesions that eventually developed cancer recurrence and in these images a 
variegated texture is visible in the ground-glass opacity regions.  
 
4.2 Methods 
4.2.1 Materials and Imaging 
A total of 24 lesions from 22 patients treated for stage I NSCLC with SABR at the VU 
University Medical Center, Netherlands between February 2004 and February 2010 were 
used for this study. Of these 24 lesions, 11 were defined as local recurrences based on 
biopsy confirmation (8/11) and/or ultimate clinical outcome (3/11). The remaining 13 
lesions developed moderate to severe radiological RILI CT changes based on expert 
assessment and had at least two years of imaging follow-up. These 13 RILI cases were 
chosen because they were especially challenging to distinguish from recurrences based 
on the first follow-up scan; for such cases computer-assisted decision support was 
deemed to have greatest potential value in the clinical context. The proportion of 
(A) (B) (C) (D)
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recurrences is artificially inflated in this data set, and the true rate of local recurrence for 
a typical stage I NSCLC cohort is around 10% [3, 4]. During follow-up, 46 post-
treatment diagnostic CT scans were taken at the first two follow-up time periods (2–5 and 
5–8 months) post-SABR on one of three scanners at the VU Medical Center: Siemens 
Volume Zoom 4-slice, Siemens Sensations 64-slice (Siemens Nederland N.V., Den Haag, 
Netherlands) or Philips Brilliance iCT 256-slice (Royal Philips Electronics, Inc., 
Amsterdam, Netherlands). To eliminate the effect of image acquisition parameters on 
quantitative image analysis, all follow-up scans were acquired with the same acquisition 
parameters at inspiratory breath hold, 120 kVp, 100 mAs, spiral acquisition, 0.5 second 
rotation time, 2.5–5 mm slice thickness, with 70 cc of intravenous contrast (Ultravist-
300; Bayer Pharma AG, Berlin, Germany) administered with a 25 second delay. Iterative 
reconstruction was not used in this imaging dataset and a standard sharp lung convolution 
kernel was applied (B60f) with 0.5–0.9 mm isotropic in-plane voxel dimensions. 
4.2.2 Region of Interest Segmentation 
4.2.2.1 Lung Regions 
 The regions of the image containing normal lung parenchyma can be obtained for 
the planning CT scan as part of the contouring normally performed during the radiation 
therapy planning workflow and mapped by image registration onto follow-up scans, or 
through the use of several automatic segmentation algorithms [18-21]. Although this step 
is outside of the scope of our method, for the purposes of reproducibility, we are 
providing the procedure that we followed to obtain this segmentation for each of our 
scans. Normal lung parenchyma was automatically segmented in ITK-SNAP (Version 
2.4.0) using region competition snakes [22]. For trachea-adjacent tumors, the trachea was 
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separately segmented superior to the carina. A 3D rectilinear region of interest was 
defined encompassing the segmentation target (the entire lung volume or the trachea) and 
pre-processed using a sigmoid function, implemented as the intensity region filter in ITK-
SNAP, with the threshold set above -300 HU and smoothness of 1.00.  One or more 
spheres within the region of interest were used for initialization of the region competition 
snakes and were evolved using a sparse field level set [14, 23]. Parameters for the 
segmentation were set as follows: curvature velocity weight of 0.20, propagation force of 
1.0, and 1500 and 250 iterations for the lung and trachea respectively. Post-processing 
was performed in MATLAB 8.4 (The Mathworks Inc., Natick, MA, USA) by a slice-wise 
morphological filling of small vessels or artifacts less than 10mm2 within plane. This 
ensures larger vessels and any large consolidative components are not included in the 
normal lung parenchyma. A whole-lung volume was achieved by manually filling in the 
normal lung parenchyma to fill any abnormal consolidative regions.  
4.2.2.2 Manual Segmentation of Consolidation and GGO 
 Segmentations were performed by a resident in radiation oncology (operator 1) on 
all follow-up CT images in ITK-SNAP 3.0 [24]. A lung window setting (level/window -
600/1500 HU) and the paintbrush tool or polygon outline were used. A mediastinal 
window setting (level/window 50/450 HU) was also used for tumours or fibrosis abutting 
the mediastinum. Consolidation changes were defined as an increased density with 
respect to normal surrounding lung with no visibility of vasculature within. GGO was 
defined as an increase in normal lung density with visibility of vasculature within. The 
segmentations were randomly checked by a thoracic radiation oncologist. The time 
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required to manually complete the consolidation and GGO segmentations was also 
recorded on a subset of images.   
4.2.2.3 Semi-Automatic Segmentation of Consolidation 
 An overview of our semi-automatic segmentation approach can be seen in Figure 
4-2. In the current clinical workflow, a physician measures the lesion’s longest axial 
diameter based on RECIST criteria to determine treatment response [17]. Since these 
measurements are taken during the normal clinical workflow by the physician; we use 
them as initializations for the segmentation algorithm. Specifically, the endpoints of the 
RECIST segment on the CT image serve as the only operator inputs to the segmentation 
algorithm. These line segments allow for localization of our post-SABR consolidative 
regions of interest on the follow-up scan eliminating the need for any deformable 
registration to localize the area from the planning scan.  
 The recently published OneCut graph cuts algorithm was used to segment the 
consolidative regions [25, 26]. This algorithm finds the segmentation that minimizes the 
L1 distance between unknown object and background appearance models. The variation 
of this algorithm that uses seeds for initialization minimizes the energy function 
 𝐸(𝑆) = −𝛽�𝜃𝑆 − 𝜃?̅?�
𝐿1
+ |𝜕𝑆|,  (1) 
where 𝑆 is the segmentation, 𝜃𝑆 and 𝜃?̅? are the distributions of object and background 
intensities, respectively, and 𝛽 is a tuning parameter (0.05 in our experiments) 
determining the relative contributions of the L1 intensity model difference and the 
segmentation perimeter length to the overall energy. In practice, 𝜃𝑆 and 𝜃?̅? are 
represented as histograms with a specified number of bins (64 in our experiments). The 
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tuning parameter was determined using a subset of 4 images (2 RILI and 2 recurrence) 
spanning differences in size, shape, and appearance of the consolidative regions. The 
input RECIST line segments used to tune the parameter was separate from the RECIST 
line segments used to validate the algorithm. The OneCut approach globally minimizes 
this energy function with a single graph cut and is particularly suited to our problem 
given its speed, its natural incorporation of object and background seeds as input, and its 
demonstrated superior performance to the closest competing GrabCut method [27] for 
bin counts > 20, allowing for segmentation of objects having more subtle intensity 
differences from background [25]. The foreground seeds were defined as voxels greater 
than or equal to a threshold of -200 HU within a sphere 𝐴, centered at the midpoint of the 
RECIST segment, with a diameter equal to the length of the RECIST segment plus 10 
mm. The background seeds were defined as all voxels within normal lung parenchyma, 
not within sphere 𝐴, and within a sphere 𝐵 centered at the midpoint of the RECIST 
segment with a diameter equal to the length of the RECIST segment plus 20 mm. The 
OneCut segmentation was performed on each slice (mapping the lung window/level 
range of -1350 to 150 HU to an 8-bit range) within a region of interest (ROI) centered on 
and enveloping the background seeds. Any parts of these segmentations lying outside of 
the whole lungs (in cases where the consolidation abutted the lung boundary) were 
removed and the 3D largest connected component closest to the RECIST line was taken. 
Due to the inclusion of small adjacent vessels in the 3D volume, a subsequent slice-by-
slice 2D largest connected component was taken to remove these disconnected vessels in 
plane. Finally, the 3D largest connected component was taken as the final consolidation 
segmentation volume.  
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Figure 4-2: An overview of our semi-automatic segmentation approach and the methods 
used in this chapter. On the original CT image, an operator places a RECIST line 
segment to measure the longest axial diameter (taken in the normal clinical workflow).  
This was used as initialization for the OneCut algorithm to automatically obtain the 
consolidation segmentation (red). An expansion of this region defined the peri-
consolidative region (blue). On the original CT image manually delineated consolidation 
and ground-glass opacity (GGO) regions were also obtained. Texture analysis was 
performed in the GGO and semi-automatic peri-consolidative regions, and classification 
results were compared using 2-fold cross validation errors, false positive rates (FPR), 
false negative rates (FNR), and area under the receiver operating characteristic curve 
(AUC). 
 
 To validate our algorithm and assess the impact of inter-operator variability on 
segmentation and classification performance, three operators provided RECIST 
measurements of the consolidative changes post-SABR. If the consolidation region was 
split into more than one disconnected region, a separate measurement was taken for each 
region. Validation was performed with typical users of the system, including a senior 
radiation oncology resident (operator 1) and two thoracic radiation oncologists (operators 
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2 and 3). To avoid biasing the results, none of the operators in this study contributed to 
the design of the semi-automated segmentation algorithm. 
4.2.2.4 Automatic Delineation of Peri-Consolidative Region  
 A peri-consolidative region within the lung parenchyma was derived 
automatically by thresholding the 3D distance transform of the consolidation 
segmentations. The threshold was set at 16 mm based on our previous observation that 
classification performance does not differ substantially from that given by the 
corresponding manually delineated GGO above this threshold [14]. The domain was also 
restricted to a sphere, centered at the midpoint of the RECIST segment, with a diameter 
equal to the length of the RECIST segment plus 32 mm (16 mm × 2). This is due to the 
possible inclusion of connected vessels distant to the consolidative mass or extra 
consolidative regions erroneously included in the semi-automatic segmentation. A sphere 
defined by the RECIST line segment will, by definition, circumscribe the lesion; this 
shape was chosen to enable concentric sampling of the tissue outside of the consolidative 
mass. We want to ensure we are sampling the peri-consolidative region adjacent to the 
treatment site and avoiding sampling additional normal lung distant to the consolidative 
mass. The size of the sphere was chosen to encompass the entire RECIST line plus a 16 
mm margin on each end, which was chosen for consistency with the 16 mm threshold 
used for expansion from the consolidative mass. An example of a resulting peri-
consolidative region is seen in Figure 4-2. 
4.2.3 Feature Extraction and Image Analysis 
 MATLAB 8.4 (The Mathworks, Natick, MA) was used to calculate first-order 
texture as the standard deviation of the density within the GGO or peri-consolidative 
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region. The Insight Segmentation and Registration Toolkit (ITK) 4.3.1 (www.itk.org) 
was used to calculate four second-order texture features based on a gray level co-
occurrence matrix (GLCM): energy, entropy, inertia and correlation [28-30]. The 
equations for calculation of these texture features are 
 Energy = ∑ 𝑔(𝑖, 𝑗)2𝑖,𝑗 , (2) 
 Entropy = −∑ 𝑔(𝑖, 𝑗)𝑖,𝑗 log2 𝑔(𝑖, 𝑗) or 0 if 𝑔(𝑖, 𝑗) = 0, (3) 
 Correlation = ∑ (𝑖−𝜇)(𝑗−𝜇)𝑔(𝑖,𝑗)
𝜎2𝑖,𝑗 , and (4) 
 Inertia = ∑ (𝑖 − 𝑗)2𝑖,𝑗 𝑔(𝑖, 𝑗), (5) 
where 𝑔 is a two-dimensional matrix where each element 𝑔(𝑖, 𝑗) contains the number of 
voxel pairs whose elements have gray levels 𝑖 and 𝑗, where 𝜇  is the weighted pixel 
average 
 𝜇 =  ∑ 𝑖 ∙ 𝑔(𝑖, 𝑗) = 𝑖,𝑗 ∑ 𝑗 ∙ 𝑔(𝑖, 𝑗)𝑖,𝑗  (due to symmetry of 𝑔), (6) 
and 𝜎 is the weighted pixel variance 
 𝜎 = ∑ (𝑖 − 𝜇)2𝑖,𝑗 ∙ 𝑔(𝑖, 𝑗) =  ∑ (𝑗 − 𝜇)2𝑖,𝑗 ∙ 𝑔(𝑖, 𝑗) (due to symmetry of 𝑔). (7) 
The number of bins and density ranges in the GLCM were set to yield 20 HU bin widths 
between -1000 HU and 200 HU (60 bins), based on analysis of the histogram 
distributions within manually delineated GGO regions. GLCMs were calculated within 
four in-plane neighbouring voxel pair directions [(-1, 0, 0), (-1, -1, 0), (0, -1, 0), (1, -1, 0)] 
for the entire 3D region of interest and texture features were averaged over all directions. 
When calculating a GLCM, the neighbouring voxel to be analyzed must be specified by 
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the distance and location (in the x, y, and z directions) from the reference voxel. An 
example of the four in-plane neighbouring voxel relationships is shown in Figure 4-3. 
Due to the voxel anisotropy typically seen in post-radiation follow-up lung CT images (5 
mm slice thickness), we did not analyze through-plane directions in this study. Features 
were analyzed within two discrete time periods: 2–5 and 5–8 months post-SABR. This 
timing of images was chosen as the focus of our study is on the early prediction of 
recurrence post-SABR. Within each time period, the images used for analysis spanned all 
22 patients and 24 tumours available. 
 
Figure 4-3: The four in-plane spatial relationships used for calculating the gray level co-
occurrence matrix (GLCM). The dark central voxel is the reference voxel, and the 
neighbouring voxels considered in the analysis are shown in gray. 
 
4.2.4 Classification 
 PRTools 5.0 (Delft Pattern Recognition Research, Delft, The Netherlands) was 
used for classification. For a stringent determination of classification performance, two-
fold CV over 1,000 repetitions was performed using a linear Bayes normal classifier. The 
mean and standard deviation of the classification error, false negative rates (FNRs), false 
positive rates (FPRs), and AUCs were measured, where recurrence is defined as positive. 
Classification performance was measured for all five extracted texture features in both 
(0, -1, 0) (1, -1, 0) (-1, -1, 0)
(-1, 0, 0)
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the automatically-defined peri-consolidative regions and the manually-delineated GGO 
regions. 
4.2.5 Comparison of the Semi-Automatic Segmentations 
 To compare the segmented regions between operators, similarity metrics were 
calculated to measure segmentation differences. The symmetric mean absolute boundary 
difference (MAD), Dice similarity coefficient (DSC)  �2 |𝑉𝐴 ⋂𝑉𝐵 ||𝑉𝐴| + |𝑉𝐵| �, volume difference 
(VD) (𝑉𝐵− 𝑉𝐴), recall � 𝑇𝑇𝑇𝑇+𝐹𝐹�, and precision � 𝑇𝑇𝑇𝑇+𝐹𝑇� were calculated, where 𝑉𝐴 and 𝑉𝐵 
are the volumes of the segmentations by operator A and B, respectively, and 𝑇𝑇 = true 
positive, 𝐹𝑇 = false positive, 𝑇𝑇 = true negative, and 𝐹𝑇 = false negative. Segmentation 
metrics were calculated on all of the images used in this study. Each metric was 
calculated on the same 3D image volume between operators. Calculation of 
segmentations differences was completed between all operators for the semi-automated 
consolidative regions. Due to the lack of a reference operator when comparing 
segmentations between operators, the F1 score was calculated to eliminate the effect of 
reference operator selection on precision and recall metrics. The F1 score is the harmonic 
mean of the precision and recall and can be used to measure the segmentation 
accuracy �2 ∙ � 𝑝𝑝𝑝𝑝𝑖𝑝𝑖𝑝𝑝∙𝑝𝑝𝑝𝑒𝑒𝑒
𝑝𝑝𝑝𝑝𝑖𝑝𝑖𝑝𝑝+𝑝𝑝𝑝𝑒𝑒𝑒
��. Additionally, the time to generate the manual and semi-
automatic segmentations was measured and compared. 
4.2.6 Statistical Analysis 
 All statistical analyses were completed in SPSS Statistics Version 22.0 (IBM 
Corp., Armonk, NY, USA). To compare segmentation differences between operators, a 
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Kolmogorov-Smirnov test was first completed to test for normality of distribution for all 
the measures. A Wilcoxon signed rank test for nonparametric data was used to compare 
differences between operators (two-sided with alpha ≤ 0.05). To compare classification 
performance between operators, an independent samples t-test with unequal variances 
was performed to test the null hypothesis that the mean classification performance 
between operators was equal. Due to the repeated sampling in the cross-validation 
metrics (1000 times), to correct for multiple testing a Bonferroni correction was applied 
with alpha ≤ 0.05/1000. To determine non-inferiority of the semi-automated classification 
results with respect to results obtained using the manual segmentations, the 95% 
confidence interval of the difference in cross-validation metrics was assessed. An 
inferiority margin of 5% was chosen as an acceptable clinical difference in cross-
validation metrics. 
4.3 Results 
4.3.1 Manual Segmentations 
 Classification performance at 2–5 months post-SABR using texture features 
within manually delineated GGO regions is shown in Figure 4-4. We examined 
classification results within this early time range, as we want to determine the ability to 
predict recurrence as early as possible post-SABR. The top-performing feature in terms 
of 2-fold CV error was entropy. At 2–5 months post-SABR, the mean 2-fold CV error 
was 27.4%, with a mean FPR and FNR of 29.5% and 25.3% respectively, and an AUC of 
0.64.  For comparison, the AUC value at 5–8 months post-SABR was 0.67 and is shown 
in Table 4-1. A 5–8 months post-SABR, the entropy feature demonstrated a 2-fold CV 
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error of 30.0%, mean FPR of 25.2% and mean FNR of 36.2%.  A qualitative 
representation of the manually delineated regions of interest is provided in Figure 4-1. 
 
Figure 4-4: Classification performance of the manual GGO and semi-automatic peri-
consolidative regions for the top-performing texture feature (entropy) at 2–5 months post-
SABR. The columns indicate the mean 2-fold cross-validation errors, mean false positive 
rates (FPR), mean false negative rates (FNR), and the area under the receiver operating 
characteristic curve (AUC). The whiskers indicated the standard deviation over 1,000 
repetitions and each color represents a different operator. The asterisks indicate a 
statistically significant difference between operators (p < 0.00005). 
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Table 4-1: Area under the receiver operating characteristic curve for the top texture 
feature (entropy) at both time points post-SABR 
 2–5 months 5–8 months 
Operator 1 (Manual) 0.64 ± 0.04 0.67 ± 0.04 
Operator 1 (Semi-auto) 0.73 ± 0.06 0.71 ± 0.05 
Operator 2 (Semi-auto) 0.70 ± 0.04 0.67 ± 0.07 
Operator 3 (Semi-auto) 0.71 ± 0.05 0.69 ± 0.07 
 
4.3.2 Semi-Automated Segmentations 
4.3.2.1 Segmentation Comparison 
 Similarity metrics for the semi-automatic consolidative segmentations are 
summarized in Table 4-2. The majority of the metrics failed a Kolmogorov-Smirnov test 
for normality, and therefore the median values are reported. A Wilcoxon signed rank test 
for nonparametric data was performed to test the null hypothesis that the medians of each 
group are equal. Overall, when using the semi-automatic approach, inter-operator 
variability was low with values for the F1 score ranging from 0.87–0.93 and boundary 
differences from 1.00–1.75 mm. Operator 3 showed the largest variability with 
significant differences in all four metrics. However, the volume overlap (DSC) 
measurements still showed high overall agreement in the segmentations, with values of 
0.87–0.93. Qualitative examples for all of the operators’ semi-automatic segmentations 
are shown in Figure 4-5.  
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Table 4-2: Inter-operator variability in the semi-automatic consolidative segmentations; 
all values are reported as the median [interquartile range]. 
Operator 
MAD bilateral 
(mm) 
DSC F1 Score 
Volume 
Difference 
(cm3) 
1 vs 2 
1.18  
[0.31, 2.62]  
 0.90  
[0.78, 0.98]  
0.90  
[0.78,0.98]  
-1.66# 
[-17.91, 0.33]  
1 vs 3 
1.75* 
[0.60, 3.19]  
0.87* 
 [0.74, 0.97]  
0.87*  
[0.74, 0.97]  
-10.56*# 
 [-22.86, -1.68]  
2 vs 3 
1.00* 
[0.45, 2.13]  
0.93* 
[0.81, 0.97]  
0.93*  
[0.81, 0.97] 
-3.57*  
[-13.58, 0.06] 
*#Indicates significant differences between rows, p < 0.05 
 
Figure 4-5: The pre-treatment lesion used for treatment planning and a 3-month follow-
up scan showing the radiological changes post-SABR for a patient with radiation-induced 
lung injury (1) and recurrence (2). Semi-automated segmentations of the consolidative 
regions (red) and peri-consolidative regions (blue) surrounding them. Operators 1, 2 and 
3 are shown for each case. 
Operator 1 Operator 2 Operator 3 
Operator 1 Operator 2 Operator 3 
(1) Radiation-induced lung injury 
(2) Recurrence
Follow-UpPlanning
Follow-UpPlanning
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4.3.2.2 Classification Performance 
 Classification performance at 2–5 months post-SABR within the automatically 
derived peri-consolidative regions is shown in Figure 4-4 for the top feature (entropy). 
Using these segmentations, entropy had mean 2-fold CV errors of 24.7-27.8% across all 
three operators. Operator 1 had a significantly lower mean 2-fold error compared to 
operators 2 and 3. There was no significant difference in mean errors between operators 2 
and 3. Overall, the decision support system based on semi-automatic segmentations 
produced balanced FPRs and FNRs of 25.8-30.6% and 23.5-25.3% respectively. There 
was no significant difference in the mean FNRs between any of the operators. All three 
operators had significantly different mean FPRs, however differences were all ≤ 5%. At 
2–5 months post-SABR entropy had AUC values between 0.70-0.73 for all operators, 
which was significantly different between all operators. For comparison, the AUC values 
at 5–8 months post-SABR are shown in Table 4-1 and were between 0.67–0.71 for all 
operators.  At this time point, the entropy feature had 2-fold CV errors of 22.8-31.3%, 
mean FPRs of 21.6-23.3% and mean FNRs of 22.8-43.9%. 
4.3.3 Comparison of System Performance: Manual vs Semi-Automatic 
Segmentations 
4.3.3.1 Classification Performance 
 Comparison of classification performance at 2–5 months post-SABR using the 
manual and semi-automatic decision support systems is shown in Figure 4-4. 
Classification using the semi-automated method was compared to classification 
performance using the manual delineations performed by the senior radiation oncology 
resident. Using the semi-automatic segmentations, the entropy texture feature produced 
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AUCs higher than the manual contours for all three operators. All AUC values using the 
semi-automated approach were significantly different from reference manual contours. In 
terms of mean 2-fold error, operator 1 demonstrated a significantly better performance 
compared to their manual segmentations. There was no significant difference in 
classification performance between the manual and the semi-automatic segmentations by 
operators 2 and 3. There were also no significant differences with respect to the FNRs. 
However, operators 1 and 3 produced significantly lower FPRs compared to the manual 
segmentations, whereas no difference was observed with respect to operator 2. A non-
inferiority study was completed to determine if the semi-automated approach was non-
inferior to the manual approach. Figure 4-6 shows the 95% confidence intervals of the 
differences between the semi-automated and manual classification metrics. Non-
inferiority was demonstrated for all metrics as the 95% confidence intervals fell within 
clinically acceptable differences of 5%. At 5–8 months post-SABR the AUC and 2-fold 
errors values were similar to 2–5 months. Results were also consistent between the 
manual and semi-automated systems, with AUC values within 0.04 and 2-fold errors 
within 7%. Overall, classification results showed robustness using the semi-automatic 
approach and were comparable to or exceeded the results using manually delineated 
regions. Individual feature values for the recurrence and injury groups, as well as all 
classification metrics are summarized in Appendix C, Table C1 and C2. 
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Figure 4-6: Non-inferiority analysis for the difference between means (semi-automated – 
manual) for the classification error metrics (A) and area under the receiver operating 
characteristic curve (AUC) (B). The markers indicate the mean differences and the 
whiskers represent the 95% confidence intervals. The vertical dashed lines represent an 
acceptable clinical difference of 5% for all metrics. 
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4.3.3.2 Timing  
 The average time (± SD) for operator 1 to manually delineate the consolidative 
and GGO regions on each image (for a subset of 20 images) was 579 ± 472 seconds (i.e. 
9.6 ± 7.9 minutes). The semi-automatic approach took 27 ± 25 seconds to obtain the 
consolidative and peri-consolidative regions on each image. The increase in segmentation 
speed was 20-fold, with an average savings of 9 minutes per image.  
4.4 Discussion 
 The ability to distinguish benign fibrosis from tumor recurrence is crucial in 
determining a patient’s care following SABR, and determine whether salvage surgery or 
additional radiotherapy is required. Current clinical guidelines recommend the use of 
serial CT imaging for follow-up assessment after treatment with SABR. Therefore, a 
reliable measure for determining recurrence on CT imaging would be extremely valuable 
as the utilization of SABR is rapidly increasing. The use of quantitative appearance 
measures could provide an early assessment of response through quantifying subtle 
patterns predictive of recurrence not typically considered by a radiologist or radiation 
oncologist.  
 Our work in Chapter 3 has shown that the entropy texture feature calculated 
within manually delineated regions of GGO could predict recurrence with 2-fold CV 
errors of 24% at 2–5 months post-SABR [13]. The results presented in this study using 
manual segmentations by a different operator were concordant, with an error of 27%. 
There exist radiographic changes to the tissue surrounding the consolidative regions as a 
result of SABR (as shown in Figure 4-1), which can cause a substantial loss of boundary 
contrast. These observations provide important context for the evaluation of automatic 
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segmentation algorithms for consolidation regions on post-SABR lung CT images by 
quantifying the uncertainty inherent in the manual reference standard. GGO regions can 
also have a highly variable appearance and an ill-defined border, rendering them very 
challenging to delineate.  This emphasizes the difficulties in delineating these regions and 
lack of a single ground truth reference standard segmentation for this problem. To 
eliminate the need for time consuming manual segmentations and any inherent variability 
between them, the goal of this study was to produce an accurate and reproducible means 
of recurrence prediction post-SABR using semi-automatic segmentations.   
  This work has shown the ability to predict recurrence post-SABR using texture 
analysis in regions delineated by means of a semi-automated segmentation algorithm, 
initialized using only the RECIST diameter measurement that is normally collected 
during the clinical workflow. This diameter measure on post-SABR follow-up scans is 
assessed according to the RECIST 1.1 criteria by comparing it to the pre-treatment scan 
[17]. Consequently, it provides a quick and efficient means for initialization of our 
decision support system. It will also guarantee localization of our post-SABR 
consolidative regions of interest regardless of deformations and retractions from the pre-
treatment location. We also considered that in the typical clinical workflow, the RECIST 
line segment would be taken by the radiologist reading the CT image and would be 
external to our workflow. In other words, we would obtain this line segment when we 
obtain the follow-up image, leading to a fully automatic overall system based on semi-
automated segmentation.  
 We reported small differences between the semi-automated segmentations 
obtained from each operator. This is due to variability in the placement of the RECIST 
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line segment. It has been well described that substantial variability exists, both between 
and within operators, in the measurement of response in lung cancer patients [31, 32]. 
This variation can be seen in the placement of line segments measuring longest axial 
diameter according to RECIST guidelines. This can be particularly evident in the post-
SABR context due to the highly variable size and shape of the consolidative masses (they 
are not typically spherical as is commonly the case for pre-treatment tumors) as shown in 
Figure 4-1. Consequently, it can be difficult to determine the correct location on which to 
place the line segment. However, the differences we observed in the physical placement 
of the line segment had a minor impact on the graph cuts algorithm, since the foreground 
and background samples (as shown in Figure 4-2) are likely to vary only slightly. The F1 
scores were all greater than 0.85, suggesting high inter-operator agreement in the semi-
automatic consolidative regions. 
 As mentioned previously, the GGO surrounding the consolidative regions on 
follow-up images decreases the boundary contrast of the consolidation. Overcoming the 
loss of contrast using smoothness and/or shape priors may not be straightforward, given 
the non-smooth and highly variable shapes of the consolidative regions (as seen in Figure 
4-1). Most importantly however, this semi-automatic segmentation provides basis for the 
automatically-defined peri-consolidative region. As shown in Figure 4-5, the peri-
consolidative regions are in general dissimilar to the manual GGO regions seen in Figure 
4-1. This is intentional, as our intention is to sample a region surrounding the 
consolidative regions within which to calculate the texture features. Our previous work 
demonstrated that sampling a region surrounding the consolidative region was sufficient 
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for predicting recurrence, and that a complete segmentation of GGO was not required 
[14]. 
 Our system shows high predictive accuracy using the second-order entropy 
texture feature with AUCs of 0.70–0.73 at 2–5 months post-SABR. It was also robust to 
inter-operator variability in the initialization of the system by placement of the RECIST 
diameter measurement. Although classification performance using the semi-automated 
method was compared only against a single operator’s manual segmentations, non-
inferiority was demonstrated among all three operators.  Robustness in classification 
performance was also demonstrated among operators, suggesting a reproducible means 
for delineating the consolidative regions even with variations in RECIST line segment 
placement among operators. Our semi-automatic approach potentially eliminates the need 
for manual segmentations and this provides an important avenue for future work on a 
larger dataset as part of our ongoing work. Results at 5–8 months post-SABR were 
comparable to the results at 2–5 months post-SABR. This demonstrates stability of 
system performance through time, and also demonstrates that the appearance of 
radiological changes at the two earliest clinically scheduled follow up time points 
(approximately 3 and 6 months) could be important in predicting recurrence. As 
previously demonstrated in patients with recurrence, these regions have a more 
variegated texture, perhaps indicative of early vascular changes as seen in Figure 4-1. 
Patients who develop only benign fibrosis seem to have a more homogenous appearance 
to the GGO, or minimal appearance of GGO changes post-SABR. Our ongoing work is 
examining these regions of post-SABR changes histologically, to determine their 
composition and correlate this to observations on CT imaging. 
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 Previous studies using qualitative high-risk appearance features have shown the 
utility of categorizing a patients risk of recurrence, however most of these features do not 
typically appear until a year post-treatment [6]. Other imaging-based features such as size 
or mass-like shape can be ineffective for early detection of local recurrence post-SABR 
[33-35]. FDG-PET has also been investigated for distinguishing fibrosis from recurrence 
post-SABR and it has been shown that maximum standardized uptake values (SUVmax) 
can be predictive of recurrence, but not until a year post-SABR [36, 37]. A recent 
approach using CT perfusion imaging for response assessment has been investigated for 
pulmonary metastases undergoing SABR; however, further analysis is needed in a larger 
cohort of patients [38]. The combination or addition of these techniques to our decision 
support system may be useful for aiding in the assessment of difficult cases. 
 To the best of our knowledge, there has been no previous study on semi-automatic 
segmentation of post-SABR consolidative changes on CT. An interesting avenue for 
future work would be in refining these segmentations to enable quantification of shape 
and size changes of these regions. Another interesting area of further study could look at 
additional methods for segmentation. One such possibility is using the tumour delineation 
on the planning scan and performing a deformable registration to the follow-up scan. 
Such an approach would be fully automated but would require highly accurate 
deformable registration capable of compensating for highly variable and localized post-
SABR radiological changes. This would also need to compensate for tissue retractions 
that can occur in the lung post-SABR, displacing the consolidations from their original 
locations in the planning scan. Nevertheless this would be an interesting future study and 
would be considered a fully automated method, eliminating the impact of variability in 
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RECIST line segment placement by different physicians. However, our initial work has 
shown robustness of the decision support system to differences in line segment placement 
by different operators. 
 We must consider our study in the context of its limitations, including the small 
sample size of patients with significant benign fibrosis. Our ongoing work involves 
validation on a larger sample set of patients matched based on patient and treatment 
characteristics. This will allow for a more comprehensive analysis of post-SABR 
changes. This study also focused solely on our previously published top five texture 
features for recurrence prediction, and further work on a more compressive radiomic 
feature set and machine learning platform may improve prediction results on a larger data 
set. The focus of this study was on the early prediction of recurrence and images analyzed 
at 3 and 6 months post-SABR. Further studies should be completed on additional time 
points to determine the usefulness of image features for recurrence prediction as time 
post-SABR increases and to determine the optimal time point for prediction. This study 
also did not consider the effect of different scanners and reconstruction techniques in the 
analysis; however, all images were taken with the same acquisition and reconstruction 
parameters to minimize discrepancies [39]. Determining the effect of different acquisition 
parameters on classification results is an interesting avenue for future study. Also, 
reference manual contours for classification were completed by a single operator and the 
validation of our semi-automated algorithm was completed with only 3 operators with 
similar expertise. Further validation should be completed with additional operators with 
different expertise (ex. radiologists or senior radiation oncologists) who would be 
considered typical users of this time of algorithm. Another limitation of the current work 
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is the use of the same imaging dataset as used in Chapters 2 and 3. Using the same small 
dataset could potentially introduce bias into our results. To enable clinical translation, a 
comprehensive validation and user study on a larger dataset is ongoing.  
4.5 Conclusion 
 Second-order texture features calculated within GGO delineated from a semi-
automated algorithm, initialized using only the RECIST diameter measurement routinely 
taken during the clinical workflow, have shown the potential to predict recurrence in 
individual patients within 6 months of SABR. At 2–5 months post-SABR, second-order 
entropy provided good recurrence prediction based on semi-automatic segmentations, 
with AUCs of 0.70–0.73; the corresponding result using a manual segmentation was 0.64. 
This system demonstrated consistent segmentations and prediction accuracies between 
operators, which were concordant with prediction accuracies, based on a single reference 
manual segmentations and obtained 20 times faster using the automated approach. The 
next step of this study is to validate our algorithm on an additional 93 patients we have 
obtained. This work has the potential to lead to a clinically useful computer-aided 
diagnosis tool which can be easily integrated into a physician’s workstation and eliminate 
the need for any manual segmentation. An automated decision support system can 
improve the physician’s assessment of response following SABR to predict recurrences 
as early as possible. This will allow patients to receive timely salvage therapies, and 
reduce the risk of patients with only benign fibrosis undergoing risky biopsy procedures. 
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Chapter 5  
Towards the goal of understanding how physicians perform in response assessment post-
SABR, we evaluated and compared a radiomics decision support system to physician 
assessment of response following SABR. 
The contents of this chapter were previously published in the ernational Journal of 
Radiation Oncology* Biology* Physics: SA Mattonen, DA Palma, C Johnson, AV Louie, 
M Landis, G Rodrigues, I Chan, R Etemad-Rezai, TPC Yeung, S Senan, and AD Ward. 
Detection of local cancer recurrence after stereotactic ablative radiotherapy (SABR) for 
lung cancer: physician performance versus radiomic assessment. Int J Radiat Oncol Biol 
Phys 2016;94(5):1121-28. Permission to reproduce this article was granted by Elsevier 
and is provided in Appendix A.6. 
 DETECTION OF LOCAL CANCER RECURRENCE 5
AFTER SABR FOR LUNG CANCER: PHYSICIAN 
PERFORMANCE VERSUS RADIOMIC ASSESSMENT 
5.1 Introduction 
 Stereotactic ablative radiotherapy (SABR) is a guideline-recommended treatment 
option for patients with early-stage lung cancer who are medically inoperable or refuse 
surgery [1, 2]. SABR can achieve local control rates comparable to surgery of 90% at 3 
years post-treatment [3]. However, following treatment with SABR, patients often 
develop benign radiation-induced lung injury which can mimic recurrence. In some cases 
this leads to resection for lesions ultimately proven to contain only fibrotic tissue [4-7]. 
Early detection of patients with local recurrence using standard follow-up computed 
tomography (CT) images may allow for timely salvage surgery, which has been shown to 
be feasible in such patients [8, 9]. Accurate recurrence detection may avoid unnecessary 
scans and interventions in patients harboring only benign fibrosis. 
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Local recurrences typically manifest at a median time of 15 months following 
SABR, but may present up to 5 years later [10]. Qualitative high-risk CT features (HRFs) 
have been validated as predictors of recurrence, and include the presence of an enlarging 
opacity, enlargement after one year, sequential enlargement from one scan to the next, 
bulging margin, linear margin disappearance, air bronchogram loss, and cranio-caudal 
growth [11-13]. However, such HRFs are subject to inter-observer variability, and may 
not be observable until beyond 1-year post treatment [12]. 
Radiomics is a developing area of research that aims to extract more complex 
information from conventional medical images, including features not easily visible or 
quantifiable with the naked eye. These features can be used to build models for clinical 
outcomes, including diagnostic, prognostic, or predictive information [14, 15]. We 
hypothesize that radiomic image features could improve prediction accuracies by 
detecting subtle imaging changes not observed by a physician. In recent pilot studies, we 
demonstrated the ability of quantitative CT image analysis for early prediction of 
recurrence after SABR [16-18]. Texture features calculated within areas intended to 
subsample post-SABR ground-glass opacity could predict recurrence at 3-months post-
SABR, with areas under the receiver operating characteristic curve (AUC) of 0.78–0.81. 
However, a limitation to clinical translation of this technique was the small dataset and 
limited set of radiomic features used. 
To our knowledge, no prior studies have assessed either physician performance or 
inter-physician variability and reliability in detecting recurrence after SABR. The goals 
of this study were to determine the accuracy of expert radiologists and radiation 
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oncologists’ assessment of local recurrence versus non-recurrence on a series of follow-
up CT images post-SABR, and to compare physician performance to a radiomics tool.  
5.2 Methods and Materials 
5.2.1 Materials and Imaging 
The study population consists of patients with T1/T2N0 non-small cell lung 
cancer (NSCLC) treated with SABR. 15 patients with local recurrence were matched 1:2 
with patients without recurrence, but with radiological radiation-induced lung injury 
(RILI), according to baseline factors including planning target volume (PTV) size, 
tumour location, and fractionation as previously described [12]. These tumours were 
treated to a dose of 54–60 Gy in 3–8 fractions, using a risk-adapted approach, as 
described previously [19]. Of the 15 patients with local recurrence, seven recurrences 
were confirmed with biopsy and the remaining eight were determined local recurrences 
based on a combination of CT, FDG positron emission tomography (PET) findings and 
subsequent clinical outcomes. The maximum inspiration phase of respiration was used 
for analysis on the pre-treatment planning CT image. Standard follow-up practices were 
to acquire diagnostic CT images at 3, 6, and 12 months post-SABR and every 6-12 
months thereafter, although the actual timing of scans were subject to normal clinical 
variability. Matched patients were required to have follow-up CT imaging at similar time 
intervals and durations.  
Pre-treatment CT scans used for treatment planning were acquired for each 
patient using four-dimensional (4D) CT (Lightspeed 16; GE Medical Systems, 
Waukesha, USA) at 140 kVp, 100–110 mAs, and 2.5 mm slice thickness. The maximum 
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inspiration phase of respiration was used for analysis. Post-treatment diagnostic CT scans 
were taken on one of three scanners: Siemens Volume Zoom 4-slice, Siemens Sensations 
64-slice (Siemens Nederland N.V., Den Haag, Netherlands) or Philips Brilliance iCT 
256-slice (Royal Philips Electronics, Inc., Amsterdam, Netherlands). Follow-up scans 
were acquired at inspiratory breath hold with standard imaging parameters of 120 kVp, 
100 mAs, spiral acquisition, 0.5 second rotation time, 2.5–5 mm slice thickness, and 70 
cc of intravenous contrast (Ultravist-300; Bayer Pharma AG, Berlin, Germany) 
administered with a 25 second delay.  
5.2.2 Observer Performance 
 Three thoracic radiation oncologists specializing in treatment of NSCLC with 
SABR (observers 1–3) and three board-certified thoracic radiologists (observers 4–6), all 
of whom were blinded to outcomes, were asked to score all follow-up images as either 
benign injury/no recurrence or local recurrence. Data collection was completed using an 
in-house developed user interface in ClearCanvas Workstation 2.0 (Synaptive Medical, 
Toronto, Canada), as shown in Figure 5-1. All images were anonymized and randomized 
for each observer. 
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Figure 5-1: In-house developed user interface in ClearCanvas Workstation 2.0 
(Synaptive Medical, Toronto, Canada) for data collection in observer study. 
  
 The custom-made interface in ClearCanvas was developed to mimic the clinical 
assessment of sequential scans over time. The interface first provided the physician with 
the planning CT scan to localize the pre-treatment lesion. After reviewing the planning 
scan, the first follow-up image was displayed. The physician was required to then provide 
an assessment (no recurrence vs. recurrence), and indicate the certainty level of the 
assessment on an ordinal scale (none, somewhat, moderately, very, or completely 
certain). Physicians were then asked to recommend the immediate next step for this 
patient (ignoring any non-local signs of disease); options included ongoing CT follow-up 
at standard or shorter time interval, biopsy, PET, or immediate salvage therapy. After 
entering these data, the responses were locked and the next follow-up image was shown. 
Assessments were made sequentially on all follow-up images available for each patient. 
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Observers were able to return to earlier scans in order to assess sequential changes, but 
could not modify responses. They also had full control over the interface to view and 
assess images at their own speed and adjust the window/level settings as needed. 
Observers were also provided written and verbal instruction prior to the reading session 
informing them of the task required, number of cases to be read and expected duration. 
To mitigate the assumption of a clinical prevalence of 10% local recurrences, observers 
were informed that the series of 45 patients contained 30–40% local recurrences. Of note, 
the term recurrence has been used throughout the chapter, although early assessment 
could indicate persistent disease. 
 At the first time point post-SABR, overall accuracy, false positive rate (FPR), and 
false negative rate (FNR) for physician assessment was measured. Sensitivity and 
specificity for assessing recurrence was also measured across all time points and 
available images. Fleiss' kappa was used to measure the reliability of agreement in all 
observations, across all six raters [20, 21]. Fleiss kappa is a measure of agreement 
between more than two raters giving categorical ratings, where agreement due to chance 
is factored out. A kappa less than or equal to 0 indicates poor agreement with agreement 
increasing as kappa approaches 1 (slight agreement=0.01-0.20,  fair=0.21-0.40, 
moderate=0.41-0.60, substantial=0.61-0.80, and almost perfect agreement=0.81-1.00) 
[21]. Statistical analyses were completed in MATLAB 8.4 (The Mathworks, Natick, MA) 
with statistical testing at the 0.05 significance level.  
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5.2.3 Radiomic Analysis  
 Consolidative and peri-consolidative regions were delineated based on our semi-
automated method, previously described in Chapter 4 [17, 18]. Briefly, on all follow-up 
CT images the tumour’s longest axial diameter based on Response Evaluation Criteria in 
Solid Tumours (RECIST 1.1) is measured during the normal clinical workflow and this is 
used to initialize the segmentation algorithm [22-24]. Further details pertaining to the 
region of interest delineation are outlined in Chapter 4. Examples of segmented 
consolidative and peri-consolidative regions are shown in Figure 5-2.  
 A custom radiomics and machine learning platform developed in-house was used 
to extract features from the consolidative and peri-consolidative regions using MATLAB 
8.4. In total, 22 first-order features and 22 second-order grey-level co-occurrence matrix 
(GLCM) textures were calculated in both regions. The number of bins and density ranges 
for the GLCMs were set to yield 20 HU bin widths with densities between -1000 HU and 
200 HU (60 bins) for the peri-consolidative regions and -600 HU and 200 HU (40 bins) 
for the consolidative regions. Due to the voxel anisotropy in post-SABR follow-up 
images, GLCMs were calculated within four in-plane neighbouring voxel directions [(-
1,1,0), (-1,0,0), (0,1,0), (-1,-1,0)] within the 3D segmented volume, and texture features 
were averaged over all directions. Additionally, in the consolidative regions, 16 size- and 
shape-based features were calculated. These features were not calculated in the peri-
consolidative regions as these regions’ sizes and shapes are defined according to the size 
and shape of the consolidation region and therefore would not be independent 
measurements. In total, 44 features were extracted from the peri-consolidative regions 
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and 60 features from the consolidative regions, for a total of 104 features per image 
volume. 
 
Figure 5-2: The 3-month post-SABR follow-up image for two patients who developed 
local recurrence (A and B) and two patients who developed only benign injury (C and D). 
The corresponding semi-automated consolidative (red) and peri-consolidative (green) 
segmentations are also shown. 
(2) Benign radiation induced lung injury
(1) Local recurrence
(A)
(B)
(C)
(D)
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Features were analyzed within the earliest follow-up time point post-SABR at 2–5 
months, corresponding to the clinically scheduled 3-month follow-up scan. PRTools 5.0 
(Delft Pattern Recognition Research, Delft, The Netherlands) was used for feature 
selection and classification [25]. Leave-one-out cross validation (LOOCV) was used for 
feature selection. At each fold of cross validation (CV), forward feature selection was 
performed on the training dataset only to select the optimal feature set, using the 1-
nearest neighbour leave-one-out classification performance. A support vector machine 
(nu algorithm, linear kernel) was used to evaluate classification performance [26]. Nu is 
the regularization parameter which is the expected fraction of support vectors estimated 
by the leave-one-out-error of the 1-nearest neighbour rule. For a direct comparison to 
physician performance at 2–5 months post-SABR, classification error, FNRs and FPRs, 
where recurrence is defined as positive, were calculated. Across all folds of cross 
validation, a voting scheme was used to determine the most frequently selected features. 
These features were chosen as the radiomic signature. Evaluation on the entire dataset 
was completed by leave-one-out, 10-fold, 5-fold, and 3-fold CV to determine the impact 
of different training and testing set sizes on classification performance. The AUC was 
also determined for this dataset. 
5.3 Results 
5.3.1 Patient Baseline Characteristics 
 Baseline characteristics for all 45 patients are presented in Table 5-1. In total, 182 
follow-up images were available for analysis with a median imaging follow-up of 20 
months. The recurrence and non-recurrence patient groups were well matched, with a 
median age of diagnosis of 70 years (range 59–84) and median PTV size of 38 cm3 
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(range 4–158 cm3). The fractionation scheme, and proportion of patients with central 
versus peripheral tumours, was also consistent across the groups. 
Table 5-1: Baseline patient characteristics. 
Characteristic 
All Patients 
(n = 45) 
Recurrence 
(n = 15) 
No-Recurrence 
(n = 30) 
Age – median (range) 70 (59−84) 71 (60−84) 70 (59−84) 
Tumour size (mm) – mean (SD) 34 (15) 35 (14) 33 (15) 
Male – N (%) 32 (71) 11 (73) 21 (70) 
Charlson score – mean (SD) 2.7 (1.8) 2.9 (1.3) 2.7 (2.0) 
Involved lobe – N (%)    
LUL 15 (33) 4 (27) 11 (37) 
LLL 11 (24) 4 (27) 7 (23) 
RUL 11 (24) 3 (20) 8 (27) 
RML 2 (4) 2 (13) 0 (0) 
RLL 6 (13) 2 (13) 4 (13) 
Location – N (%)    
Central 6 (13) 2 (13) 4 (13) 
Peripheral 39 (87) 13 (87) 26 (87) 
PTV (cm3) – median (min, max) 38 (4, 158) 38 (5, 144) 40 (4, 158) 
RT technique – N (%)    
Fixed Beam 37 (82) 12 (80) 25 (83) 
Rapid Arc 8 (18) 3 (20) 5 (17) 
Fractionation – N (%)    
3 12 (27) 4 (27) 8 (27) 
5 21 (47) 7 (47) 14 (47) 
8 12 (27) 4 (27) 8 (27) 
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5.3.2 Observer Performance  
 To determine the physicians’ ability to assess response over the entire course of 
follow-up, the sensitivity and specificity for identifying a recurrence at any time point 
during follow-up was assessed. Physicians had varying sensitivities and specificities for 
making a diagnosis of recurrence as observed in Table 5-2. The median sensitivity for 
physician assessment was 83.8% (range 67–100%) and median specificity was 75.0% 
(range 67–87%) across all observers. There was only a moderate level of agreement 
among all 6 observers, with a kappa value of 0.54 for all 182 assessments of recurrence 
vs. no recurrence. In all cases, radiologists (observers 4–6) had lower specificity 
compared to radiation oncologists (observers 1–3), but on average radiologists had higher 
sensitivity in detecting recurrence. The average time for each physician to first detect a 
local recurrence correctly post-SABR was greater than one-year post-SABR. However, 
radiologists were typically able to detect the recurrence earlier (mean of 13.4 months) 
than the radiation oncologists (mean of 18.2 months).  
 Although observers were informed that the dataset contained 30–40% local 
recurrences, the actual percentages of patients identified as recurrences varied among the 
observers. All three radiation oncologists assessed 38% of the patients as having a 
recurrence, consistent with the true percentage they were provided. However, all three 
radiologists assessed 49–53% patients as having a recurrence; a higher percentage than 
what was provided as truth.  
 The physicians’ certainty levels in their assessment varied substantially, with 
almost no agreement between observers (Table 5-2). One radiation oncologist (observer 
2) and the three radiologists (observer 4-6) tended to score the majority of images as very 
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or completely certain. Across all images, physicians’ certainty of assessment had a Fleiss 
kappa of 0.06, indicating only slight agreement. 
Table 5-2: Physician assessment of response post-SABR based on all follow-up images. 
 Radiation Oncologists Radiologists 
Observer 
1 
Observer 
2 
Observer 
3 
Observer 
4 
Observer 
5 
Observer 
6 
Sensitivity 86.7% 80.0% 66.7% 80.0% 100% 100% 
Specificity 86.7% 83.3% 76.7% 66.7% 70.0% 73.3% 
Average Time to 
Correctly Identify 
Recurrences*, Months 
(SD) 
16.8 
(10.6) 
19.4 
 (9.9) 
18.4 
(10.8) 
13.7 
 (5.7) 
14.2 
(7.0) 
12.4  
(7.0) 
Certainty Level,  
Number of Images (%) 
 
None 7  (3.8) 
7 
(3.8) 
0  
(0) 
0 
 (0) 
2  
(1.1) 
0 
(0) 
Somewhat 34  (18.7) 
19 
 (10.4) 
49  
(26.9) 
1 
 (0.5) 
26  
(14.3) 
12 
(6.6) 
Moderately 63  (34.6) 
23 
 (12.6) 
50 
 (27.5) 
32  
(17.6) 
50  
(27.5) 
33  
(18.1) 
Very 70  (38.4) 
43  
(23.6) 
52 
 (28.6) 
56  
(30.8) 
84  
(46.2) 
76  
(41.8) 
Completely 8  (4.4) 
90 
 (49.5) 
31  
(17.0) 
93  
(51.1) 
20  
(11.0) 
61  
(33.5) 
*For each observer, the average time across all patients to first detect a true local 
recurrence correctly. Abbreviations:  SD: standard deviation. 
 Figure 5-3 depicts the recommendations made for the next clinical intervention 
for each image dataset. Approximately 5% of all non-recurrence images (17 of 30 
patients) were recommended for additional intervention with PET imaging. There were 
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also 8 patients in which at least one observer recommended more invasive interventions 
including biopsy or immediate salvage for patients with only benign injury. The inter-
observer agreement in terms of recommendation across all images had fair agreement 
with a Fleiss kappa of 0.31.  
 
Figure 5-3: Inter-observer variability in follow-up recommendations across all follow-up 
image for patients with (REC) and without (NOREC) local recurrence. 
 
 The ability of physicians to predict recurrence within six months of SABR (using 
the 2–5 month follow-up scans) is shown in Table 5-3. At 2–5 months post-SABR, 38 of 
45 patients had a CT image available for analysis. Physicians assessed the majority of 
images this time point as benign injury/no recurrence, with a false negative rate of 100% 
for five of six physicians. In 5 instances during this time period (of 228 total 
assessments), a PET scan was recommended. In no scenarios was a biopsy or surgical 
salvage recommended. 
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Table 5-3: Leave-one-out cross-validation results of the radiomic signature compared to 
physician assessment at 2–5 months post-SABR. 
  Radiation Oncologists Radiologists 
 Radiomic 
signature 
Observer 
1 
Observer 
2 
Observer 
3 
Observer 
4 
Observer 
5 
Observer 
6 
Error 23.7% 34.2% 34.2% 36.8% 34.2% 36.8% 31.6% 
FPR 24.0% 0% 0% 4.0% 0% 4.0% 0% 
FNR 23.1% 100% 100% 100% 100% 100% 92.3% 
Percent 
Very or 
Completely 
Certain 
- 50% 100% 68% 100% 55% 95% 
 
5.3.3 Radiomics Performance 
 To determine the final radiomic feature set for validation, the top features which 
had votes in at least 80% of the feature selection folds (i.e. at least 30 votes) were chosen. 
The top five most-selected features over CV folds were four features in the peri-
consolidative region (minimum grey-level, GLCM homogeneity, GLCM correlation, and 
GLCM energy) and one feature in the consolidative region (grey-level uniformity) as 
shown in Table 5-4. This left a total of five features in the radiomic signature. 
Interestingly, nine of the top ten features were all appearance features within the peri-
consolidative region.  
 To assess the predictive power of this five-feature radiomic signature, folded CV 
was performed. Leave-one-out CV produced an error of 23.7%, FPR of 24.0%, and FNR 
of 23.1%. The results of leave-one-out, 10-fold, 5-fold, and 3-fold cross validation are 
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shown in Figure 5-4. The radiomic signature demonstrated robustness to differences in 
training and testing dataset size, with classification error increasing by only 8% from 
leave-one-out to 3-fold CV. It also demonstrated balanced FPRs and FNRs, with the 
exception of 3-fold CV. The AUC for this radiomic signature on this dataset was 0.85. 
Examples of six correctly classified recurrence and injury cases in the LOOCV are shown 
in Figure 5-5. A false positive and false negative case are also shown for comparison. 
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Table 5-4: Top selected features at 2–5 months post-SABR based on leave-one-out 
feature selection (38 folds). 
Features Equation Region of Interest Number 
of votes 
Minimum grey-
level  
The minimum intensity value of 
the region of interest. 
Peri-consolidative 32 
GLCM 
homogeneity   ��
𝑇(𝑖, 𝑗)1 + |𝑖 − 𝑗|𝐹𝑔
𝑗=1
𝐹𝑔
𝑖=1
 
Peri-consolidative 31 
GLCM 
correlation  ��
(𝑖 − 𝜇𝑖)�𝑗 − 𝜇𝑗�𝑇(𝑖, 𝑗)
𝜎𝑖𝜎𝑗
𝐹𝑔
𝑗=1
𝐹𝑔
𝑖=1
 
𝜇𝑖 = ��𝑖𝑇(𝑖, 𝑗)𝐹𝑔
𝑗=1
𝐹𝑔
𝑖=1
 
𝜇𝑗 = ��𝑗𝑇(𝑖, 𝑗)𝐹𝑔
𝑗=1
𝐹𝑔
𝑖=1
 
𝜎𝑖
2 = �(𝑖 − 𝜇𝑖)2𝑇(𝑖, 𝑗)𝐹𝑔
𝑖=1
 
𝜎𝑗
2 = ��𝑗 − 𝜇𝑗�2𝑇(𝑖, 𝑗)𝐹𝑔
𝑗=1
 
Where:  
Peri-consolidative 31 
GLCM energy  
��𝑇(𝑖, 𝑗)2𝐹𝑔
𝑗=1
𝐹𝑔
𝑖=1
 
Peri-consolidative 30 
Grey-level 
uniformity   �𝑇(𝑥)2𝐹𝑙
𝑥=1
 
Consolidative 30 
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*Grey-level co-occurrence matrix (GLCM) features: 𝑇(𝑖, 𝑗, ) is the GLCM, 𝑇𝑔 is the 
number of discrete grey level intensities, 𝑖 is the ith row of the GLCM, 𝑗 is the jth column 
of the GLCM. 
First-order features: P(x) is the intensity value of voxel x within the region of interest; x = 
1, 2, 3, …, N, where N is the number of voxels within the region of interest. 
 
 
Figure 5-4: Results of folded cross-validation at 2–5 months post-SABR using the five-
feature radiomic signature. 
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Figure 5-5: Example 2–5 month post-SABR scans for four patients who developed local 
recurrence (A-D) and four who developed only benign injury (E-H). Correctly classified 
recurrence (A-C) and injury patients (E-G) in LOOCV by the radiomic signature are 
shown. A false negative (D) and false positive (H) patient are also shown. 
 
5.4 Discussion 
 Surveillance following SABR for lung cancer is a major clinical challenge as 
radiographic fibrosis can mimic local recurrence. Recent reports of patients undergoing 
‘salvage resection’ for benign disease [4-6] underscore the difficulty in accurately 
distinguishing recurrence from fibrosis. To our knowledge, this is the first study assessing 
physician performance and accuracy in detecting local recurrence post-SABR. Overall, 
physicians demonstrated high sensitivity (83%) and moderate specificity (75%) for 
detecting recurrences, but the median time to detection of recurrence was 15.5 months. In 
addition, 9.4% of scans in patients with only benign changes resulted in a 
recommendation for further intervention with PET, biopsy, or immediate salvage 
treatment. Physicians were generally unable to detect recurrences within 6 months of 
(2) Benign radiation induced lung injury
(1) Local recurrence
(E) (G)
(A) (C)(B) (D)
(F) (H)
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SABR. In contrast, radiomics assessment was able to correctly classify 76% of patients 
using scans done <6 months post-SABR.  
 In our study, scans performed within 6 months post-SABR did not often result in 
suspicion of local recurrence by physicians, and this finding is consistent with the 
published literature on early post-SABR imaging. In a study examining the impact of 
early post-SABR imaging within 6-months post-treatment in 62 patients, only 3% of 
patients had changes on those scans that ultimately led to a diagnosis of early recurrence 
[27]. Overall, we demonstrated the ability of physicians to detect recurrences at a later 
time point, typically when the HRF’s become more salient on imaging. Agreement 
between observers in terms of assessments of recurrence was only moderate and the 
certainly level of assessments varied across all images and physicians. This suggests the 
importance of a multi-disciplinary group discussion when assessing responses post-
SABR. 
The appearances detected by radiomics may be early indicators of the disease 
persistence and progression to local recurrence, which were not typically considered by 
physicians. Radiomics could augment a physician’s assessment of response post-SABR 
to potentially allow for earlier detection of recurrence post-SABR and fewer 
investigations of only benign fibrosis. Future work includes measuring the performance 
of the physician when provided with the output of the radiomics system. The importance 
of radiomic appearance features in the peri-consolidative region supports the work 
presented in Chapters 2-4 on the importance of features surrounding the consolidative 
regions for recurrence prediction [16-18]. As seen in Figure 5-5, patients with recurrence 
tend to have increased presence of ground-glass opacity surrounding consolidative 
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changes compared to patients with benign injury. The false negative cases predicted by 
radiomics tended to have minimal ground-glass opacity as seen in Figure 5-5(D) and 
false positives tended to have a larger presence of ground-glass opacity as seen in Figure 
5-5(H). These appearances were similar to those cases correctly classified by the 
radiomics signature. Previous studies have also demonstrated the ability of CT texture 
analysis for predicting the development of radiation pneumonitis [28]. Radiomic 
signatures may identify patients in whom more frequent imaging, and regular reviews by 
multidisciplinary tumour boards are warranted. 
This study must be considered within the context of its strengths and limitations. 
We used actual clinical cases with standard-of-care imaging follow-up, assessors were 
blinded, and we used a large number (six) of expert observers. We used solely CT 
imaging for physician assessment, however in clinical practice the patient’s clinical 
information would be available and may be considered in their assessment, and additional 
investigations, such as PET, could be ordered before proceeding to the next time point. In 
this study, although physicians were able to assess images on their own time with their 
preferred reading and room conditions, they were unable to obtain multidisciplinary 
input. In addition, not all patients with recurrence had pathologic confirmation, as 
pathologic confirmation of recurrence may not be possible in patients who are ill due to 
comorbidities, or may not be pursued if no treatment options are available. Also, since 
histologic patterns of recurrence post-SABR are still unknown, validation of our radiomic 
signature with histology is needed. Future work includes the assessment of physician and 
radiomic performance in the context of pathologic specimens for lung SABR patients 
planned for surgical resection within 10 weeks of radiotherapy (MISSILE clinical trial, 
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NCT02136355). This will involve correlating post-SABR CT changes with histologic 
findings. 
Regarding the radiomic signature, analysis was only performed at the early 2–5 
month time point. Future studies should be completed on how radiomic performance 
changes as time post-SABR increases. Although this is one of the largest series of 
recurrences post-SABR, further validation of the radiomics signatures is needed on a 
larger dataset. Another limitation of the current study is the use of a pre-validated 
radiomic signature for comparison to physicians’. Future work includes measuring 
radiomic performance on a separate validation set as well as prospective studies.  
5.5 Conclusions 
 Physician assessment of post-SABR CT images shows high sensitivity and good 
specificity, but median time to detection of recurrence is long, inter-observer agreement 
is moderate, and unnecessary interventions are sometimes recommended for patients with 
only benign changes. Although physicians generally perform poorly in detecting 
recurrences within 6 months post-treatment, radiomic assessment demonstrates excellent 
classification ability during that time point, with an AUC of 0.85. This suggests that there 
are CT features predictive of recurrence that are not salient to the human expert at this 
early, clinically-important time point. This radiomic tool has the potential to lead to a 
clinically useful computer-aided decision support tool based on routinely-acquired CT 
imaging, which could lead to earlier salvage opportunities and fewer unnecessary 
invasive investigations of patients with only benign injury.  
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Chapter 6  
 Conclusions and Future Directions 6
The final chapter of this thesis reexamines the research objectives and provides a 
summary of the key findings and conclusions of Chapters 2-5.This chapter will also 
address limitations of the current study and potential solutions. Finally, future directions 
for response assessment following SABR are presented. 
6.1 Overview of Rationale and Research Objectives 
 Stereotactic ablative radiotherapy (SABR) is now a guideline recommended 
treatment option for patients with early-stage NSCLC [1]. SABR has demonstrated local 
control rate similar to surgery of over 90% at 3 years follow-up [2, 3]. However, the 
presence of substantial post-radiotherapy radiological changes are found on CT follow-
up, which can appear with similar shape and size to a recurring tumour [4]. 
Misclassification of benign fibrosis as local tumour recurrence has been reported, 
resulting in patients undergoing unnecessary and invasive surgical procedures to remove 
only scar tissue [5]. Current approaches to aid in response assessment have focused on 
qualitative high-risk features on CT imaging or metabolic imaging with FDG-PET, which 
do not typically detect recurrence until after a year following treatment. There is currently 
an unmet clinical need to provide timely and accurate assessment of response following 
SABR for early stage NSCLC. 
 The recent introduction of radiomics, has demonstrated the ability to quantify 
tumour phenotypes based on quantitative image features [6, 7]. This has the potential to 
personalize patient care based on predicted responses to therapy and has the ability to 
detect treatment failure at an earlier time point following treatment. In response to this 
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unmet clinical need, we aim to develop a radiomics decision support tool to aid in 
response assessment following SABR for early stage NSCLC. A means for predicting 
recurrence on routine CT imaging within 6 months of treatment would allow for timely 
intervention of recurrence, which typically manifests after 1 year [8]. Accordingly, the 
overarching objective of this thesis was to develop a radiomic software system to aid in 
treatment response assessment on follow-up CT after SABR. 
6.2 Summary and Conclusions 
 In this thesis the overarching objective was evaluated by testing the following 
central hypothesis: a radiomic software system will outperform physicians in the early 
assessment of response post-SABR. Radiomics demonstrated the ability to predict local 
recurrence with higher accuracy than physicians within 6 months of treatment. This thesis 
has advanced knowledge and technology towards the improvement of response 
assessment following SABR for early stage NSCLC. Prior to this work, there was no 
study assessing a physician’s performance in distinguishing fibrosis from recurrence 
following SABR for lung cancer. The use of quantitative image appearance features to 
detect recurrence following SABR had also never been investigated.  
 Prior to the work presented in this thesis, physicians relied on qualitative image 
characteristics of an enlarging opacity and the RECIST guidelines for basic quantitative 
measurements on CT imaging, to assess response after SABR. PET imaging is also used 
to detect recurrence after SABR; however most of these tools do not typically detect 
recurrence until a year after treatment. The use of biopsy to confirm recurrence is also 
used, but can be risky and may not be feasible in all patients. The work completed in this 
thesis has advanced knowledge and technology, suggesting the possibility for integration 
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of quantitative radiomic features to assist physicians in early detection of recurrence 
following SABR. Quantitative image features can be easily acquired on routine follow-up 
CT imaging after SABR. These features also have the ability to obtain much richer 
information from the CT image compared to a single measurement which is typically 
done with RECIST. Compared to response assessment on PET imaging, CT is more 
accessible, is inexpensive, does not require a radiotracer or additional imaging session, 
and standardization is less complex. An automated decision support system may also be 
more reproducible and consistent compared to qualitative image assessment, which can 
be subject to operator variability. CT is also less invasive and risky compared to a biopsy. 
This decision support system outperformed physicians for the early assessment of 
response and has the potential to improve response assessment following SABR by 
providing more accurate and timely prediction of recurrence compared to standard 
techniques in the current clinical workflow. 
 In Chapter 2, we evaluated the potential of quantitative image feature analysis for 
distinguishing recurrence and benign fibrosis patient groups. In this hypothesis 
generating study, regions of common post-SABR consolidative and ground-glass opacity 
changes were manually delineated on all follow-up CT images for 24 lesions treated with 
SABR. Quantitative size and appearance image features were extracted from both regions 
and analyzed according to time post-SABR. Traditional size measurements including 
longest axial diameter and 3D volume could not distinguish patient groups until 15 
months post-SABR. Appearance features including density of consolidative changes and 
first-order texture of ground-glass opacity regions could distinguish patient groups at 9 
months post-SABR. These findings suggest that advanced appearance measures may 
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provide an earlier detection of recurrence compared to traditional measure of size. Thus, 
the thesis advanced knowledge in SABR response assessment by demonstrating that 
quantitative appearance features of post-SABR CT changes were able to significantly 
distinguish local recurrence and benign injury patient groups. 
 In Chapter 3, we examined the ability of radiomic features to predict recurrence in 
individual patients. Second-order texture features were evaluated for their ability to 
predict local recurrence within 6 months post-SABR and compared to traditional 
measures of size. Once again, manual delineation of post-SABR consolidation and 
ground-glass opacity was performed. We demonstrated the ability of second-order texture 
features within regions of ground-glass opacity to predict recurrence within 6 months 
post-SABR with accuracies greater than 75%. Traditional size measures at the same time 
point produced accuracies less than 60%. Classification based on the clinical standard 
response evaluation criteria in solid tumours (RECIST) progressive disease guidelines, 
demonstrated accuracies of 52%. These findings suggest that CT texture features on post-
treatment images taken within 6 months post-SABR has the potential to predict eventual 
local recurrence. Thus, the thesis advanced knowledge in SABR response assessment by 
demonstrating that texture features within post-SABR regions of GGO can predict 
eventual cancer recurrence in individual patients within 6 months post-SABR with higher 
accuracies than standard measures of size and response criteria measures. 
 In Chapter 3, we also examined the impact of perturbations on the borders of the 
manually segmented regions of post-SABR changes. We demonstrated minimal changes 
in classification performance with perturbations of the manual GGO boundaries, 
signifying that perhaps a complete and accurate delineation of the GGO may not be 
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necessary for prediction of recurrence with radiomic features. Thus, the thesis advanced 
knowledge in SABR response assessment by demonstrating that complete delineations of 
the GGO regions are not needed for recurrence prediction, suggesting the use of a 
sampling method could allow for a faster segmentation and clinical translation of a 
radiomics decision support tool to aid in assessing response. 
 In Chapter 4, we developed and evaluated the use of a graph cuts based semi-
automated segmentation system to predict local recurrence following SABR. For clinical 
translation of our system to a useful computer-aided diagnosis system, the use of a faster 
and more reproducible delineation or sampling method of the GGO regions is needed. A 
semi-automated segmentation system was developed using the clinical standard longest 
axial diameter measurement taken as part of the RECIST guidelines. This system 
segmented the consolidative changes and performed a 3D concentric expansion to create 
a peri-consolidative region, intended to sample regions of GGO surrounding the 
consolidative mass. Radiomic features could then be extracted for classification. This 
system was evaluated with three expert observers to examine consistency and 
reproducibility of segmentations and classification performance. We found that our semi-
automated system produced more reproducible segmentations and could predict 
recurrence with non-inferiority to manual segmentations. Thus, the thesis advanced 
knowledge in SABR response assessment by demonstrating a semi-automated decision 
support system could predict recurrence with similar accuracies to a manual approach. 
This system is an advance in technology that was 20 times faster than manual 
delineations and could be integrated into the clinical workflow to aid in response 
assessment post-SABR.  
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 In Chapter 5, to provide a basis of comparison for our radiomics system, an 
observer study to measure expert physician performance in response assessment was 
completed. Three radiation oncologists and three radiologists scored all follow-up images 
after SABR and classified the images as recurrence or no recurrence. Physicians had high 
sensitivity (median of 83%) and specificity (median of 75%) for detecting recurrence at 
any time point during follow-up. However, the median time to detect local recurrences 
was 16 months following treatment.  Radiologists tended to have higher sensitivity but 
lower specificity for detecting recurrence compared to radiation oncologists. Within 6 
months of treatment, physicians tended to assess all image as no recurrence, suggesting 
there are not suspicious of recurrence at this early time point and tend to wait until an 
enlarging mass is evident on CT to assess patients as a local recurrence. Thus, the thesis 
advanced knowledge in SABR response assessment by demonstrating a physician’s 
ability to detect local recurrence on follow-up CT imaging and provides for a base level 
of performance to assess the incremental value of a decision support system. 
 Also in Chapter 5, a multi-feature radiomic signature was developed on a larger 
dataset of 45 patients to predict recurrence within 6 months of treatment. We identified 
five radiomic appearance features within regions of post-SABR consolidative and peri-
consolidative regions which could predict recurrence with a leave-one-out cross 
validation error of 23%. Texture features within the peri-consolidative regions were the 
top performing features, demonstrating that appearance measures within these regions are 
more predictive of recurrence compared to size, shape, or appearance features in the 
consolidative regions. Patients with recurrence tended to have increased presence of 
GGO surrounding the consolidative changes. The appearances in the GGO also tended to 
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be spiculated and were emerging from the consolidative mass, compared to a smoother 
appearance in patients with only benign fibrosis. Radiomics outperformed physicians at 
this early follow-up time point, where physician assessed almost all images as no 
recurrence. These appearances picked up by radiomics may be early indicators of either 
disease persistence following treatment or progression to local recurrence. Thus, the 
thesis advanced knowledge in SABR response assessment by demonstrating the ability of 
radiomic appearance features of post-SABR radiological changes to predict eventual 
cancer recurrence earlier than expert physicians. This demonstrates the possible role of 
radiomic features to provide additional information for physicians by means of a decision 
support tool to assist in response assessment post-SABR. 
 In summary, we have provided: (1) evidence that quantitative image appearance 
features of post-SABR radiological changes can distinguish recurrence and benign patient 
groups earlier than traditional measures of size; (2) evidence that radiomic texture 
features within post-SABR ground-glass opacity changes can predict recurrence in 
individual patients within 6 months of treatment; (3) evidence that a new semi-automated 
segmentation system could delineate regions of common post-SABR changes based on 
the clinically acquired longest axial diameter measurement, extract radiomic features, and 
predict recurrence with non-inferiority to manual segmentations; and (4) evidence that 
radiomics can detect early changes within 6 months of SABR treatment that may be 
associate with disease persistence or progression to local recurrence which are typically 
not picked up by expert physicians.  
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6.3 Limitations 
 The contents of this thesis must be considered within the context of its limitations. 
Specific limitations for Chapters 2-5 are presented in the discussion section of the 
respective Chapters. However, there are general limitations of this thesis that should be 
addressed. One limitation to all studies was that a relatively small dataset of patients was 
analyzed. All patients analyzed throughout this thesis were treated and followed at the 
same institution. Therefore all follow-up imaging was performed at the same centre, with 
a standard acquisition and reconstruction protocol. Although images were from a single 
institution with set scanning parameters, variation may exist between scanners [9]. This 
system should be evaluated with a larger dataset of patients from multiple institutions, to 
account for any variability image acquisition or reconstruction. Another limitation of this 
work is that not all patients with recurrence had pathologic confirmation. However, to 
avoid imaging-based definitions of recurrence which may introduce substantial bias, in 
these studies, patients with recurrence were assessed based on multidisciplinary group 
discussion, a combination of PET and CT findings and eventual clinical outcomes.  
6.4 Future Directions 
 The methods developed in this thesis support research initiatives in several future 
directions. This section will address remaining gaps in knowledge that exist and potential 
applications of this system on future research directions. 
6.4.1 External Validation and Evaluation of Additional Imaging 
 Radiomics has shown the potential to outperform expert physicians in the early 
assessment of response following SABR treatment. However, prior to clinical validation, 
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radiomic features must be validated on multiple large independent datasets. We have 
shown the potential of radiomics to predict local cancer recurrence within 6 months of 
treatment. However, further investigation on radiomics at later follow-up time points is 
warranted and may provide supplemental information to the early time points. Delta 
radiomics is an emerging area of study which refers to analyzing the change in radiomic 
features over time. The use of delta radiomics to assess changes in radiomic features over 
the course of post-SABR follow-up may provide additional information in longitudinal 
image analysis [10]. A thorough investigation of pre-treatment tumour characteristics 
may also yield insight into factors associated with recurrence [11]. This could result in 
personalized management of lung cancer patients to inform treatment decision making or 
risk stratification. The combination of these approaches may provide additional 
information to improve response assessment following SABR and provide personalized 
patient care and follow-up assessment. 
6.4.2  Incorporation of High-Level Domain Knowledge 
 This thesis has made significant contributions to improve timely and accurate 
assessment of response following SABR for early stage NSCLC. However, there remains 
room for improvement in SABR response assessment. To date our decision support 
system to aid in treatment response assessment has focused on analysis of the treatment 
area on follow-up CT. Our analysis has focused on evaluating regions of post-SABR 
consolidative and ground-glass opacity changes. Therefore, we have been focusing on 
solely the quantitative characteristics of the lesion on CT imaging. However, more 
information may be available regarding the lesion or patient as a whole. Therefore, the 
utility of additional features in combination with radiomics should be evaluated. 
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Qualitative high risk CT features have been independently validated and could provide 
useful information at later follow-up time points [12, 13]. 
 The use of FDG-PET imaging has been shown to distinguish local recurrence 
from benign RILI on pre- and post-treatment imaging. Previous work has also 
demonstrated that abnormal texture of pre-treatment SUV uptake was associated with 
nonresponse and poorer prognosis following chemo-radiotherapy for NSCLC [14]. The 
combination of PET and CT features has also been shown to predict response in lung 
cancer [15].  The addition of quantitative SUV values on PET may provide additional 
metabolic information to complement the radiomic features seen on CT, and allow for a 
more comprehensive view of the tumour. Although there are limitations with using post-
SABR SUV values for response assessment, the use of radiomic analysis on post-
treatment PET imaging may provide a measure of regional heterogeneity of SUV uptake 
values within the tumour or reveal changes from pre-treatment values. This information 
may play a role in response following SABR and warrants further investigation. The 
combination of radiomic information on CT and PET can provide phenotypic and 
metabolic information regarding the tumor. However, the addition of genomic or 
molecular markers may provide associations of outcomes or radiomic features with gene 
expression patterns [6].   
 Although all patients in our study were early stage (T1/T2, N0) lung cancer, there 
can exist substantial variability in patient history and clinical characteristics of the 
disease. Tumour size has been shown to be an important predictor of local control 
following treatment for NSCLC [16]. Therefore, characteristics of the patients’ disease, 
including T stage, may augment the decision support system. Additional clinical 
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information and prognostic factors related to the patients’ history, including age, gender, 
past smoking history, lung function, and performance status could also be useful [17]. 
This thesis did also not consider the effects of co-morbidities and the potential impact on 
the normal lung tissue on CT. Future work analyzing the impact of these co-morbidities 
on normal lung appearances and radiomic features warrants further investigation. 
Pathological features including tumour grade and histological cell type, as well as other 
genomic or biological marker may also play a role in lung cancer prognosis and should 
be considered in a decision support system [18]. These clinical prognostic factors may 
augment radiomic image features to improve prediction of local recurrence following 
SABR. 
 All patients in our study were treated with a risk-adapted approach with one of 
three fractionation regimens: 60 Gy in 3, 5, or 8 fractions. The impact of different dose 
fractionation regimes has not been considered in any of our studies and may provide 
additional information for predicting recurrence. Other dosimetric factors of both the 
tumour (e.g. maximum PTV dose) and normal tissue (e.g. V20, percent of the lung 
volume receiving 20 Gy or more) may be useful for predicting outcomes. The dose-
response relationships may also provide additional information regarding the radiological 
changes seen post-SABR [19]. Registration of pre-treatment dose distributions to follow-
up images may allow for the association of radiomic features with dose levels. This could 
provide insight into changes associated with high or low dose regions and the location of 
the local recurrence with respect to dose received.  
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6.4.3 Use in Clinical Decision Support 
 Currently assessment of response following SABR relies on expert qualitative 
assessment [20]. A combination of metabolic imaging with FDG-PET and/or biopsy may 
augment and confirm a physician’s assessment of response. The radiomic decision 
support tool developed in this thesis has the potential to aid in this clinical decision. 
Therefore, the impact of a radiomic decision support system on clinical management 
must also be determined in an additional observer study. First, effective presentation of 
this information from the decision support system must be investigated. The decision 
support tool could provide information on the regions of interest being analyzed or a 
confidence value of the classifier. Providing information regarding the radiomics 
confidence or decision could be presented in a continuous or discrete manner. 
Consultation with radiation oncologist and radiologist users should be performed to 
determine preferences and suggestions for decision support tools. 
 The integration of computer aided detection and diagnosis tools in lung cancer has 
demonstrated the ability to improve radiologists performance in detecting and diagnosing 
lung nodules [21]. The work completed in this thesis was the first-ever study to determine 
physician ability to assess response post-SABR. Effects of this decision support tool on 
physician assessment of response post-SABR must be assessed to determine the 
incremental value of performance without any decision support. Training of the operators 
may also have an impact on the effect of the decision support tool, and selection of 
physicians for this study must be considered [22]. Integration into the clinical workflow 
could allow for earlier detection of local recurrence following SABR to allow for timely 
salvage interventions. If this tool demonstrates success by improving a physician’s 
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assessment of response, a prospective clinical trial evaluating its impact on clinical 
decision making and patient outcomes could be determined.  
 Finally, the correlation of radiomic features with post-SABR histology would also 
be extremely valuable. This would allow for evaluation of tissue components within 
different regions of post-SABR changes. This could provide insight into the biological 
properties associated with certain radiomic features. This information may be important 
to provide to physician users to allow for the interpretation of what the radiomic features 
mean biologically.  
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APPENDIX B – Supplementary Material to Chapter 2 
Scan Parameters 
Planning scans used for treatment planning were acquired using four dimensional (4D) 
CT (Lightspeed 16; GE Medical Systems, Waukesha, USA) at 140 kVp , 100-110 mAs, 
and a 2.5 mm slice thickness. 4D CT was completed using free breathing with binning by 
respiratory phase.  Pre-treatment 4D-CTs used for image analysis were maximum 
inspiration of each patient. 
For the purposes of this analysis, diagnostic CT scans taken post-treatment were used. All 
diagnostic CT scans done at the treating center were performed on one of three scanners 
[Siemens Volume Zoom 4-slice, Siemens Sensations 64-slice (Siemens Nederland N.V., 
Den Haag, Netherlands) or Philips Brilliance iCT 256-slice (Royal Philips Electronics, 
Inc., Amsterdam, Netherlands)].  Standard machine settings for post-treatment scans were 
120 kVp, 100 mAs, spiral acquisition, 0.5 second rotation time, and 2.5-5 mm slice 
thickness.  Scans were acquired at inspiratory breath hold and 70 cc of intravenous 
contrast [Ultravist-300; Bayer Pharma AG, Berlin, Germany] was administered with a 
delay of 25 seconds. 
Importing and Contouring 
All images were received in an anonymized form and imported into ClearCanvas 
Workstation 2.0 (ClearCanvas Inc., Toronto, Canada). Contouring was completed in 
ITK-SNAP (Version 2.2.0) (15) using a lung window setting (window width of 1500 HU 
and window level of -600 HU), and a mediastinal window setting (window width of 350 
HU and window level of 40 HU) for tumours or fibrosis abutting the mediastinum.  
Contours were manually segmented slice-by-slice using a polygon tool and/or paintbrush 
tool.  
Calculation of Measures 
Response Evaluation Criteria in Solid Tumours (RECIST) measures were taken using the 
ClearCanvas Workstation ruler, for the consolidative areas on the pre- and post-treatment 
images, according to RECIST 1.1.  MATLAB 7.13 (The MathWorks Inc., Natick, MA, 
USA) was used in the calculation of three dimensional (3D) volume and CT density 
measures for both the consolidative and ground glass opacity contours.  3D volume was 
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calculated by determining the voxel volume encompassed by the contours, based on the 
voxel dimensions.  The number of voxels contained within each contoured region was 
determined and then multiplied by the voxel volume to determine 3D volume of each 
contoured region. CT density was determined based on the mean intensity values (HU) of 
all voxels in each contoured region of interest.   
Analysis of Measures 
The measures were analysed cumulatively from the treatment end date until a specific 
follow-up time point.  The follow-up time points used in this study included 3, 6, 9, 12, 
15, 18, 21, 24, 36, and 42 months post treatment.  For a given time point, all images up to 
that time point were used in the analysis.  For a given lesion, the following cumulative 
measures were calculated: 
1) RECIST – Mean of all RECIST measures per scan 
2) CT density – Mean of all voxels’ intensities (HU) 
3) Standard deviation of CT density – Standard deviation of all voxel intensities 
(HU) 
4) 3D volume – Mean of all 3D volume measures per scan 
Differences between groups were assessed using an independent samples t-test with 
unequal variances in MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA). All 
statistical tests were two-sided with p ≤ 0.05 indicative of statistical significance.   
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APPENDIX C – Supplementary Material to Chapter 4 
Table C1: Individual texture feature values and classification metrics including error, 
false positive rate (FPR), false negative rate (FNR), and area under the receiver operating 
characteristic curve (AUC) at 2–5 months post-SABR. All values are reported as the 
mean ± the standard deviation. 
 
Observer 
Feature 
Value - 
Recurrence 
Feature 
Value - 
Injury 
p-value Error FPR FNR AUC 
Correlation Operator 1 
(Manual) 
0.006 ± 
0.002 
0.01 ± 
0.007 
0.098 33.6 ± 10.9 37.8 ± 12.9 29.0 ± 12.8 0.61 ± 0.06 
Operator 1 
(Semi-
auto) 
0.008 ± 
0.001 
0.014 ± 
0.01 
0.082 28.3 ± 7.4 43.8 ± 7.0 11.3 ± 10.8 0.67 ± 0.06 
Operator 2 
(Semi-
auto) 
0.009 ± 
0.001 
0.014 ± 
0.010 
0.077 25.8 ± 7.4 39.0 ± 7.8 11.4 ± 9.4 0.69 ± 0.06 
Operator 3 
(Semi-
auto) 
0.009 ± 
0.001 
0.014 ± 
0.010 
0.079 26.5 ± 7.1 38.1 ± 7.6 13.9 ± 9.1 0.72 ± 0.06 
Energy Operator 1 
(Manual) 
0.002 ± 
0.001 
0.004 ± 
0.003 
0.032* 27.2 ± 4.7 37.8 ± 6.5 15.8 ± 5.4 0.70 ± 0.05 
Operator 1 
(Semi-
auto) 
0.003 ± 
0.001 
0.007 ± 
0.010 
0.131 27.3 ± 6.3 45.3 ± 7.8 7.7 ± 9.0 0.77 ± 0.05 
Operator 2 
(Semi-
auto) 
0.003 ± 
0.001 
0.007 ± 
0.010 
0.142 30.9 ± 5.4 49.1 ± 7.5 11.0 ± 8.5 0.72 ± 0.05 
Operator 3 
(Semi-
auto) 
0.003 ± 
0.001 
0.008 ± 
0.010 
0.138 30.9 ± 5.8 48.1 ± 8.0 12.2 ± 8.9 0.73 ± 0.06 
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Entropy Operator 1 
(Manual) 
9.35 ± 0.51 8.62 ± 0.91 0.030* 27.5 ± 8.5 29.5 ± 8.1 25.3 ± 11.5 0.64 ± 0.04 
Operator 1 
(Semi-
auto) 
8.68 ± 0.31 8.05 ± 0.86 0.032* 24.7 ± 8.3 25.9 ± 7.9 23.5 ± 11.1 0.73 ± 0.06 
Operator 2 
(Semi-
auto) 
8.64 ± 0.29 8.02 ± 0.87 0.036* 27.8 ± 6.0 30.6 ± 7.0 24.7 ± 8.0 0.70 ± 0.04 
Operator 3 
(Semi-
auto) 
8.58 ± 0.29 7.96 ± 0.86 0.035* 26.7 ± 7.3 28.0 ± 7.1 25.3 ± 9.9 0.71 ± 0.05 
Inertia Operator 1 
(Manual) 
56.82 ± 
23.84 
47.90 ± 
46.02 
0.563 48.5 ± 12.1 33.4 ± 22.7 65.1 ± 12.2 0.54 ± 0.05 
Operator 1 
(Semi-
auto) 
44.06 ± 
16.49 
32.65 ± 
17.24 
0.120 34.2 ± 9.9 21.9 ± 10.6 47.5 ± 14.2 0.64 ± 0.06 
Operator 2 
(Semi-
auto) 
42.70 ± 
16.19 
32.64 ± 
17.44 
0.166 37.8 ± 11.1 27.8 ± 13.7 48.8 ± 14.7 0.60 ± 0.05 
Operator 3 
(Semi-
auto) 
42.10 ± 
16.04 
31.71 ± 
16.96 
0.146 34.0 ± 10.1 21.8 ± 10.4 47.4 ± 15.1 0.63 ± 0.06 
Standard 
Deviation 
Operator 1 
(Manual) 
240.46 ± 
37.10 
205.48 ± 
62.16 
0.115 36.1 ± 9.1 27.6 ± 10.4 45.5 ± 12.4 0.59 ± 0.06 
Operator 1 
(Semi-
auto) 
197.79 ± 
15.92 
171.15 ± 
38.56 
0.044* 36.2 ± 5.4 36.5 ± 6.8 35.8 ± 7.9 0.58 ± 0.04 
Operator 2 
(Semi-
auto) 
196.73 ± 
14.81 
169.50 ± 
37.89 
0.036* 31.0 ± 4.7 31.3 ± 4.6 30.6 ± 8.9 0.64 ± 0.04 
Operator 3 
(Semi-
auto) 
191.18 ± 
16.69 
165.59 ± 
36.13 
0.042 33.6 ± 5.6 29.6 ± 6.8 38.0 ± 7.9 0.62 ± 0.04 
* Feature values are significant between recurrence and injury groups at the 0.05 level. 
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Table C2: Individual texture feature values and classification metrics including error, 
false positive rate (FPR), false negative rate (FNR), and area under the receiver operating 
characteristic curve (AUC) at 5–8 months post-SABR. All values are reported as the 
mean ± the standard deviation. 
 
Observer 
Feature 
Value 
Recurrence 
Feature 
Value 
Injury 
p-value Error FPR FNR AUC 
Correlation Operator 1 
(Manual) 
0.006 ± 
0.001 
0.009 ± 
0.004 
0.030* 31.9 ± 5.5 22.7 ± 8.8 43.9 ± 8.1 0.67 ± 0.05 
Operator 1 
(Semi-
auto) 
0.008 ± 
0.001 
0.012 ± 
0.009 
0.086 34.3 ± 5.8 26.1 ± 6.0 44.8 ± 10.1 0.65 ± 0.06 
Operator 2 
(Semi-
auto) 
0.008 ± 
0.001 
0.012 ± 
0.009 
0.110 41.3 ± 5.6 31.1 ± 6.9 54.7 ± 10.4 0.60 ± 0.06 
Operator 3 
(Semi-
auto) 
0.008 ± 
0.001 
0.013 ± 
0.009 
0.086 33.4 ± 5.2 27.4 ± 5.8 41.3 ± 9.6 0.66 ± 0.06 
Energy Operator 1 
(Manual) 
0.002 ± 
0.001 
0.004 ± 
0.003 
0.014* 27.9 ± 4.8 32.2 ± 6.2 22.4 ± 6.8 0.68 ± 0.04 
Operator 1 
(Semi-
auto) 
0.003 ± 
0.001 
0.007 ± 
0.012 
0.192 31.3 ± 5.0 10.2 ± 6.1 58.7 ± 10.3 0.70 ± 0.06 
Operator 2 
(Semi-
auto) 
0.003 ± 
0.001 
0.007 ± 
0.012 
0.212 36.5 ± 5.3 11.6 ± 6.7 68.8 ± 12.7 0.66 ± 0.06 
Operator 3 
(Semi-
auto) 
0.003 ± 
0.001 
0.008 ± 
0.012 
0.205 35.2 ± 5.1 11.7 ± 6.2 65.8 ± 13.1 0.68 ± 0.07 
Entropy Operator 1 
(Manual) 
9.29 ± 0.46 8.48 ± 0.76 0.005* 30.0 ± 4.5 25.2 ± 5.4 36.2 ± 7.4 0.67 ± 0.04 
 209 
 
Operator 1 
(Semi-
auto) 
8.87 ± 0.44 8.13 ± 0.89 0.019* 22.8 ± 4.8 22.8 ± 2.7 22.8 ± 10.8 0.71 ± 0.05 
Operator 2 
(Semi-
auto) 
8.73 ± 0.37 8.15 ± 0.93 0.057 31.3 ± 5.0 21.6 ± 4.6 43.9 ± 10.8 0.67 ± 0.07 
Operator 3 
(Semi-
auto) 
8.68 ± 0.32 8.1 ± 0.92 0.050 28.3 ± 5.7 23.3 ± 3.0 34.7 ± 12.3 0.69 ± 0.07 
Inertia Operator 1 
(Manual) 
55.14 ± 
19.08 
52.35 ± 
53.76 
0.864 43.5 ± 6.4 16.7 ± 9.2 78.4 ± 9.8 0.48 ± 0.06 
Operator 1 
(Semi-
auto) 
47.77 ± 
15.93 
34.19 ± 
12.88 
0.042* 32.8 ± 5.2 16.6 ± 6.1 53.8 ± 10.0 0.60 ± 0.05 
Operator 2 
(Semi-
auto) 
46.15 ± 
15.27 
34.46 ± 
13.33 
0.070 34.9 ± 6.9 20.8 ± 8.0 53.3 ± 12.3 0.58 ± 0.05 
Operator 3 
(Semi-
auto) 
45.45 ± 
13.79 
33.52 ± 
13.05 
0.049* 32.3 ± 7.6 21.1 ± 6.8 46.9 ± 13.5 0.61 ± 0.05 
Standard 
Deviation 
Operator 1 
(Manual) 
240.75 ± 
22.24 
206.39 ± 
39.28 
0.016* 33.3 ± 4.8 22.3 ± 7.4 47.5 ± 8.7 0.61 ± 0.04 
Operator 1 
(Semi-
auto) 
206.57 ± 
24.53 
175.84 ± 
35.26 
0.023* 36.8 ± 4.9 24.9 ± 6.8 52.2 ± 9.1 0.61 ± 0.05 
Operator 2 
(Semi-
auto) 
200.56 ± 
17.47 
176.56 ± 
36.26 
0.051 44.0 ± 5.7 31.8 ± 6.8 59.9 ± 11.4 0.55 ± 0.05 
Operator 3 
(Semi-
auto) 
198.40 ± 
16.76 
171.94 ± 
33.53 
0.023* 37.3 ± 4.4 30.0 ± 5.2 46.7 ± 7.9 0.60 ± 0.04 
* Feature values are significant between recurrence and injury groups at the 0.05 level.” 
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APPENDIX D – Curriculum Vitae 
 
EDUCATION 
 
Western University, London, ON                                                                                   Sept. 2011 – present  
 Doctor of Philosophy - Medical Biophysics  
(Reclassified from the Master of Science program in Aug. 2012)  
 
University of Toronto/The Michener Institute for Applied Health             Sept. 2008 – Apr. 2011 
Sciences, Toronto, ON  
 Bachelor of Science (with Honours) – Medical Radiation Sciences 
Diploma in Radiation Therapy 
 
 Western University, London, ON                   Sept. 2004 – Apr. 2008 
Honours Bachelor of Medical Sciences  
• Double major in Medical Sciences and Microbiology & Immunology  
 
 
RESEARCH  
 
Prediction of tumour recurrence after stereotactic ablative radiotherapy                Sept. 2011 – present 
(SABR) for lung cancer 
• MSc/PhD project, Western University 
• Supervisors: Dr. Aaron Ward & Dr. David Palma 
• Determine differences in quantitative measures of post-SABR radiological  
changes on CT between patients with recurrence and radiation fibrosis 
• Image analysis and machine learning using MATLAB  
• Feature extraction using Insight Segmentation and Registration Toolkit  
(ITK) in C++ 
• Statistical analyses in SPSS and MATLAB 
• Observer study design and implementation for evaluating decision  
support systems 
 
An interprofessional approach to establishing image guided radiotherapy                         2010 – 2011 
(IGRT) registration guidelines in gynaecological sites                                    
• Radiation therapy research methods course 
• Supervisors: Ms. Caitlin Gillan & Dr. Michael Milosevic 
• Princess Margaret Hospital, Toronto, ON 
• Determine inter and intraobserver variability in manual soft tissue image 
matching in the gynecological site group 
• Determine the reproducibility and consistency of patient specific matching 
strategies in IGRT practice 
 
Quantifying tumour microvasculature                                                                              Jan. – Apr. 2006 
• Medical Biophysics 6-week research project, Western University 
• Supervisor: Dr. Ian MacDonald 
• Assisted in analyzing tumour microvasculature images 
• Compared quantitative results using statistical analysis 
• First-hand experience with image analysis through MATLAB 
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cancer recurrence after stereotactic radiotherapy using second order texture statistics. SPIE Medical 
Imaging, San Diego, California, USA. Feb. 15-20, 2014. (7 pages; podium presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. CT image feature analysis in 
distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy 
(SABR) for lung cancer: a preliminary study. SPIE Medical Imaging, Orlando, Florida, USA. Feb. 9-
14, 2013. (7 pages; podium presentation) 
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Refereed abstracts (*Indicates presenting author) 
 
Mattonen, S.*, Palma, D., Johnson, C., Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-
Rezai, R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after 
stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic 
assessment. American Society for Radiation Oncology (ASTRO) Annual Meeting. Boston, 
Massachusetts, USA. Sept. 25-28, 2016. (submitted) 
 
Mattonen, S.*, Palma, D., Johnson, C., Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-
Rezai, R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after 
stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic 
assessment. Canadian Association of Radiation Oncology (CARO) Annual Scientific Meeting, Banff, 
AB. Sept. 14-17, 2016. (accepted for podium presentation) 
 
Mattonen, S.*, Palma, D., Johnson, C., Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-
Rezai, R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after 
stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic 
assessment. International Conference on the use of Computers in Radiation Therapy (ICCR). London, 
UK. June 27-30, 2016. (accepted for podium presentation, shortlisted for Young Investigator 
prize) 
 
Mattonen, S., Palma, D., Johnson, C.*, Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-
Rezai, R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after 
stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic 
assessment. Cancer Care Ontario (CCO) Research Day. Toronto, ON. April 18, 2016. (poster 
presentation) 
 
Mattonen, S.*, Palma, D., Johnson, C., Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-
Rezai, R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after 
stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic 
assessment. Imaging Network Ontario Symposium (ImNO). Toronto, ON. March 30-31, 2016. 
(podium presentation) 
 
Mattonen, S.*, Palma, D., Johnson, C., Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-
Rezai, R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after 
stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic 
assessment. London Health Research Day. London, ON. March 29, 2016. (podium presentation) 
 
Qi, Q.*, Mattonen, S., Kwan, K., Inculet, R., Malthaner, R., Fortin, D., Frechette, E., Landis, M., 
Palma, D., & Ward, A.D. Correlation of digital histology images of the human lung to in vivo 
computed tomography imaging: a feasibility study. London Health Research Day. London, ON. 
March 29, 2016. (poster presentation) 
 
Mattonen, S.*, Tetar, S., Palma, D.,  Senan, S., &. Ward, A.D. Automated texture analysis for 
prediction of recurrence after stereotactic ablative radiotherapy for lung cancer.  American Society for 
Radiation Oncology (ASTRO) Annual Meeting. San Antonio, Texas, USA. Oct. 17-21, 2015. 
(podium presentation) 
 
Yeung, T.P.C.*, Rodrigues, G., Mattonen, S., Warner, A., Johnson, C., Lagerwaard, F., Palacios, M., 
Bohoudi, O., & Ward, A.D. Magnetic resonance imaging radiomics to personalize brain metastases 
treatment. American Society for Radiation Oncology (ASTRO) Annual Meeting. San Antonio, Texas, 
USA. Oct. 18-21, 2015. (podium presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using texture analysis of automatic graph cuts 
 213 
 
segmentations. World Congress on Medical Physics and Biomedical Engineering, Toronto, ON. June 
7-12, 2015. (podium presentation) 
 
Yeung, T.P.C., Rodrigues, G., Mattonen, S.*, Warner, A., Johnson, C., Lagerwaard, F., Palacios, M., 
Bohoudi, O., & Ward, A.D. Magnetic resonance imaging radiomics to personalize brain metastases 
treatment. World Congress on Medical Physics and Biomedical Engineering, Toronto, ON. June 7-12, 
2015. (podium presentation) 
 
Pike, D.*, Capaldi, D., Mattonen, S., Guo, F., Ward, A.D., McCormack, D.G., & Parraga, G. 
Second-order texture analysis of hyperpolarized 3He MRI - beyond the ventilation defect. The 
International Society for Magnetic Resonance in Medicine (ISMRM), Toronto, ON. May 30 – June 5, 
2014. (electronic poster presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second order texture statistics. London Health 
Research Day, London, ON. Apr. 1, 2015. (podium presentation) 
 
Yeung, T.P.C.*, Rodrigues, G., Mattonen, S., Warner, A., Johnson, C., Lagerwaard, F., Palacios, M., 
Bohoudi, O., & Ward, A.D. Personalized treatment selection for brain metastases using MRI 
radiomics. London Health Research Day, London, ON. Apr. 1, 2015. (poster presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second order texture statistics. Imaging 
Network Ontario Symposium (ImNO). London, ON. Mar. 30-31, 2015. (podium & poster 
presentations) 
 
Johnson, C.*, Mattonen, S., Yeung, T.P.C., &. Ward, A.D. Translation of medical image analysis 
tools to a clinical trial. Imaging Network Ontario Symposium (ImNO). London, ON. Mar. 30-31, 
2015. (poster presentation) 
 
Yeung, T.P.C.*, Rodrigues, G., Mattonen, S., Warner, A., Johnson, C., Lagerwaard, F., Palacios, M., 
Bohoudi, O., & Ward, A.D. Personalized treatment selection for brain metastases using MRI 
radiomics. Imaging Network Ontario Symposium (ImNO). London, ON. Mar. 30-31, 2015. (podium 
& poster presentations) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using texture analysis of automatic graph cuts 
segmentations. OICR Scientific Meeting, Toronto, ON. March 12-13, 2015. (poster presentation 
and 2 minute poster teaser presentation). 
 
Johnson, C.*, Mattonen, S., Yeung, T.P.C., &. Ward, A.D. Translation of medical image analysis 
tools to a clinical trial. OICR Scientific Meeting, Toronto, ON. March 12-13, 2015. (poster 
presentation) 
 
Yeung, T.P.C.*, Rodrigues, G., Mattonen, S., Warner, A., Johnson, C., Lagerwaard, F., Palacios, M., 
Bohoudi, O., & Ward, A.D. Treatment selection for brain metastases using magnetic resonance 
imaging radiomics. OICR Scientific Meeting, Toronto, ON. March 12-13, 2015. (poster 
presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. London 
Imaging Discovery, London, ON. June 26, 2014. (poster presentation, awarded 2nd prize) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. Oncology 
Research & Education Day, London, ON. June 20, 2014. (poster presentation) 
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Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. Canadian 
Student Health Research Forum. Winnipeg, MB. Jun. 10-12, 2014. (Selected to attend and present a 
poster by Dr. Andy Watson, the Associate Dean of Graduate and Postdoctoral Studies as one of 
the top ranked PhD students in the Schulich School of Medicine & Dentistry, received an award 
of excellence, gold category) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. Imaging 
Network Ontario Symposium (ImNO). Toronto, ON. Mar. 24-25, 2014. (podium & poster 
presentations, awarded 2nd prize) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung 
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. London Health 
Research Day, London, ON. March 18, 2014. (podium presentation, awarded 2nd prize) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after 
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis 
predict recurrence?  Canadian Cancer Research Conference (CCRC). Toronto, Ontario. Nov. 3-6, 
2013. (poster presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after 
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis 
predict recurrence?  American Society for Radiation Oncology (ASTRO) Annual Meeting. Atlanta, 
Georgia, USA. Sept. 22-25, 2013. (podium presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., & Ward, A.D. Assessment of response after 
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis 
predict recurrence?  Canadian Association of Radiation Oncology (CARO)/Canadian Organization of 
Medical Physicists (COMP) Joint Scientific Meeting, Montreal, QC. Sept. 18-21, 2013. (podium 
presentation, COMP Young Investigators Award Finalist) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after 
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis 
predict recurrence?  Oncology Research & Education Day, London, ON. June 21, 2013. (poster 
presentation, awarded poster award) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Distinguishing radiation 
fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a 
study of CT image feature analysis. International Stereotactic Radiosurgery Society (ISRS) Congress. 
Toronto, ON. June 16-20, 2013. (podium presentation) 
  
 Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after 
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis 
predict recurrence?  London Imaging Discovery, London, ON. June 13, 2013. (poster presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Prediction of cancer 
recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer using CT image feature 
analysis. London Health Research Day, London, ON. Mar. 19, 2013. (podium presentation) 
 
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. CT image feature analysis in 
distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy 
(SABR) for stage I non-small cell lung cancer: a preliminary study. Imaging Network Ontario 
Symposium (ImNO). Toronto, ON. Feb. 4-5, 2013. (podium & poster presentations, awarded 2nd 
prize) 
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Mattonen, S.*, Ward, A.D., Haasbeek, C.J.A., Senan, S., & Palma, D. Differentiating radiation 
fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: the 
impact of CT-based image texture analysis. Canadian Association of Radiation Oncology (CARO) 
Annual Scientific Meeting, Ottawa, ON. Sept. 12-15, 2012. (podium presentation) 
 
Mattonen, S.*, Ward, A.D., Haasbeek, C.J.A., Senan, S., & Palma, D. Differentiating radiation 
fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: the 
impact of CT-based image texture analysis. London Imaging Discovery, London, ON. June 27, 2012. 
(podium & poster presentation) 
 
Mattonen, S.*, Ward, A.D., Haasbeek, C.J.A., Senan, S., & Palma, D. Differentiating radiation 
fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: the 
impact of CT-based image texture analysis. Oncology Research & Education Day, London, ON. June 
22, 2012. (podium presentation) 
 
Mattonen, S.*, Ward, A.D., Senan, S., & Palma, D. Lung density changes of radiation-induced lung 
injury vs. cancer recurrence following stereotactic radiation therapy of early stage non-small cell lung 
carcinoma. London Health Research Day, London, ON. March 20, 2012. (podium presentation, 
awarded 1st prize) 
 
Mattonen, S.*, Gillan, C., Li, W., & Milosevic, M. Communicating clinical information in IGRT 
practice to facilitate an individualized approach to online image matching guidelines in gynecological 
sites. RTi3: Radiation Therapy Conference, Toronto, ON. March 4-5, 2011. (podium presentation) 
 
Invited presentations 
 
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy 
for lung cancer. Sunnybrook Medical Image Analysis Laboratories Seminar Series, Sunnybrook 
Research Institute, Toronto, ON. May 16, 2016. 
 
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy 
for lung cancer. Department of Radiation Oncology, Harvard Medical School. Boston, MA. Apr. 25, 
2016. 
 
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy 
for lung cancer. Department of Radiology, Stanford University. Stanford, CA. Apr. 22, 2016. 
 
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy 
for lung cancer. Department of Radiology, University of Chicago. Chicago, IL. Apr. 19, 2016. 
 
Mattonen, S & Huang, K. Assessing response after SABR for lung cancer: from clinic to lab and 
back again. Citywide Cancer Imaging Seminar. London, ON. Sept. 24, 2014. 
 
Mattonen, S. & Ward, A.D. Assessment of response after stereotactic ablative radiotherapy (SABR) 
for lung cancer: can advanced CT image feature analysis predict recurrence?  Techna Institute - 
Medical Image Processing Seminar. Toronto, ON. Oct. 21, 2013. 
 
Mattonen, S. Prediction of cancer recurrence after stereotactic ablative radiotherapy (SABR) for lung 
cancer using CT image feature analysis. Department of Medical Biophysics Annual A.C. Burton Day. 
London, ON. Mar. 21, 2013. (one of two invited graduate speakers) 
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PATENTS 
 
United States Patent Application No. 61/896349: Method and Apparatus for               Oct. 2014 
Analyzing Three-Dimensional Image Data to Classify a Region of Interest   
 
 
HONOURS AND AWARDS 
 
Natural Sciences and Engineering Council of Canada (NSERC) [$90,000]                   2016 – 2018 
 Postdoctoral Fellowship 
 $45,000/year for 2 years 
 Ranked 2/55 in the Computing Sciences Committee 
 
Natural Sciences and Engineering Council of Canada (NSERC) [$105,000]                 2013 – 2016 
 Alexander Graham Bell Canada Graduate Scholarship – Doctoral 
 $35,000/year for 3 years 
 Ranked 14/121 in the Computing Sciences Committee 
 
American Society for Radiation Oncology (ASTRO) Annual Meeting Abstract        2015 
Award [$1,000]   
 Basic/Translational Science - Junior Investigator Radiation Physics  
 
Dr. Alfred Jay Medical Biophysics Award for Translational Research [$2000]        2016 
 
Imaging Network Ontario Symposium (ImNO) Magna cum Laude Abstract Award       2016 
 Top rated abstract - Imaging Translation Program 
 
London Health Research Day Top Abstract by Category [$100]           2016 
 Medical Physics, Engineering and Imaging 
 
Centre for Translational Cancer Research Trainee Travel Award [$1000]                                 2016 
 Schulich School of Medicine & Dentistry, Western University 
 
Canadian Cancer Society Research Institute (CCSRI) Travel Award [$1850]        2016 
 
International Conference on the use of Computers in Radiation Therapy (ICCR) -       2016 
Young Investigator prize shortlist 
 
SPIE Medical Imaging Robert F. Wagner All-Conference Best Student         2016 
Paper Conference Finalist 
 Computer-Aided Diagnosis Conference 
 
Western Graduate Research Scholarship, Western University [$2,900/term]         2011 – 2016 
 
Canadian Cancer Society Research Institute (CCSRI) Travel Award [$2000]        2015 
 
Nellie Farthing Fellowship, Western University [$3,000]            2015 
 Recognizing excellence in research to a full-time doctoral student in  
 the Medical Sciences at Western University 
 
American Society for Radiation Oncology (ASTRO) Annual Meeting Abstract        2015 
Award [$1,000]   
 Annual Meeting Travel Award in the Physics category 
 
London Imaging Discovery 2nd Place Poster Award [$150]           2014 
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Canadian Institute of Health Research (CIHR) National Research Poster            2014  
Competition Award [$500]   
 Award of Excellence (Gold category) - Canadian Student Health Research Forum 
 1 of 12 Gold category winners out of approx. 120        
 
Canadian Institute of Health Research (CIHR) Travel Award [$833.33]        2014 
 Canadian Student Health Research Forum - CIHR Poster Presentation   
 
Imaging Network Ontario Symposium (ImNO) Poster Award [$200]                                    2014 
 2nd Place Poster - Imaging Translation Program  
 
2013-2014 National Volunteer Award Nomination, Let’s Talk Science Outreach       2014 
 
London Health Research Day Platform Award [$600]                            2014 
 2nd place for podium presentation in platform competition – Theatre 
 
Ontario Graduate Scholarship (OGS) [$15,000]                         2013 – 2014 
 Declined 
 
The Canadian Organization of Medical Physicists (COMP) Young Investigators                   2013 
Award Finalist [$250]           
 
Oncology Research and Education Day Poster Award [$100]          2013 
 
Let’s Talk Science – Volunteer of the Month (March)           2013 
 
Imaging Network Ontario Symposium (ImNO) Poster Award [$200]                       2013 
 2nd Place Poster - Imaging Translation Program  
 
Natural Sciences and Engineering Council of Canada (NSERC) [$17,500]         2012 – 2013 
 Alexander Graham Bell Canada Graduate Scholarship – Master’s 
 
Ontario Graduate Scholarship (OGS) [$15,000]                          2012 – 2013 
 Declined 
 
London Health Research Day Platform Award [$700]                                     2012 
 1st place for podium presentation in platform competition – Salon B 
 
University of Toronto/                         2011 
The Michener Institute for Applied Health Sciences, Toronto, ON 
Graduated with Honours 
Faculty Nominated: Excellence in Clinical Preparation Scholarship 
• For consistently exhibiting professional behavior and the ability to work 
effectively both as an individual and in an inter-professional team in the 
clinical preparation semester 
Graduation Award: Outstanding Achievement in Research Methods [$100] 
• Excellence in research by a final year Medical Radiation Sciences  
student 
 
Western University, London, ON        
Dean’s Honours List                                                                     2005 – 2006 
Dean’s Honours List                           2004 – 2005 
Western Scholarship of Excellence [$2,000]                                    2004 
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EMPLOYMENT HISTORY 
 
Graduate Research Assistant, London, ON         2011 – present 
 MSc/PhD Student 
 Supervisors: Dr. Aaron Ward & Dr. David Palma 
 
Let’s Talk Science Outreach Senior Coordinator, London, ON             Jul. 2015 – present 
 Western University 
 
Teaching Assistant: Medical Biophysics 9520B – Practical Medical Imaging         Jan – Apr. 2015  
  Supervising weekly labs using the desktop imaging systems 
  Marking lab reports 
 
Let’s Talk Science Teacher Partnership Coordinator, London, ON          Jul. 2014 – Jul. 2015 
 Western University 
 
Ontario Women’s Hockey Association (OWHA) Level II Official, Aurora, ON         2001 – 2004 
 Central York Girls Hockey Association             2008 – 2010      
                                             
Wright Dental (WD) Canada, Richmond Hill, ON                                              2007 – 2008 
 Summer Student 
 
Vertex Outsourcing, Markham, ON                            2005 – 2006 
 Summer Student, Human Resources/Application Support   
 
 
SPECIAL TRAINING 
 
Graduate Recruitment Committee            2014 – 2015 
• Discuss and prepare/plan for recruitment of new graduate trainees  
• Participate in graduate student recruitment fairs 
• Departmental contact with potential graduate students 
 
 
Design of Medical Imaging Labs - Medical Biophysics Course         2014 
• Gained experience on principles of good teaching and curriculum 
design 
• Designed 10 hours of lab material for the DeskCAT optical CT system 
• These materials were used for course “Medical Biophysics 9520B – 
Practical Medical Imaging” beginning in Winter 2015 
 
 
VOLUNTEER EXPERIENCE 
 
Let’s Talk Science, Western University                                   2011 – present 
• Organized and demonstrated hands-on science activities, and lead 
children (preschool through teen) through their completion 
• Partnered with a science class at Robarts School for the Deaf  
• Planning committee co-chair for Let’s Talk Cancer high school symposium 
• Medical Biophysics department representative 
• Nomination for National Volunteer Award, Let’s Talk Science 
Outreach 
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Canadian Cancer Society                                       2015 – 2016 
• Sold daffodil pins during Daffodil Month 
 
Thames Valley Science and Engineering Fair Judge         2015 
• Judged grade 6-8 students science fair projects in the physical  
sciences category 
• Team lead for final judging 
 
Community Outreach – Homecoming Medical Biophysics Demonstration       2014 
• Provided an explanation and demonstration of the DeskCAT system 
• Provided an overview of my thesis to Schulich Medicine alumni 
 
Community Outreach – London Regional Cancer Program Lab Tour        2014 
• Provided an explanation and demonstration of the DeskCAT system 
• Provided a tour of the Baines Imaging Research Lab 
 
March Break Open House, Western University                                     2014 
• Provided an explanation and demonstration of the DeskCAT system 
 
Consult the Experts, Western University           2013 
• Provided support and feedback to graduate/undergraduate students on their 
research proposals for national and provincial scholarship competitions 
 
Central York Girls Hockey Association Annual House League and                    2012, 2008 – 2010  
Silverstick Tournaments                 2000 – 2004                                                                           
• Organized team registration, scheduling, and fundraising for the 
tournament 
• Communicated information regarding schedules, registration, 
and provided directions to players and families  
 
Peer Tutor, The Michener Institute for Applied Health Sciences          2009 – 2011 
• Communicated fundamental and practical concepts of physics 
and treatment planning to radiation therapy students (three 
students on a regular basis throughout the two-year period, plus 
several others on a one-time basis) 
 
Doors Open Toronto, The Michener Institute for Applied Health Sciences                    2009 
• Provided approx. 25 tours of the computed tomography suites 
during this one-day event to the general public, and 
communicated information regarding the equipment and 
education of technologists using an approach suitable for a lay 
audience 
 
 
REVIEWER 
 
 International Journal of Radiation Oncology • Biology • Physics (IJROBP)      2016 
 Journal of Medical Imaging           2016  
 
 
CERTIFICATION 
 
Canadian Association of Medical Radiation Technologists                      Jun. 2011 
Registered Radiation Therapist (RTT) 
